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Developing Approaches Towards the Treatment of Covid-19
Chana Weis
Chana Weis graduated in January 2021 with a Bachelor of Science degree in Honors Biology

Abstract
In late 2019 a newly identified strain of coronavirus, SARS-CoV-2 emerged, causing a worldwide pandemic of respiratory illness,
Covid-19. Covid-19 has drastically transformed the world in numerous ways.The virus is highly contagious and, in some cases, fatal.
A successful cure has not yet been discovered and therefore society is urged to take proper precautions to prevent the spread of
the potentially fatal virus. This paper analyzes the proper precautions that should be taken as well as the ongoing research that
has been done to stop the spread of the virus.
Introduction
The novel Corona Virus, the underlying cause of Covid19, is an infectious virus that primarily affects the respiratory tract. It was first diagnosed in 2019 in Wuhan, China
where thousands of people were stricken with the virus.
The virus eventually spread across the globe and was
eventually categorized as a global pandemic. Symptoms of
Covid-19 include fever, cough, difficulty breathing, shortness of breath, muscle fatigue, and loss of smell or taste.
Recent studies revealed that Coronavirus impacts the
gastrointestinal tract causing nausea, vomiting and diarrhea (Clinical Trials Week, 2020). While most people with
the virus portray mild symptoms, a small but significant
percentage of people develop more serious symptoms
such as pneumonia which can be fatal. Elderly people,
individuals with preexisting health conditions, as well as
people with compromised immune systems are at the
greatest risk for developing the most serious symptoms.
The virus is highly contagious and spreads, most commonly, through small droplets via coughing and sneezing.
Additionally, people may catch the virus by touching a surface that is contaminated, followed by then touching their
face (Mohan, 2021). Therefore, the Centers for Disease
Control (CDC) enforce face coverings such as masks or
bandanas to minimize transmission through droplets. The
CDC strongly recommends people to properly social distance and stay six feet apart from each other to prevent
the spread of the virus. Additionally, people are advised to
constantly wash their hands with soap for roughly twenty
seconds to rid themselves of any viral particles that they
may have encountered.
Symptoms may not develop for two to seven days
after coming in contact with the virus, which may make
affected people unaware that they are infected, and which
strongly contributes to the mass spread of the virus.
Although Covid-19 is highly contagious, it is most contagious during the first three days that the patient exhibits
symptoms. The incubation period for the virus is roughly
two to fourteen days, and, therefore, patients who experience symptoms are strongly recommended to isolate
themselves for fourteen days (Deibie, 2020). Currently,
there are no proven drugs or vaccines to combat the
virus and thus prevent the spread. However, over the past
several months a great deal of covid-19 research has been
performed to meet the global demand. Researchers have
been experimenting with several anti-viral drugs that may

disrupt the viral proteins and ultimately stop the virus.
Additionally, there are numerous vaccines that are being
manufactured and researched that can possibly immunize
society and thereby stop the spread of the lethal virus.
Discussion
As noted, there is no current treatment which has proven to be effective in combatting the virus. Researchers
recognize that it is impossible to kill the virus and are,
therefore, working to “deactivate” the virus so that it
can not spread further. Dozens of pharmaceutical companies, as well as thousands of researchers are working
on producing a vaccine as well as seeking treatments and
medications to help combat the virus. Vaccines typically
contain an antigen, consisting a weakened or dead strain
of the virus. When introduced to the bloodstream, the
antigen triggers the immune system to produce antibodies towards that specific antigen. Researchers are trying
several methods to produce a vaccine in hope to find a
preventative cure for the lethal Coronavirus.
One approach that researchers are experimenting with
is with a DNA vaccine. A DNA vaccine simply delivers
genetic instructions how to build a viral protein. A DNA
vaccine does not introduce the entire virus to the body,
rather, it contains nucleotides that encode a portion of
the virus. Upon injection, the nucleotide travels to the
cell where it gets translated and a protein product is
produced in the form of messenger RNA. The mRNA
then assembles viral proteins which the immune system
recognizes and tries to conquer. Researchers in China
have used this approach and found particular genes that
code for the spikes in the coronavirus, specifically genes
which code for the receptor binding domain. The receptor binding domain is the unit of the virus that is found
externally and on surfaces and are, therefore, the primary
contributors for spreading the deadly virus. DNA plasmids are placed in the vaccine and, when injected into
the body, they target the genome upon which they are
translated into proteins, thereby introducing the cell to
traits of coronavirus which initiates the production of
antibodies. The cells then secrete the antibodies into the
bloodstream which stimulate the B and T cells to act accordingly (Lee et al, 2020). The advantage of DNA and
RNA vaccines is that they can be produced quicker than
typical vaccines. (The usage of DNA vaccines is an emerging field and is rapidly developing.)
5
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Another method that may be beneficial is the introduction of similar virus like particles into vaccines. These
particles are not actual viruses and therefore do not
cause disease. Yet, these particles prepare the immune
system for what the virus proteins look like so that it
can produce antibodies prior to coming in contact with
the actual virus. When combatting the coronavirus, some
researchers believe that by inserting some adenovirus
into the vaccine, it will familiarize the cell to traits of
coronavirus and thus prepare the body to fight off the
corona virus when the two encounter. The adenovirus
is missing one its own genes which prevents itself from
reproducing and is therefore nonhazardous. When the
adenovirus is injected, it places information into the cell
by unraveling the gene, which then stimulates the immune system to produce antibodies. A strand of DNA
that codes for coronavirus is inserted into the missing
genes which trigger the body’s immune response thus deactivating specific genes that are found in the coronavirus
(Khadilkar, 2020). This method has been effective for the
HPV vaccine that was introduced in 2006 and researchers are hopeful that this method will also be effective for
combating the coronavirus.
Antibiotics are generally used to fight bacterial infections and are, therefore, ineffective for coronavirus.
Accordingly, researchers are trying to create and find an
effective antiviral medication. There have been several
medications and treatments that have undergone trials
but not yet proven to combat the coronavirus.
In September 2020 international clinical trials tried
a new approach to combat the virus by using steroids.
Steroids are often used by doctors to alleviate inflammation as well as to relax the immune system to prevent an overresponse. Patients who are seriously ill from
coronavirus are at greater risk of dying from the immune
system’s overreaction to the virus, rather than from the
actual virus itself (Lee et al., 2020). Accordingly, researchers hope to treat these patients with steroids to relax
the body and prevent it from overreacting before the
inflammation becomes serious and, in some cases, fatal.
Researchers at Oxford University found that dexamethasone was extremely effective when given to critically
ill patients. In addition, the World Health Organization
(WHO) carried out studies using hydrocortisone and
methylprednisolone on critically ill patients. The steroids
were given to seriously ill patients and a surprising number of the patients did not require mechanical ventilation.
Moreover, death rates were lowered with the patients
who took these drugs (The Times, 2021). However, like
many other drugs, steroids can cause serious side effects
such as raising the body’s blood glucose levels and causing
6

confusion in the patient. Therefore, optimal doses of steroids need to be established prior to treating patients
with steroids on a larger scale. Nevertheless, many researchers are confident that steroids will eventually be an
effective tool in fighting the coronavirus.
Another approach to treating the coronavirus is with
the drug hydroxychloroquine. Hydroxychloroquine is a
less toxic derivative of chloroquine which was developed
decades ago to prevent and treat malaria (Liuzzo, 2020). It
is now commonly used for other diseases such as lupus
and rheumatoid arthritis. Hydroxychloroquine works
by regulating the immune system. The exact mechanism
through which hydroxychloroquine benefits Covid-19 patients is unclear. As mentioned earlier, many patients with
Covid-19 develop severe complications due to the body’s
aggressive immune response upon perceiving the virus.
Researchers are hopeful that hydroxychloroquine can prevent the immune system from over responding which will
in essence, reduce the unnecessary inflammation. Initially,
when the virus first reached the United States, the Food
and Drug Administration (FDA) approved the emergency
use of hydroxychloroquine. However, after experimenting
with the drug, researchers did not find sufficient supporting
evidence that it is a safe and effective treatment for coronavirus. A clinical study using hydroxychloroquine did not
demonstrate the ability to alleviate symptoms and shorten
hospital stays (Liuzzo, 2020). Therefore, in June 2020 the
FDA banned the usage of the drug until additional research
on safety and efficiency of the drug was performed. While
there is some evidence that the drug is effective, it has
not been estimated that the potential benefits outweigh
the risks. Some risks of hydroxychloroquine include heart
disease, headaches, dizziness, and vomiting. In addition, patients suffering from malaria and other diseases, who are
dependent on hydroxychloroquine, were unable to obtain
the drug because it had been used widely for patients suffering from Covid-19.
Another drug that is being experimented as a potential cure is Remdesivir. Remdesivir was first developed
in 2009, by Gilead Sciences to help treat patients suffering from Hepatitis C. Unfortunately, Remdesivir did not
prove to be effective in fighting against Hepatitis C. In the
following years, scientists experimented with Remdesivir
as a potential cure for Ebola, and then again in 2020 for
coronavirus (The New Nation, 2020.) Remdesivir serves
as a broad-spectrum antiviral medication that is used
to treat single stranded RNA viruses such as Ebola and
coronavirus. This class of medication targets and inhibits
RNA replication through various mechanisms (Nguyen
et al, 2020). In regard to coronavirus, Remdesivir works
as a pro-drug, meaning, that after it is infused, it is then
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metabolized into its active form and converted into a
ribonucleotide analogue, more specifically an adenine nucleotide analogue.
RNA is composed of four nucleotides including Adenine
(A), Guanine (G), Cytosine (C), and Uracil (U). When
coronavirus replicates, it takes these nucleotides that serve
as the building blocks for the virus, and then chains them
together thus allowing itself to replicate. Remdesivir serves
as an adenine nucleotide analogue, and therefore inhibits
viral replication. Thus, during viral replication attempts,
Remdesivir is incorporated into the RNA in place of adenine.This essentially stops transcription of the viral genome
by preventing the building blocks from being available to
properly form the virus. Moreover, it ultimately reduces
the body’s viral load which gives the body an opportunity
to combat the viral cells that were replicated prior to taking Remdesivir (Drugs and Therapies, 2020).
Currently, Remdesivir is in the investigational stage and
has not yet been FDA approved as a safe treatment for any
sort of disease. However, in May 2020, the FDA authorized
the emergency use of Remdesivir via intravenous (Drugs
and Therapies, 2020). Optimal doses of Remdesivir have
not yet established and are under investigation.
Another approach that is being tested is the usage of
convalescent plasma. When patients recover from Covid19 their blood plasma contains antibodies that are able to
fight off any future encounters with the virus. In the current situation, patients with antibodies who are eligible to
donate plasma do so and the plasma is then transfused
into a needy patient. The donor’s antibodies may aid the
patient in fighting off the virus as well as possibly shortening the length or severity of the illness. The concept of
convalescent plasma has been used widely for decades to
help patients recover from certain diseases such as chickenpox, measles and polio (Janice, 2020) (CotentEngine,
2020). Researchers still do not know how effective this
approach will be with the coronavirus. Nevertheless, the
FDA has approved the emergency usage of this treatment
option. There are currently multiple studies being run
that are testing the validity of this treatment. Although
the evidence is not completely clear, the FDA determined that convalescent plasma has a great likelihood
of improving symptoms as well as shortening hospital
stays. In addition, it is estimated that the potential benefits outweigh the possible risk factors of the treatment.
Risk factors include allergic reactions, lung damage and in
some cases pulmonary embolism (Sanfilippo et al. 2020).
These risk factors are low since donors must be completely recovered from the virus for at least two weeks
prior to donating plasma. Some doctors believe that this
is the most effective form of treatment when given to a

patient during the beginning stages of the virus in as early
as three days onset. (Newswire, 2020).
There are two categories of medicine- preventative
and curative. Preventative medicine aims to promote
and maintain health as well as prevent disease by living a
healthy lifestyle. Vaccines fall under this category because
they promote health by preventing disease and illnesses.
On the other hand, curative medicine seeks to aid individuals who have already contracted a disease and have
fallen ill, this includes treatment and medications. In regard
to coronavirus, there has not been a successful preventative or curative treatment plan proven mainly because the
virus has roughly 380 different mutations. Mutations occur
through viral replication.When the virus replicates, the genetic code does not always exactly duplicate resulting in
mutation. Over time, parts of the coronavirus genome have
expanded into many mutations which contributes to the
struggle that researchers are facing. Additionally, over time
new strains of viruses evolve. Researchers have not found
evidence that the different mutations and strains had significant change in how the virus affected society. However,
with new data being observed and recorded researchers
are optimistic that there will be a vaccine by the end of
2020 as a preventative measure towards the lethal virus.
Viruses are the most abundant biological entity on
earth. They are simple nucleotides consisting of genetic
material cased in a protein shell and capable of surviving
only in another living cell. When a virus enters a living
cell the immune system perceives the threat and begins
to battle it. However, in some instances the immune system is not trained to fight off a specific germ or virus,
causing the pathogen to overpower the immune system,
and cause illness. Once a pathogen suppresses the cell, it
replicates itself and kills the cell thus releasing particles
so that it can infect more healthy cells.
Researchers believe that when facing a new virus,
detection and containment are two keys that can help
fight it off. Experts realize that when they are dealing
with a new virus it is essential that they figure out the
gene sequence so that they can create test kits so doctors can test to see whether or not patients are infected
by that particular virus. After detection, containment is
vital, because once a virus reaches the human population
it spreads rapidly. Each virus has a different method of
spreading. Coronavirus in transmittable through respiratory droplets, mainly in the forms of spray such as coughing and sneezing. Researchers are doubtful the virus will
go away on its own and are, therefore, working to create
lines of defense such as vaccinations as well as seeking
proper treatment and medications. As discussed numerous researchers are working on producing a vaccine
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that can highly limit Covid-19 and potentially eradicate
it. However, vaccines need to go through strict testing
and experimenting before they become available to the
market. This process can take months and sometimes
even years. This contributes to the struggle researchers
are facing being that viruses are notorious for changing
and adapting to the environment, which makes it difficult
to nail down a precise vaccine. In addition, the WHO
is testing many drugs that are used for illnesses, but just
like vaccines this process can take a while. With all of this
on the rise, society is urged to stay calm and not panic.
Modern technology and further research prepare us
better than previous pandemics in history. Nevertheless,
the virus has had catastrophic consequences, however, if
people stay vigilant and quarantined when told to do so,
the spread of Covid-19 can be greatly slowed down until
a cure is found.
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Abstract
Neuroblastoma originates from the cells in the neural crest. High-risk neuroblastoma, patients have poor outcomes even with the
multi-step treatment plans, including immunotherapy maintenance treatment. Researchers in developmental biology search for
unique antigens in neuroblastoma cells to utilize monoclonal antibodies (mAbs). Currently, GD2 is the most effective antigen that
scientists have isolated in the tumor; these anti-GD2 mAbs are administered in the forms of Dinutuximab or Dinutuximab beta to
attack the tumor. Monoclonal antibodies are currently administered in neuroblastoma instead of CAR T (that has seen success in
curing different types of leukemias) due to the heterogeneity of this tumor. Although GD2 treatment has made significant strides
in outcomes, there is still a high rate of relapse and treatment failure. Scientists continue to pursue further developments to help
cure high risk neuroblastoma through better technology and more research.
Introduction: Neuroblastoma accounts for 15% of all pediatric oncologic deaths and is the most common extracranial solid tumor
in children (Kholodenko et. al., 2018). Through understanding the tumor’s origin and developmental biology, researchers have
zeroed in on unique markers to utilize natural killers (NK) in targeting and eliminating the cancer. In the high-risk phase, neuroblastoma is deadly and has a high rate of relapse. Despite improvements in outcome, rates of recurrent neuroblastoma are high;
in about 50% of cases treatments fail (Jabbari,2019). Currently, the final part of the treatment plan is a monoclonal antibody
immunotherapy that targets the GD2 antigens on the cancer cells.
Origin
It is important to understand the developmental biology and neuroblastoma origins because its proliferation,
guide tissue morphogenesis, and differentiation resemble
cancer cells’ progression. From studying the unique physiology seen in the neural differentiation of the sympathoadrenal lineage, researchers can apply that knowledge to
treat neuroblastoma. For example, one of the backbones
of maintenance therapy is isotretinoin because scientists
found that the neural differentiation is driven by retinoids
in vitro (Cheung and Dyer,2013).
The neural crest cells that form neurons can be divided into five functional types: vagal, sacral, cranial, cardiac
and trunk cells. The trunk cells then separate into two
lineages in the early stages of embryonic development
– sympathetic and adrenal. When the cells migrate from
the neural crest, they undergo epithelial-mesenchymal
transition (EMT). Both neural crest cells and tumor
cells undergo similar EMT processes and express matrix
metalloproteinases (MMPs), disintegrins and metalloproteinases (ADAMs) that facilitate cell invasion and migration (Kholendenko, 2018).
The migrating neural crest progenitor cells committed
to the sympathoadrenal lineage initiate their differentiation due to the signaling of bone morphogenetic protein
(BMP). The cells then commit to becoming either adrenal
chromaffin cells or sympathetic ganglia. Members of the
MYCN family are expressed throughout this process in
the migrating trunk neural crest cells and are committed
to the sympathoadrenal lineage (Cheung,2013).
Neuroblastoma arises from the progenitor cells of
sympathoadrenal lineage of the neural crest during development. More specifically, scientists believe that neuroblastoma may develop from this chromaffin lineage
because most tumors are localized in the adrenal gland
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region.The expression of different transcription factors is
critical for neural crest development and is upregulated
in cancers including Snail, Twist, SoxE, and FoxD families.
The neural crest cells are a transitional type of cell that
quickly pass from multipotent progenitors to a variety
of differentiated cell types. Scientists previously thought
that the neural crest cells gradually lose their multipotent
properties and plasticity when they reach the postmigration stage, but it has been seen that is not the case.
Adult neural crest-derived cells retain the properties of
stem cells and even mimic the transcriptional expression
profiles of both embryonic stem cells and neural crest
progenitors. These progenitor cells of the neural crest
are found in many types of tissues, including skin, dorsal
root ganglia, adrenal medulla, bone marrow, among other
tissues (Kholendenko et. al., 2018).
Presentation of Neuroblastoma
A 2016 study showed that 50% of neuroblastoma patients presented with metastases at diagnosis (Tolbert
and Matthay 2018). Most cases of neuroblastoma are
diagnosed in the abdomen or arise in the adrenal medulla
or lumbar sympathetic ganglia. (Cheung, 2013).The tumor
can appear anywhere from the neck to the pelvis because
the origin is along the paraspinal and sympathetic ganglia.
The clinical presentation varies based on the tumor’s primary and secondary metastatic sites (Tolbert and Matthay,
2018).The most common metastatic site is the bone marrow, at 89%; therefore, bone marrow aspirates are used
for diagnosing and responding to the cancer (ShumacherKuckelkorn, 2020). Due to the tumor’s involvement
with the central nervous system (CNS) other common
metastatic sites are bones and regional lymph nodes.
Tumors can present at the top of the paraspinal ganglia,
causing Horner’s syndrome in some patients because
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neuroblastoma involves surrounding nerve roots of the
sympathetic ganglia. Thoracic tumors present in only
5% of patients, arising from the posterior mediastinum
and paraspinal ganglia, and, often, the tumor will invade
the neural foramina. The neural foramina can be invaded
anywhere adjacent to the spinal cord compressing it. In
the abdominal cavity, masses can cause distention with or
without pain. Furthermore, extensive liver involvement
can be seen in infants and can cause liver disease such
as coagulopathy as well as renal and lung dysfunction
due to abdominal distention. The neurologic symptoms
that can accompany pelvic tumors include bladder dysfunction, constipation, lower extremity pain or weakness
due to nerve root involvement. Another symptom seen
predominantly in infants’ metastases in the skin is painless subcutaneous nodules that have a blue hue. If the
tumor metastasizes in the bone of lower extremities, the
patient may limp or refuse to bear weight. Only 80% of
patients who need bone marrow infiltration will present
with anemia and thrombocytopenia. The common symptom of racoon eyes is caused by bone lesions in the skull,
within the periorbital region, that can cause periorbital
bruising. The catecholamines released can cause flushing,
hypertension, or tachycardia, and in rare cases, a paraneoplastic phenomenon will secrete vasoactive intestinal
peptides causing profuse diarrhea. If children present with
opsoclonus myoclonus syndrome (OMS) or varying neurologic symptoms such as opsoclonus, myoclonus, ataxia,
or other cerebellar symptoms, they should be tested for
neuroblastoma. Fifty to eighty percent of these patients
will then be diagnosed with neuroblastoma, but only
2-3% of neuroblastoma patients are affected by OMS.
(OMS can be attributed to the anti-neuronal antibodies
cross-reacting with the cerebellum.) (Tolbert,2018)
Stages of Neuroblastoma
The international neuroblastoma community organized
neuroblastoma into four distinct stages.The first L1, is a localized tumor confined to one body compartment, which
does not involve vital structures as defined by the list of
image-defined risk factors.The second stage L2, is a locoregional tumor with presence of one or more image-defined
risk factors. The third stage is M: a distant metastatic disease. MS is confined to children younger than 18 months metastases are confined to skin, liver and/or bone marrow.
Further classification is based on age, histologic category,
grade of tumor differentiation, MYCN amplification, 11q
aberration and ploidy (Tolbert,2018). Patients with low-risk
classifications have a favorable prognosis with >90% survival; in contrast, patients with high-risk neuroblastoma have a
5-year survival rate that is still below 50% (Weinke,2021).

Treatment Steps Overview
Most children who present with low and intermediate
risk disease respond well to treatment plans, but children
with high-risk neuroblastoma need an intense “multimodal” approach as the cure rates are estimated at <50%
(Khan et. al., 2021). The current treatment for high-risk
neuroblastoma has three phases and lasts approximately
18 months. Induction, the first phase, is where patients receive 5–8 cycles of intensive chemotherapy and start stem
cell collection to prepare for their autologous stem cell
transplant (ASCT). Surgery is usually preformed towards
the end of this phase (Smith and Foster, 2018). Next is
consolidation, which includes high dose chemotherapy
followed by ASCT, shown to be especially beneficial in neuroblastoma, unlike in most other high-risk diseases with
solid tumors (Khan, 2021). Radiation therapy usually starts
after ASCT recovery. The last step is maintenance, which
deals with the residual disease, trying to prevent the 50%
relapse rate (Smith,2018). This phase uses immunotherapy
which is a combination of monoclonal antibody targeting
called disialoganglioside (GD2) / Chimeric antibody 14.18
(ch14.18), GM-CSF, and interleukin-2 (IL-2), which were
added to previous maintenance therapy of just administering isotretinoin. In the cases when the patient relapses or
the cancer becomes refractory, the cancer is rarely cured.
Salvage therapy is administered to improve symptoms and
quality of life (Tolbert and Mathey, 2018).
Monoclonal Antibodies’ History
B-lymphocytes are activated when a foreign substance enters the body, and antibodies are produced in response to
this antigen. Monoclonal antibodies (mAbs) are the main
antibodies used in immunotherapy treatment for cancer.
The history of mAbs began in 1975 with future Nobel
Prize winners Georges Kohler and Cesar Milstein using
hybridoma technology to produce mAbs, an antibody
that only recognizes a single epitope. Antibodies that are
made for immunotherapy are based on the Fv’s region
affinity for antibody targeting and the Fc’s region ability
to participate in the host’s immune system.The two classes of mAbs are non-conjugated: naked mAbs and mAbs
that work with chemo drugs or radioactive particles that
target to enable the mAbs to reach the objective. MAbs
use three different mechanisms of action via targeting and
binding the target cell’s antigen on the cell membrane and
blocking the pathways that lead to the cells multiplying.
Firstly, they inhibit the factors and receptors that activate
the pathways allowing cancer cell proliferation. Second,
they cause antibody dependent cell-mediated cytotoxicity (ADCC), where the mAbs bind to the tumor associated antigens in the surface of target cells. Then the
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Fc receptors of immune cells recognize cell-bound mAbs,
followed by cross-linking of these receptors, releasing cytotoxic agents that lead to apoptosis of tumor cells. The
third way is through complement dependent cytotoxicity
(CDC). The mAbs bind to the antigen on the target cell,
causing a “complement cascade”. These complements
bind an attack complex and activate the cell’s complement system lyses (Kimis-Gebologlu et. al., 2018).
GD2
Scientists isolated GD2 for the mAbs to target. GD2 in
its humanized forms is called hu3F8 and ch14.18. GD2 is
an oncofetal differentiation antigen that was identified
by comparing neuronal differentiation and tumorigenesis
(Cheung,2013). GD2 is a perfect candidate for antibody
therapy because it is abundantly expressed in most neuroblastoma cells, and GD2 is limited in normal cells, including peripheral nerves (Nguyen et. al., 2018). It belongs to
a unique class of T cell-independent carbohydrate antigens
with high density, membrane proximity, homogeneity within
and across neuroblastomas, and rare occurrence of antigen
loss. Anti-GD2 mAbs attach tumor cells to NK cells and
rescue NK cells from being suppressed or inhibited by neuroblastoma. GD2 is also ideal for tumor-selective delivery of
radioisotopes, liposomes, or nanoparticles (Cheung,2013).
Further future applications of GD2 were seen in association with tumor-associated macrophages (TAMs). These
TAMS are myeloid effectors that can become polarized
into type 1 antitumor or type 2 pro-tumor phenotypes.
But researchers discovered that in the presence of anti-GD2 mAbs in vitro, ADCC can turn protumor M-CSFactivated macrophages into antitumor killers. Even though
mAb therapy is considered a passive immunotherapy, introducing a host anti-tumor following mAb therapy might
benefit long-term tumor control (Cheung,2013).
MYCN, KIR-HLA, ALK, ATRX
In addition to GD2 researchers continue to search for
unique features of the tumor that can lead to a cure.
Scientists specifically look at the distinctive genes and
mutations seen in a lot of cases and the effect they have
on the outcomes.
Only less than two percent of patients have mutations
in the signaling pathways involved with the sympathoadrenal line that causes familial neuroblastoma. PHOX2B
was another mutation identified that promotes cell cycle
exit and neural differentiation. Though in sporadic neuroblastomas, 6-10% carry somatic anaplastic lymphoma
receptor tyrosine kinase (ALK) activating mutations,
while 3-4% have a high frequency of ALK gene amplification. ALK plays a role in ensuring the balance between
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proliferation and differentiation. (PHOX2B and ALK gene
have been linked because PHOX2B may directly regulate
ALK expression) (Cheung,2013). ALK is expressed only
in neural tissues, and mAbs designed to recognize ALK on
neuroblastoma cell surfaces have shown increased ADCC
of ALK-amplified NB cells. This ALK expression is linked
to the MYCN expression (Jabbari,2019).
The most common focal genetic lesion in sporadic
neuroblastoma is MYCN amplification. It is a major oncogenic driver since it controls proliferation, growth, differentiation, and survival of cells in the developing CNS
(Cheung,2013). MYCN is expressed prenatally in different
tissues, but its expression is lost during the first week postnatally. MYCN amplification is associated with metastases,
reduced T-cell infiltration to TME, and invasiveness of the
tumor and its progression during induction treatment. But
MYCN-amplified patients were found to have better early
response to treatment, however their survival rates were
unaffected. Recent studies have employed miRNAs to suppress MYC family (Jabbari,2019).
ATRX mutation is another mutation seen in some neuroblastomas. ATRX is associated with increased telomere
activity that is vital for the cancer cells to survive.This high
telomere activity is found in 30% of neuroblastomas at
diagnosis and is predictive of reduced EFS and overall survival. There are currently no molecular therapies targeting
these pathways associated with telomeres (Cheung,2013).
NK cells are capable of inhibiting colony formation of
human neuroblastoma cells and infusion of NK cells into
mice bearing human metastatic neuroblastoma showing
improvement in OS (Venstrom,2009). NK activity is regulated by inhibitory and activating signals following engagement of cell membrane receptors with their cognate
ligands on target cells (Tarek,2012).
NK cells expressing inhibitory killer cell immunoglobulin-like receptors (KIR ligand) for self- human leukocyte
antigen (HLA) class I molecules are equipped with effector function, ensuring that potentially autoreactive NK
cells expressing KIR for non-self HLA (“missing ligand”)
are not able to work when they encounter cells lacking
their cognate ligand. (Venstrom,2009). Untreated NB tumors and cell lines are widely reported to have reduced
to no HLA class I expression, rendering them potentially
susceptible to NK killings due to lack of engagement of
HLA class I–specific inhibitory KIRs (Tarek,2012).
Clinically, the “missing ligand” KIR-HLA compound genotype is a strong predictor of response and survival.When
treated with anti-GD2, patients with neuroblastoma who
lack one or more HLA ligand for their inhibitory KIRs
respond better to treatment, have lower rates of relapse,
and survive longer compared with patients who possess
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all HLA KIR ligand. This suggests that the unlicensed NK
cells expressing KIRs for non–self-HLA ligands are more
effective in tumor eradication than the licensed NK cells
expressing KIRs for self HLA. HLA class I expression on
neuroblastoma cell lines selectively inhibits licensed cell
activity, allowing unlicensed NK cells to mediate ADCC,
showing the importance of unlicensed NK cells for the
antitumor role in patients undergoing mAb therapy. This
explains the “missing KIR ligand” benefit in patients with
neuroblastoma. Since licensed NK cells expressing S-KIRs
have higher ADCC capacity in general, rescuing licensed
NK activity from class I inhibition is advantageous because it could increase response in all patients, even those
with all the KIR ligands present (Tarek,2012).
In addition, the use of exogenous NK cells in the treatment of patients with NB may be potentially useful if
the patient lacks class I ligands for the donor inhibitory
KIRs. Augmentation of innate immunity through adoptive
transfer of allogeneic NK cells or the use of agents that
increase endogenous NK cell number and activity, such
as IL-2, lenalidomide, and anti-CD137 antibody, may all
improve NB control, particularly in the presence of 3F8.
While transplantation and mAb therapy are hardly normal physiological conditions, they both take advantage
of the important pool of unlicensed NK cells, previously
thought to be hyporesponsive and therefore potentially
less clinically relevant. (Tarek,2012).
GM-CSF, IL 2, Retinoid Acid
Dinutuximab is augmented by GM-CSF and IL-2 because
they stimulate the immune response and specifically the
antitumor effect. IL-2 works to stimulate NK cells, and
GM-CSF activates granulocyte and macrophage cytotoxicity (Armideo et. al.,2017). Granulocyte-macrophage
colony-stimulating factor (GM-CSF) is a cytokine that
enhances the activity of macrophages (Jabbari,2019).
IL-2 is an important component of immunotherapy because it can improve the cytolytic function of NK cells
against neuroblastoma cells. Though 23% of patients receiving IL-2 suffer from capillary leaks, IL-15 has been
considered as an alternative to IL-2 for combination
with anti-GD2 mAbs in neuroblastoma. Furthermore,
administration of IL-15 is necessary for the NKT cells, an
anti-neuroblastoma lymphocyte, to survive the hypoxic
neuroblastoma environment (Cheung and Dyer, 2013).
The International Society of Pediatric Oncology Europe
Neuroblastoma (SIOPEN) has even removed IL-2 infusions with dinutuximab beta because of the toxicities
related. They suggest dinutuximab beta and isotretinoin
for maintenance therapy (Ladenstein et. al., 2020). The
isotretinoin is used with anti-GD2 as a differentiating

agent that induces the maturation of neuroblastoma
cells since GD2 is a marker on only mature neurons
(Armideo et. al., 2017).
Reasons CAR T does not Work in
High-Risk Neuroblastoma:
Neuroblastoma is an extremely heterogeneous disease,
meaning each tumor has unique molecular, cellular, and
genetic features, all affecting the tumor’s response to the
treatment. It can continue to metastasize or even become
refractory to a specific therapy. Furthermore, scientists
are unsure how heterogeneity evolves with treatment and
disease progression remains unknown. Neuroblastoma
has a narrow epitope range hence the T cell-based therapy is not effective; therefore, antibody-based immunotherapy is used targeting GD2, and oncofetal antigens.
Unlike its restriction in normal tissue, GD2 (disialogangliosides) present on tumors that arise from the neuroectoderm (neuroblastoma, melanoma, small cell lung cancer,
and sarcomas) are expressed.. Also, there are few natural
antibodies opposed to neuroblastoma. Further, fighting
the rare variants of somatic mutations seen in neuroblastoma contrast with the lack of mutations in adult cancers.
Then the intensive use of chemotherapy further damages those T cells that were attacking the neuroblastoma.
Specifically, active adaptive immunity is harder for patients
with high-risk neuroblastoma because of the primary and
metastatic tumor’s bulk together with its rapid proliferation that overwhelms the immature immune system in
children (Cheung,2013). Another technique used to gain
long term control over cancers is an immune checkpoint
blockade that targets the immune system by activating
previously exhausted or dysfunctional T cells.These mAbs
(programmed cell death protein 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4)) used in the
blockade in adults’ tumors are efficient, but in pediatric
tumors, these checkpoint inhibitors have shown no significant benefit (Liu,2020).
Neuroblastoma recruits pro-tumor macrophages and
silences natural killer (NK) cells. Furthermore, neuroblastoma evades T cells by downregulating or losing human
leukocyte antigen (HLA) expression, but they simultaneously cause damage by re-expressing HLA to resist NK
cell-mediated antibody dependent cell-mediated cytotoxicity (NK-ADCC). Once bound to GD2, anti-GD2 mAbs
bind to Fc-receptors on the surface of granulocytes and
neurokinin cells and eliminate NB cells through ADCC
and CMC (Jabbari et. al., 2019).
Side Effects of Anti-GD2
As with all treatments when dinutuximab - using mouse
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SP2/0 cells (and dinutuximab beta- In Europe) was recloned in Chinese hamster ovarian (CHO) cells), is administered, patients can experience a range of adverse
effects (McKeage et. al., 2018; Ladenstein, 2020).
Dinutuximab beta was also found to be a cost-effective
treatment option (Pennington,2019). Dinutuximab beta is
an orphan medicine that is approved in the EU for the
treatment of high-risk neuroblastoma in patients aged 12
months who have previously received induction chemotherapy, and achieved at least a partial response, followed
by myeloablative therapy and SCT, relapsed or refractory neuroblastoma ± residual disease (Ladenstein, 2020).
The continuous, 10-day infusion regimen appears to be
associated with less toxicity than the once-daily infusion
on 5 consecutive days (McKeage,2018). These side effects
usually do not continue once treatment ends, but it may
interrupt the treatment.
Doctors can prescribe medications during treatment to
deal with some of the side effects. The most frequent of
these is neuropathic pain. This appears to be caused by
dinutuximab, which targets GD2, a protein that is present
on the neuroblastoma cell and is also present on neurons and peripheral nerve fibers, which causes the pain
(Bartholomew, 2017). The pain can be controlled to some
extent by analgesic therapy, including intravenous morphine, prior to and during the infusion (McKeage et. al.,
2018). Furthermore, infusing an antibody can cause severe
reactions including anaphylaxis and cytokine-release syndrome (Bartholomew et. al., 2016). Since 39% of patients
run a fever, acetaminophen is administered prophylactically prior to treatment (Armideo et. al., 2017). The fever
may stem from a few different factors including, the IL-2
releasing pyrogenic factors, immune stimulation or the
cytokines that are released when the antibody is administered (Bartholomew,2017). Patients may also require
premedication of antihistamines before each infusion.
Furthermore, Dinutuximab can cause hypersensitivity
reactions (25%) and even more so when IL-2 and dinutuximab are administered together; this is due to immune
stimulation and cytokine release (Aust Prescr,2020).
The 23% of patients that experience capillary leak syndrome (CLS) can be attributed to endothelial cell damage,
a cytotoxic response of dinutuximab, GM-CSF, and IL-2.
Common treatment for CLS uses furosemide, which has a
higher association with hypokalemia (Bartholomew,2017).
The rare side effect of a liver dysfunction can be evidenced through the elevated alanine transaminase (ALT),
(23%); and aspartate transaminase (AST) (10%) along with
electrolyte disturbances (Armideo,2017). A small population have ocular changes such as mydriasis and accommodation issues along with anisocoria and sluggish pupillary
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response; therefore, patients should be monitored for
photophobia, papillary reactivity, and visual changes
(Bartholomew,2017). Other common toxicities seen are
infection (39%), hypokalemia (35%), hyponatremia (23%),
gastrointestinal side effects (nausea, vomiting, diarrhea;
22%), hypotension (18%), hypoxia (13%), and urticaria.
(Armideo,2017).
Immunosuppressive Environment:
Factors that are unique to pediatric solid tumors are the
paucity of neoantigens, development of resistance, and
an immunosuppressive environment. The neuroblastoma
tumor microenvironment (TME) studies have identified
tumor associated macrophages (TAMs) within the immunosuppressive microenvironment in neuroblastoma that
specifically inhibit both innate and adaptive immune responses (Liu,2020).
Other immunosuppressive components affecting the T
cells function in attacking the tumor are defects in antigen
presenting machinery (APM) and low levels of MHC class
I molecule displayed by neuroblastoma tumor cells that
lead to decreased cytotoxic T-cell activation. Secretion of
different solubles, including transforming growth factor-β
(TGF-β), and galectin-1 by tumor cells, directly inhibits
T cell function. Furthermore, some myeloid cells in the
tumor may not fully differentiate into dendritic cells, macrophages, or granulocytes, but instead generate a heterogeneous population of immature immunosuppressive myeloid cells, MDSCs. Hypoxia-inducible factor 1α (HIF1α)
is a soluble factor that promotes the differentiation of
MDSCs into TAMs, creating a feedback loop to support
immunosuppression. Targeting these MDSCs enhance anti-tumor immune responses in neuroblastoma, implying
that MDSCs play roles in cancer-related inflammation,
enhancing the tumor’s progression (Liu and Joshi, 2020).
Cytokines can be used for intercellular communication;
therefore, the cancer cells can use them to alter the TME
according to their needs. When tumor cells release VEGF,
which promotes angiogenesis within TME, it is usually associated with higher stages of neuroblastoma and its poor
prognosis. IL-6 is a cytokine, that positively affects tumor
growth and distant metastases while IL-10 is an immunosuppressive cytokine found in neuroblastoma. Blocking
IL-10 receptors has been shown to enhance immune response to tumors and improve outcomes of treatment.
Also, INF-γ, a cytokine, can also induce tumor regression
by promoting ADCC (Jabbari et. al, 2019).
Traditionally the thymus eliminates T-cells through T-cell
receptors (TCRs) with high affinity toward tumor (self)-antigens. T-cells with high-affinity TCRs can be eliminated or
converted into regulatory T-cells (Tregs) (Jabbari,2019).
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Treg cells exhibit their suppressive activity via several
mechanisms including inhibition of antigen-presenting
cell maturation through the CTLA-4 pathway, secretion
of inhibitory cytokines such as IL-10, TGFβ, IL-35, and
granzyme and perforin expression that kill effector T-cells.
Studies are currently inconclusive of Treg’s exact effect
on patients with neuroblastoma, but they do correlate a
higher proportion of Treg cells in the bone marrow and
peripheral blood with MYCN amplification (Liu,2020).
Since Tregs lack IL-7Rα, it can be exploited for increasing
expansion and enhancing function of CAR T-cells without
concomitant expansion of Tregs (Jabbari,2019).
Further challenges stem from the neuroblastoma cells.
Gangliosides and sialic are highly expressed surface carbohydrates that are important for migration, adhesion, and
metastasis, but are also poorly immunogenic and sometimes even immunosuppressive. Since natural anti-ganglioside antibodies are rare, it allows the neuroblastomas to
survive in the circulation despite not having a complement
decay accelerating factor (CD55). Myeloid suppressor
cells, regulatory T cells, and it exploits protectin (CD59)
to resist or suppress immunity (Cheung and Dyer, 2013).
Further Developments
Almost 80% of patients with the clinically aggressive disease do not show sustained responses to recent advances
in anticancer therapy. More research is necessary to understand neuroblastoma’s biology and an accurate representation of the tumor to identify agents that can be used
in pediatric drug development. Additionally, since there is
a low occurrence of neuroblastoma there are less clinical
trials (Corallo et. al., 2020).
Current neuroblastoma studies primarily employ
two-dimensional (2D) cell cultures. A three-dimensional (3D) culture would improve the research since it can
reconstruct a physiologically relevant TME. Also, current
models do not reflect the pediatric context of neuroblastoma, immature immune systems, differences in drug
metabolism, and continuing developmental changes. A 3-D
platform would also address the lack of clinical trials issue
and can lead to more efficient treatment plans, hopefully
reducing the exposure of pediatric patients to additional
rounds of chemotherapy (Corallo et. al., 2020).
Scientists have looked at instances of spontaneously
regressing neuroblastomas (NBL-4S) where an advanced
metastasizing neuroblastoma that had spread to the skin,
peripheral blood, bone marrow, and peripheral ganglia
(but excluding the bone) suddenly regresses.This situation
shows that neuroblastoma may be different and disconnected from the GD2 marker. Although GD2 is present
in NBL-4S, the study showed its expression may be lower

(this should infer a worst prognosis, but the exact opposite occurred). Scientists have not been able to define the
immune response nature and signature of neuroblastoma
rejection in NBL-4S, but they assume NK cells are involved
(Rovigatti,2021).
Researchers are working on a vaccine to prevent neuroblastoma relapses. Once integrated to the cell genome,
lifelong expression of transfecting genomes can detect
neuroblastoma cells presenting the tumor associated
antigens (TAAs). This is of utmost importance in cases
of minimal residual disease. Vaccines have been directed
against TAAs such as survivin, MYCN, and GD2 have been
somewhat effective for this purpose. Retroviruses have
been used to transfer IL-2 genes to neuroblastoma cells in
mice and have resulted in sustained production of IL-2 and
tumor growth control in these animal models, and neuroblastoma cells transfected with IL-1β and TNF-α by means
of retroviral vectors showed tumor growth arrest in vitro
(Jabbari,2019).
Neuroblastoma evades the attack of the mAbs by escaping to the CNS, which is not accessible to circulating antibodies (Cheung,2013). Studies are working to create an
anti GD2 CAR T treatment to redirect T cells against GD2
(Prapa,2015). Though CAR T treatment has a long way to
go until it will be effective; therefore, there is not sufficient
evidence to abandon the advantages of passive immunotherapy with anti-GD2 monoclonals (Ugo Rovigatti.2021).
Scientists used an anti-GD2 single-chain variable fragment
(scFv) derived from a murine antibody of IgM class that
was linked to the signaling domains of the costimulatory
molecules 4-1BB (CD137) and CD3-ζ. The receptor was
expressed in T lymphocytes. Then transduced T cells expressed high levels of anti-GD2 CAR into cultures that
infiltrated the tumors and persisted into blood circulation
inducing massive apoptosis of neuroblastoma cells and
destroying the tumor growth. Since the preclinical had
positive results, more clinical testing with this approach
will be tested in neuroblastoma and other GD2-positive
malignancies (Prapa et. al., 2015).
Conclusion
Cancer treatments have improved greatly throughout
the years, but researchers are still looking for the best
way to eliminate high risk neuroblastoma. The current
treatment plans employ the use of an immunotherapy
using mAbs that targets the GD2 antigens on the tumor
cells. Although this treatment has toxicities while it is administered, there is an overall higher EFS rate in patients
receiving it in their maintenance therapy. Sadly, the rate of
relapse is still high with the GD2 treatments; therefore,
researchers continue to search for better options.
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Abstract
This paper reviews the antibacterial potential of enzybiotics against Methicillin-resistant Staphylococcus aureus (MRSA). Due
to the increasing occurrence of antibiotic resistance, researchers are looking to make use of the natural antibacterial qualities
of virus bacteriophages, viral derived lysins, and antimicrobial peptides to fight MRSA infections. The efficacy of bacteriophages,
endolysins, and bacteriocins as potential antibacterial agents against MRSA was extensively researched through Touro’s online
library database. Each of their mechanisms of action allows them to effectively lyse S. aureus cells, by essentially disrupting the
peptidoglycan in the cell wall, causing it to burst.The narrow host range of these antimicrobials causes eradication of only pathogenic bacteria while maintaining the state of normal flora. Researchers have tested the ability of bacteriophages to effectively
eliminate MRSA and have experimentally created therapeutically effective phage cocktails to delay the development of bacterial
resistance. Different in-vitro and in-vivo studies demonstrate the ability of endolysins to rapidly kill S. aureus regardless of their
metabolic state. Truncated and chimeric endolysins are used to optimize certain endolysin properties while eliminating negative
ones. The therapeutic use of bacteriocins has significantly reduced and even completely eradicated MRSA infections in rabbit
and mice in-vivo studies. Additionally, bacteriocins display synergy when used along with endolysins. All areas of enzybiotics show
synergy with antibiotics when both treatments are combined. Additional research must be done before bacteriophages, endolysins,
and bacteriocins can be used as a new antibacterial agent against MRSA.
Introduction
One of the greatest medical discoveries was the discovery
of antibiotics in the 20th century, which caused the mortality rate of patients suffering from infectious diseases to
drop dramatically. Other methods of treating bacterial infections were available at that time but were discontinued
after the use of antibiotics became prominent. There are
two major disadvantages to the use of antibiotics, the first
being that aside from killing the unwanted bacteria they
also kill the beneficial ones. The second is antibiotic resistance. Antibiotic resistance occurs when bacteria evolve
mechanisms that protect themselves against the effects
of antibiotic drugs. With a major misuse of antibiotics
globally, antibiotic-resistant bacteria are quickly increasing
each year. The discovery of new classes of antibiotics has
been slow and is not keeping up with the rapid increase
of resistant bacteria. This is causing common infections
to become untreatable and once again deadly (Matilla, et.
al. 2015).
An example of this is Staphylococcus aureus, a
gram-positive, round-shaped bacterial pathogen that
is responsible for many infections including bacteremia, pneumonia, sepsis, and wound and bloodstream
infections. It is quickly becoming resistant to more and
more forms of antibiotics which are making it increasingly difficult to cure. Methicillin-resistant staphylococcus
aureus (MRSA) is a group of S. aureus isolates resistant
to methicillin as well as many other kinds of antibiotics.
Vancomycin is one antibiotic that is used to treat MRSA
however vancomycin-resistant MRSA strains have started
to emerge (Jensen, et. al. 2015). The inability to effectively
treat MRSA has led to a resurgence in attempts to use
previously neglected antibacterial therapies to treat it.
This review is aimed at researching enzybiotics as one
alternative method to treating MRSA infections

Methods
This study was performed through the analysis of various
original and peer-reviewed articles which were accessed
from Touro’s online database including Proquest, PubMed,
and Plos One databases. The articles were critically read
analyzed and compared to determine the efficacy of enzybiotics as a possible treatment against multi-drug resistant MRSA.
What are Enzybiotics?
Enzybiotics fight bacterial infections through the use of
virus bacteriophages, viral derived lysins or antimicrobial
peptides. Some advantages enzybiotics have over regular antibiotics are their different mechanisms of killing
bacteria, including antibiotic-resistant bacteria. Most importantly, the use of certain enzybiotics has not resulted
in new development of bacterial resistance. For these
reasons, enzybiotics represent a promising alternative
to traditional antibiotic use by complimenting as well as
replacing antibiotics in treating bacterial pathogenic infections including MRSA.
Originally, Enzybiotics referred to designated bacteriophage enzymes provided with the ability to break down
cell walls which could be used as antimicrobial agents.
However, eventually, enzybiotics began referring to all
enzymes that displayed antibacterial or antifungal activity.
Bacteriophages
Bacteriophages are viruses that insert their genetic material into bacteria in order to replicate.The tails of phages
bind to receptors found on the surface of bacteria allowing
them to inject the DNA into the bacterial cell. For virulent phages, DNA replication produces many new phages
which burst from the host cell and kill it. These replicated
phages now move onto the next bacterial cell and repeat
the process (Thurber, 2009). Their characteristic of being
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able to replicate at the site of infection and therefore be
available in abundance where needed, gives bacteriophages
an advantage over traditional antibiotics (Gu, et. al. 2012).
Binding to a specific receptor is required for bacteriophages to infect bacteria, making phages extremely host-specific. Due to their narrow host range, using
phages to treat infections is advantageous, because phage
treatment can focus accurately on the pathogen infecting
human cells while not harming normal flora. For this reason, there are thought to be minimal side effects associated with phage therapy (Jensen, et. al. 2015).
Phage therapy has been used previously in the early
20th century, however, when antibiotics were discovered,
research in the phage treatment ended. Now that antibiotics are beginning to fail and there is a major need for
alternatives, phage therapy is being looked at as a possible option (Mattila, et. al. 2015). Although bacteria can
become resistant toward phages as well, phage therapy
can possibly be a greater option because of its ability to
change in response to the development of resistance by
target bacteria.
Nosocomial infections are infections that are contracted within a hospital environment. Transmission of
these infections often occurs via hospital equipment and
fomites that are not properly disinfected. This is a common way that MRSA infections get transmitted and is a
major concern amongst immunocompromised patients in
hospitals. Researchers have studied the ability of phages
to successfully decontaminate fomites associated with
nosocomial transmission. Glass coverslips were used to
represent decontamination of solid surfaces and cloth
from a lab coat to represent the coats worn by clinicians.
Strains of S. aureus were isolated from many sources
such as human nasal swabs, hospitals, dog hair, and poultry. Isolated phages were able to significantly reduce the
colony-forming units of MRSA from the surfaces of the
glass and fabric.They tended to demonstrate greater lytic
activity toward the MRSA strains isolated from human
sources. They were able to isolate at least six different
phages that displayed lytic activity against human MRSA
isolates and were able to decontaminate hard surfaces as
well as fabric surfaces (Jensen, et. al. 2015).
Phage Cocktails
Phage therapy isn’t infallible because bacteria have been
shown to develop resistance towards phages. In attempt
to solve this, the use of phage cocktails was studied. Phage
cocktails are when multiple phage types each possessing
different host ranges are combined. Studies have shown
that using this method delays the development of phage
resistant variants. However, it is difficult to acquire a set
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of phages that are effective against all variants of a specific
bacteria, and if too many different phages are used in effort to increase the host range the therapeutic efficiency
of the cocktail decreases.
Researchers have studied the possibility of creating
patient-specific phage cocktails containing phages specific for the infection present. Compared to pre-made
cocktails, this method of tailored phage cocktails ensures
that unnecessary phages aren’t used. For this method of
treatment to be possible, hospitals would be required to
have access to a large variety of phages at all times so that
when a pathogen is identified they can obtain the specific
phages that are effective against it.
The probability of successfully isolating phages effective
against common hospital-acquired bacterial infections on
demand was experimentally tested. Researchers found
that the probability of finding phages from sewage, an optimal resource of phages, varied greatly for different host
bacterium. Out of a total of 117 attempts, phages for only
a single strain of S. aureus were discovered. After continuing to investigate whether alternative sources would be
more suitable for obtaining phages effective against MRSA,
only phages for strain SA10 of S. aureus were found. This
specific study concluded that creating personalized phage
cocktails on demand is not possible for treating MRSA
like it is for other common infections. To treat these infections using this method, pre-made wide range cocktails
would have to be used. (Mattila, et. al. 2015).
Phages cocktails were also used to determine their potential synergistic ability to decontaminate fomites. The
difference is that the phages used weren’t required to be
extremely specific. Results of this study showed that the
cocktails were effective in decontaminating both the lab
coat fabric and the glass coverslips (Jensen, et. al. 2015).
Combination of Phage and Antibiotic Therapy
One way to use bacteriophages to combat infections is
to combine phage therapy with antibiotic therapy. The
combination of both antimicrobial agents seems to be
synergistic; the interactions between both antimicrobial
agents create a combined effect that is greater than than
each of their individual effects. Not only has using this
combination therapy shown to be helpful in effectively
controlling bacteria, but studies have shown that phage
therapy used along with antibiotics prevents the development of resistant strains. Therefore, using methods of
combined treatment of bacteriophages with antibiotics
can be effective in helping to resolve the issue of antibiotic resistance (Torres-Barceló, et. al. 2016).
S. aureus is one of the most common pathogens found
in diabetic foot infections. Overuse of antibiotics to treat
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these infections resulted in MRSA accounting for almost
half of the S. aureus isolates found in diabetic foot infections. It’s estimated that at least 50% of deaths caused by
diabetic foot infections are because of strains that were antibiotic resistant and therefore untreatable. One available
alternative treatment option is linezolid, an antibiotic that
is known to cure diabetic foot infections without causing
major side effects. Researchers have attempted to used
phage therapy along with linezolid to treat induced foot
infections in diabetic mice. To test their synergy, they used
phage MR 10 alone and in combination with linezolid.
Results of the study demonstrated that in a group of
mice that received an injection of phage MR 10, the infection was completely resolved after seven days. However,
greater results were observed in a group of mice that were
administered both phage MR 10 and linezolid. There, the
infection was also completely resolved by day seven but
there were comparatively lower bacterial loads on each
day when compared to treatment with phage 10 alone.This
showed that phage given along with linezolid were synergistic in controlling the pathogen population. Linezolid
prevented further growth of the pathogen because it is
a bacteriostatic antibiotic, and phage 10 killed the already
existing bacterial population (Chhibber et. al., 2013).
Endolysins
A major disadvantage to phage therapy is the ability of bacteria to develop resistance to the phages. Because of this,
researchers have looked into the possibility of purifying the
lysins from bacteriophages to be used separately as antimicrobial agents. Holin and lysin are two proteins that allow
reproduced phages to exit the infected bacterial host cell.
The holin creates pores in the cytoplasmic membrane and
allows the endolysin to access the peptidoglycan in the cell
wall of the bacteria.This causes water to flow into the cell,
resulting in its rupture, and release of the replicated phages.
Because of their properties endolysins are being studied as
possible antimicrobial agents that when applied to pathogenic gram-positive bacteria attack the peptidoglycan and
lyse the cell wall (Pastagia, et. al. 2013).
Cell walls of S. aureus are primarily composed of peptidoglycan, teichoic acids, and different surface proteins.
Peptidoglycan is a structural polymer that is composed
of glycan chains of repeating N-acetylglucosamine and
N-acetylmuramic acid that are cross-linked with peptide
side chains (Vacek, et. al. 2020). Peptidoglycan hydrolases
are often specific to certain species and genera since
their peptidoglycan structures vary. Consequently, the
use of phage endolysins as antimicrobials can help provide
a targeted therapeutic approach, without killing unrelated
commensal bacteria. It could also be useful in avoiding

the use of broad range antibiotics which often cause the
development of resistance (Becker, et. al. 2009).
LysK
Phage endolysins are found to have two or three domains.
One or two N-terminal catalytic domains and a C-terminal
cell wall binding domain. LysK is an endolysin derived from
staphylococcal bacteriophage K, a phage that has proven
to kill a broad range of pathogenic staphylococci. LysK is
characterized as an endopeptidase, an enzyme that breaks
peptide bonds. It contains three domains, two N-terminal
catalytic domains, cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain, an amidase-2 domain,
and one c-terminal SH3B cell wall binding domain. LysK has
shown to have the ability to kill MRSA without permitting
bacterial resistance to develop.
In one specific study, researchers attempted to determine whether all three domains found on LysK were necessary for it to perform exolysis (lysis from outside the
cell). Analysis of their activity indicated that the CHAP
domain is sufficient for exolysis of S. aureus cells but it’s
activity was enhanced greatly when the SH3b domain was
present (Becker, et. al. 2009).
Researchers have cloned and expressed LysK in
Lactococcus lactis to test whether it can inhibit a range
of different staphylococci species including MRSA. Results
confirmed that the recombinant LysK had the ability to
degrade staphylococci cell walls. It was found to be active against a variety of live staphylococci, including MRSA
strains from Irish hospitals. Gram-positive bacterial strains
from other genera were not affected by the lysates containing LysK, suggesting that LysK is specific to staphylococcus.
These results suggest that LysK could have widespread
applications as a therapeutic agent against staphylococci
infections including MRSA (O’Flaherty, et. al. 2005).
CF-301
CF-301 is another example of a lysin that demonstrates
activity against S. aureus. In one particular study, CF-301’s
activity was examined alone and in combination with standard-of-care (SOC) antibiotics. It was tested in vitro against
laboratory and contemporary clinical strains of MRSA, and
in vivo against MRSA-induced murine bacteremia.
CF-301 killed S. Aureus rapidly both in vitro and in vivo.
Its rate of antimicrobial activity in vitro was found to be a
lot faster than that of the SOC antibiotics. CF-301 began
killing MRSA laboratory strains within 30 minutes in contrast to the antibiotics, which required six hours to reach
the same point. The same results were true when CF-301
was used to treat MRSA-induced mice. MRSA CFU (colony
forming unit) was tested in their blood prior to and post
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treatment.They found that after just 15 minutes there was
a large decrease in CFU and even more after an hour. This
rapid killing property of lysins makes them well suitable to
quickly reduce the bacterial load in infected hosts.
Aside from its activity alone, CF-301 exhibited synergy when combined with SOC antibiotics both in vitro
and in vivo. The synergy between the lysin and antibiotics
was assessed in three different ways. First with a timekill assay that studies the activity of antimicrobial agents
against bacteria over time. Two antibiotics, daptomycin,
and vancomycin were tested alone and in combination
with CF-301. Sub-MIC levels (minimal inhibitory concentration) of lysin demonstrated synergy with sub-MIC
levels of the two tested antibiotics. To confirm synergy, a
checkerboard assay was also used. When CF-301 treatment was combined with the two antibiotics it was more
effective at killing the majority of the tested MRSA strains
than when each treatment was used alone. A third method was used which further confirmed these findings by
showing that when in the presence of CF-301 the MIC
levels of the antibiotic majorly decreased.
Additionally, there was little to no resistance of S. aureus to CF-301 seen after treatment for 26 days, compared to high bacterial resistance of S. aureus to SOC
antibiotics which were 128 and 16 times the initial MIC.
When the two treatments were combined and MRSA
was treated with increasing concentrations of antibiotics in the presence of sub-MIC CF-301 for twenty-eight
days, there was only a 4- fold increase in their resistances.
These results demonstrate that the presence of the lysin
suppressed the formation of antibiotic resistance.
Mice with staphylococcal-induced bacteremia were
treated with CF-301 and daptomycin together and separately, in low and high challenge models. In some of the
studies, the lysin yielded a higher survival of the mice and
in others the antibiotics did, but, in all the cases the survival
rate yielded from the combination treatment significantly
outperformed the treatments with each of them alone.
These results can have clinical implications when designing new treatments using combinations of lysins and
antibiotics. Because CF-301 proved to act fast, it would
quickly reduce the burden of the pathogenic bacteria,
while the antibiotic would act on the remaining bacteria. Additionally, when the bacteria are exposed to small
amounts of lysin, which break the bonds of peptidoglycan,
it causes the bacterial structure to become more permeable which allows for the antibiotic to penetrate more
easily (Schuch, et. al. 2014).
Endolysins and Biofilm Eradication
S. Aureus forms biofilms within infected tissue which help
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them grow and survive in the presence of antibiotics and
the immune system. Biofilm infections tend to develop
in patients with prosthetic objects implanted into their
bodies. They are harder to treat than free-living bacteria,
and even more so biofilms of antibiotic-resistant pathogens such as MRSA (Chopra, et. al. 2015a). These biofilms
are difficult to destroy because of their altered metabolic
activity as well as the presence of an extracellular matrix
making them difficult to penetrate (Rani et al, 2007).
Researchers attempted to test the efficiency of phage
lysins in eradicating old and new biofilms formed by
MRSA, possessing or lacking ica-locus. Phage-borne endolysin MR-10 was tested alone and in conjunction with minocycline. First, both kinds of biofilms were treated with
endolysin MR-10 alone. They found that the optimum
concentrations for eradicating young ica-negative MRSA
biofilm was 18 g/ml, and for ica-positive MRSA biofilms,
36 g/ml. Here, the difference in intracellular adhesion
seemed to affect the optimum concentrations needed.
The effectiveness of any antimicrobial agent against
biofilms is largely determined by the age of the biofilm.
Young biofilm formed by ica-negative and positive MRSA
can be controlled by using the antibiotic minocycline
alone at high concentrations, however, once the biofilm
gets older the minocycline becomes ineffective (Chopra,
et. al. 2015b). Since any lysin concentration was ineffective
against completely eradicating mature biofilm, minocycline was used at its highest concentrations together with
endolysin MR-10, in an attempt to completely eradicate
the biofilm. No significant decreases were observed when
equal concentrations of endolysin MR-10 and minocycline were used. The researchers believe the reason for
this is because both agents worked together on the top
layers of the biofilm and did not reach the interior. It is
known that antibiotics are unable to penetrate deep into
biofilms because of their complex matrix structure, and
since lysins are one-use enzymes it’s possible that both
agents bound to the same cells resulting in little activity
against them.
To test this theory, the researchers studied if sequential
treatment of both page endolysin MR-10 and minocycline
would have positive results in eliminating older MRSA
biofilm. Two sequences were studied and each had different results. First, they exposed the biofilm to endolysin
MR-10 for six hours and then treated it overnight with
minocycline. A decrease in mature biofilm was observed
to some extent after being treated using this method.
However, when the biofilm was first treated which minocycline for three hours followed by endolysin MR-10
overnight there was a more significant decrease in cell
count of the mature biofilm.
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The reasons for these results are as follows. Antibiotic
can not penetrate the layers of the biofilm and is only
effective against the active cells so when the antibiotic
was used first it was able to kill the metabolically active
cells which are found at upper layers if the biofilm. Since
endolysins are effective against bacteria regardless of
their metabolic activity and have low molecular weights,
endolysin MR-10 was able to penetrate more effectively
into the deeper layers of the biofilm which the antibiotics
could not reach. This study provides important research
that lysins have the potential as an antimicrobial agents in
the eradication of MRSA biofilm. Its mode of action targets the bacteria peptidoglycan and does not require the
bacterial cells to be metabolically active which is unlike
antibiotics (Chopra, et. al. 2015b).
Truncated and Chimeric Endolysins
Because endolysins have modular structures, domains can
be swapped or removed to create newly combined lysins
that have altered catalytic activities and binding specificity.
Doing so can optimize different properties lysins have
and eliminate possible downsides such as low solubility
and poor expression in heterologous hosts.
CHAPk is a truncated single domain lysin that has been
used experimentally to eliminate S. aureus from the nostrils
of artificially infected mice. It demonstrated high solubility,
rapid lytic activity, and high specificity against S. aureus. A
single treatment with CHAPk greatly reduced the bacteria
after just one hour. Using this enzyme may be an effective
way to eliminate MRSA colonization in the human nares.
The human nostril is the most frequent carriage site
of S. aureus which often serves as a reservoir for the
spread of the pathogen. It had been found to play a vital
role in the development of S. aureus infections, particularly in immunocompromised patients. Because CHAPk
has the potential to quickly reduce the reservoir, it can be
valuable in the prevention and spread of life-threatening
MRSA infections. This is a property that is not found in
antibiotic topical treatments which often take a couple of
days to effectively remove S. aureus (Fenton, et. al. 2010).
In a different study, the catalytic domains of two highly
soluble E. faecalis phage endolysins were fused with the
c-terminal cell wall binding domain of the staphylococcal
phage endolysin, Lys87. Two different chimeric endolysins
were created in hopes to solve the problem of low solubility. The combined endolysins were able to efficiently
lyse 96% of the 143 S. aureus clinical isolates that were
tested. Included in the clinical isolates were strains of
MRSA that represented some of the most relevant MRSA
epidemic clones. The MRSA strains showed to be susceptible to both of the chimeric endolysins.

Aside from showing activity against Staphylococcus, the
combined endolysins showed a broadened lytic activity towards enterococcus as well. This demonstrates that engineering chimeric endolysins can be a good way of obtaining
soluble and highly effective peptidoglycan hydrolyses that
have a broad lytic spectrum (Fernandes, et. al. 2012).
Bacteriocins
Bacteriocins are antibacterial proteins produced by
non-pathogenic bacteria that inhibit the growth of closely
related bacterial strains (Farkas-Himsley, 1980).They have
relatively narrow spectra of antimicrobial activity due to
being directed primarily toward bacterial strains closely
related to their producing strain. Bacteriocins make up a
family of proteins comprised of many different types, each
exhibiting different properties (Hanchi, et. al. 2017).
Lysostaphin
Lysostaphin is a bacteriocin that is secreted by
Staphylococcus simulans, a gram-positive bacteria.
Lysostaphin possesses the ability to lyse a staphylococcus
bacterial cell by disrupting its peptidoglycan layer (Schindler,
Schuhardt, 1964). The major substrate for lysostaphin is
the pentaglycine interpeptide bridge (Bowder, et. al. 1965).
Since this is an obvious feature of the cell wall of S. aureus, lysostaphin can selectively target it, thereby killing the
bacteria. Lysostaphin cleaves the staphylococci cell wall
between two amino acids in the pentaglycine cross bridge.
By cleaving these amino acids the lysostaphin destabilizes
the bacterial cell wall causing a loss of osmotic equilibrium
which ruptures the cell (Zygmunt, et. al. 1972).
Purifying, as well as cloning the lysostaphin gene into
different expression systems has led to creating a highly
purified recombinant lysostaphin with high specific activity. The availability of this recombinant as a potential
antimicrobial agent against S. Aureus has become of interest as new methods are being researched to combat
bacterial resistance.
Durancin 61A is a bacteriocin produced by Enterococcus
durans which is also being studied as a possible treatment
against MRSA. It has been found to exhibit antibacterial
activity when tested in vitro (Hanchi, et. al. 2017).
Lysostaphin Antimicrobial Activity in Vivo
Multiple studies have researched the use of recombinant
lysostaphin in treating S. aureus. One experiment tested
its ability to treat S. aureus-induced infections in mice.
It was found that administering 5mg/kg of lysostaphin
once a day for three days successfully cleared their
kidney infections caused by MRSA and significantly reduced their liver and spleen infections.This demonstrates
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lysostaphin’s ability to penetrate tissue when administered intravenously. Compared to a higher dose treatment over one day, repeated administration of a lower
dose of lysostaphin was found to be more effective for
the treatment of S. aureus (Kokai-Kun, et. al. 2007).
S. aureus is a leading cause of bacterial keratitis which
can result in irreversible damage, e.g. a loss of visual acuity
or even complete blindness. Keratitis is normally treated
with a topical treatment of antibiotics, such as ciprofloxacin, however more and more MRSA strains have become
resistant to it. Lysostaphin was used experimentally to
treat bacterial keratitis in rabbits against vancomycin, an
antibiotic used to treat MRSA infections. Results demonstrate that lysostaphin is an effective treatment for experimental keratitis caused by S. aureus.
Minimal inhibitory concentrations of lysostaphin were
determined for multiple strains of MRSA and were found
to be many times lower than the MIC’s of vancomycin. In
addition, Lysostaphin successfully sterilized the rabbit corneas when treated early on in the infection, compared to
vancomycin which did not completely sterilize them.When
treated later on in infection, although lysostaphin did not
completely sterilize the corneas, it reduced the CFU (colony forming unit) per cornea more than the vancomycin
therapy did when used to treat early in the infection.
Just like endolysins, bacteriocins share the property
remaining effective regardless of the metabolic status of
the bacterial cells. They can kill both rapidly growing cells
as well as non-dividing cells. Through experimentation,
lysostaphin proved to be an effective therapy during the
late stages of the staphylococcal infection when there is
minimal bacterial replication. This gives bacteriocins an
advantage over most antibiotics to which this is an unusual characteristic.
Infected eyes that were treated were found to be free
of detectible pathological changes after being observed
for seven days. Lysostaphin did not cause any conjunctival inflammation or corneal edema as did vancomycin. However, further studies are needed to determine
whether there are any adverse effects caused by repeated uses of topical lysostaphin since it has the potential
to cause an immune response against itself. The availability of recombinant lysostaphin can help with this issue
(Dajcs, et. al. 2000).
Bacteriocin Combination Treatments
Studies have shown that there is a synergistic effect
between lysostaphin and antibiotics. When lysostaphin
was experimentally used with oxacillin to treat MRSA in
vivo it improved its efficiency and allowed for a lower
therapeutic dose to be used. Treatment with this method
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would also be beneficial in preventing the emergence of
S. aureus that is resistant to lysostaphin (Kokai-Kun, et.
al. 2007).
Researchers have also attempted to combine the treatment of lysostaphin with endolysin LysK. They did so by
combining enzymes consisting of both the catalytic domains of LysK and Lysostaphin to treat infections. An experiment that combined the two enzymes demonstrated
greater growth inhibition of MRSA then each enzyme
showed alone (Becker, et. al. 2009).
Synergy between durancin 61A and vancomycin was
observed in inhibition of growth of S. aureus ATCC
700699, a methicillin-resistant staphylococcus strain. By
combining the two, each of their MIC levels were reduced drastically (Hanchi, et. al. 2017).
Conclusion
As antibiotic resistance continues to become a more
prevalent medical concern, scientists are constantly searching for new effective antimicrobial therapies.
Research and experimentation suggest that enzybiotics
may serve as possible solutions for combating multi-drug
resistant bacteria and particularly for the treatment of
MRSA. Each area of enzybiotics provides different advantages over antibiotics, however possible downsides need
to be taken into account.
Phage lysins seem to be a favorable way of combating
MRSA infections. Their speed of bactericidal activity, low
probability of affecting normal flora, as well as the small
chances of bacterial resistance, gives endolysins an advantage over traditional antibiotics. Additionally, the use
of phage lysins incorporates all the positive aspects of
phage therapy without the negative possibility of creating
resistant mutations.
Utilizing combination treatments of enzybiotics along
with antibiotics is another effective method of combating
MRSA. When tested, combination treatments tended to
be synergistic and showed the greatest results for killing MRSA than when each therapy was used alone. Each
therapy provides its own mechanism of action, so when
used together, each provides its specific capability’s to effectively combat the bacterial infection.
Despite the growing potential of enzybiotics, further
research must be conducted as well as implementing enzybiotics into clinical trials in order to establish enzybiotics as a tried and true therapeutic option for combating
MRSA infections.
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Abstract
The physiological effects of early childhood dance training are constantly being explored and adjusted. It was observed that children in training experience a higher than normal percentage of delayed maturation, both in puberty and bone development. It was
suggested that the environmental conditions in which dancers practice, such as malnutrition and too much time spent indoors, as
well as biological factors, contribute to the hormonal and cellular disruptions responsible for late development. Undernourishment,
as is common in dancers, was found to have a direct correlation with reproductive hormone levels, including reduction in gonadotropin-releasing hormone secretion as well as lower Luteinizing hormone and Follicle-stimulating hormone levels. Low energy
availability due to overexertion also plays a role in pubertal development. Furthermore,Vitamin D deficiency from lack of sunlight
seems to influence dancers’ bone health and development.This paper aims to present some abnormalities in dancers’ growth and
development, as well as explore the physiological, hormonal, and metabolic reasoning behind such a phenomenon.
Introduction
The universally practiced form of dance, known as ballet, is learned and taught by many in today’s world. The
biological consequences that follow those who practice
it, however, may be hiding beneath the surface. In the
United States today 650,000 to 10,400,000 young girls
and boys in the United States study ballet in a professional dance studio. Of these students, 9,000 to 45,000 of
them move on to higher education in dance training after
that (Bronner, et. al. 1999). Considering the prevalence of
dance in American children today, one must examine the
effects, short term and long term, that intensive training has on the dancer’s biological functioning. One of the
major areas impacted by ballet training is the development and maturation into puberty. Perhaps the strenuous
physical exertion and specific unnatural positioning of the
body that ballet training often requires causes some form
of malfunction in the onset of menarche, bone development, and general maturation of the body into adulthood.
Discussion
For females, puberty hits most commonly around the age
of 12.This means a young girl will begin to experience many
changes involving hormonal activity resulting in the development of secondary female characteristics and the start
of menstruation. The two main hormones responsible for
regulating the menstrual cycle are the Follicle Stimulating
Hormone (FSH) and the Luteinizing Hormone (LH). FSH
is released by the pituitary gland which then stimulates
the ovaries to release estrogen into the bloodstream and
stimulates the formation of the ovarian follicle. LH, also
released from the pituitary, then takes over and encourages egg maturation and triggers ovulation, the release of
the oocyte from the ovary. Low levels of LH specifically
can be the result of nutrition disorders such as bulimia
and anorexia. Since the ballet world encourages a thin
figure, many students suffer from eating disorders leading
to delayed reproductive development.
A major factor that contributes to delayed menarche
and sexual development has to do with energy dispersal,
specifically low energy availability. The body needs energy
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in order to start the process of the various developmental cycles. However, when one is overexerting oneself and
therefore using more energy than the body has readily
available, it uses up energy required for physical maturation. This does not necessarily relate to the amount of
calories one burns when doing physical activity, but rather
to the amount that the subject is pushing him or herself
beyond the body’s normal limits. This applies to children
in professional training courses, who generally practice
for at least 50 hours a week, as well as other sports that
require intensive professional level training (Rigby 2012).
However, ballet training specifically causes females to experience delayed development. Late maturation is defined
as a girl who has not shown signs of secondary sexual
characteristics by the age of 14 or has not begun menstruating by the age of 16 (Kapczuk 2017). Researchers
revealed that the main hormone related to malfunction in
the reproductive system is GnRH (gonadotropin-releasing hormone). When the secretion of GnRH is disrupted,
LH cannot be released and therefore the regulation of
the reproductive cycle is disturbed. A later study revealed
that kisspeptin, a hormone directly related to metabolic
functioning and nutrition, was discovered to be a positive
regulator of GnRH. Undernourishment and low energy
availability, as is common in most professional dancers,
reduce kisspeptin production. This in-turn, causes a decrease in GnRH secretion, which slows down the entire
chain of hormonal reactions that regulate the reproductive functions. An experiment demonstrated that due to a
lack of sufficient energy, a group of female dancers experienced delayed menarche. Although proper sexual functioning returned after a break in their training or once
they significantly reduced their training time, amenorrhea,
or complete lack of menstruation, returned as soon as
they restarted heavy physical activity. This study utilized
the concept of energy monitoring in the brain. When
there is a lack of metabolic nutrition in the brain, it needs
to balance the energy among the areas in the most immediate need of energy, such as the large amount of energy
used to fuel the performance of grueling dance exercises
(Frisch, et al.) This takes away from energy needed for
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healthy menarche development and can therefore lead to
delayed onset as well as recurring amenorrhea once the
high performance activity is reinstituted (Iwas, et.al 2018).
Besides the obvious effects that reproductive hormones have on adolescent maturation, other parts of
the endocrine system can influence changes within the
reproductive cycles as well. Stress hormones, mainly cortisol, have been shown to play a crucial role in delaying
puberty. A group of carp fish who were exposed to extreme changes in water temperature three times a week
and successively exhibited a delay in sexual development.
Later, researchers assumed this was due to the cortisol
released in the carp under stress-inducing conditions.
Another experiment was executed in which one group of
carp was injected with high concentrations of cortisol and
the other group had their cortisol regulators “switched
off”.While the second group developed normally, the first
group showed signs of delayed development of reproductive organs. This confirmed that high levels of stress,
indicated by the increase in cortisol production, directly
impact proper onset of puberty (Allsworth et. al. 2007).
A later study in 2002 tested this theory with human beings.The experiment studied 446 women under the age of
45 who were incarcerated. Many of these women in prison
had suffered from highly stressful situations in their lives,
including sexual abuse, stressful living conditions, or a parent who was incarcerated. Nine percent of this population
of women reported amenorrhea, and 33 percent reported
irregularity in their menstrual cycle. Most of the subjects
had experienced some stressor or trauma as a child. The
conclusion drawn from this study was that incarcerated
women are more likely to exhibit irregularity in their menses cycle, which may specifically relate to the high levels of
stress that the subjects faced (Thompson).
Considering the fact that young ballet dancers, as
well as any child dance training professionally, is subject
to a great amount of pressure, whether it be from the
parents, the competitive nature of the dance world, or
self-induced pressure to perform well, one can conclude
that they experience high levels of stress. Recent surveys
have shown that professional dancers are more likely to
have a psychological stress disorder such as PTSD; 22%
percent of dancers showed signs of PTSD as opposed to
the average population of which 7 percent have PTSD.
Stressful conditions cause the body to react in ways that
then prevent the proper reproductive functions from occurring (Munoz 2004).
Another point to consider is the effects vitamin D levels
have on the body. The sun is the main source of Vitamin D,
and considering the fact that dancers spend a great deal
indoors, it is reasonable to suggest that they may be lacking

in vitamin D. Many young dancers are also undernourished,
and therefore have a deficiency in many key nutrients, including Vitamin D. Vitamin D plays a major role in bone
strength and development. It is involved in regulating intestinal calcium absorption and calcium resorption in the
bone. Therefore, when there is Vitamin D deficiency, calcium absorption from the intestines is significantly decreased,
which in turn stimulates osteoclast production, causing the
bone to break down. Osteoclasts also release enzymes to
break down the bone matrix, allowing the mobilization of
calcium from the bone into the body’s circulation.Without
Vitamin D, the calcium levels in the bone and body, in general, are not sustained, and calcium begins to consistently
leave the skeletal system. If this cycle of bone degradation
occurs during the years of childhood development, the
bone does not have a chance to be nourished and may not
form properly (Mathews, et. al. 2006).
The female athlete triad has become the common term
used in reference to the top three disorders in female
athletes: eating disorders, amenorrhea, and osteoporosis.
While the first two are most well-known in women who
play all kinds of sports, osteoporosis is most commonly
associated with dance-related activity, specifically ballet.
Osteoporosis is directly related to one’s bone mass density (BMD), since osteoporotic bones are characterized
by a loss in bone density and exist as brittle networks
with many holes in the bone’s structure.
Bone density may be another element of maturation
that is possibly delayed by early dance lessons. On the
one hand, it seems that high-impact weight-bearing
sports, such as football and hockey, are beneficial for
bone strength. This type of activity has been shown to
increase bone mass, bone density, and bone turnover, and
therefore can help prevent osteoporosis later in life. This
is because the tension from the muscles and tendons surrounding the bone force the bone to produce more tissue
and build up bone mass and in turn increase bone health.
These types of activities such as running, weight lifting,
jumping rope, and strength training (i.e. push-ups etc.) involve working the body against gravity. However, the positioning and delicate movements required in ballet training
seem to not be conducive for bone mass augmentation. In
fact, many professionally-training dancers have reported
experiencing osteopenia earlier than normal. Osteopenia,
or the gradual loss of bone mass, typically begins around
age 35, and is a healthy phenomenon when developed
at the normal rate (as opposed to osteoporosis, which
is more severe). Premature loss of bone mass appeared
to be common in dancers. However, this may be due to
the fact the professional dancer figure, typically one of a
thin woman is prone to brittle and weak bones (Mathews
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et. al. 2006). Furthermore, one might argue that although
ballet is not generally classified as a weight-bearing sport,
certain key leaping movements, such as grande je tes and
entrechats, studied in the field of ballet mimic the gravity-defying activities of standard high impact sports. This
could likely cause an increase in bone density and balance
out any bone loss caused by low BMI or unnatural twisting of the limbs that grind away at the joints. In fact, a
recent 3 year long longitudinal study has shown that prepubertal dancers do experience bone mass augmentation
in certain areas of the body, most significantly in the femoral neck and lumbar spine regions. The hip flexors and
abdominal muscles are the muscles most often used in
ballet and likely put pressure on the femoral neck and lateral lumbar spine areas increasing bone tissue and bone
mineral content. The subjects, however, demonstrated
that the other upper extremities had not built up a significant level of bone mass when compared with the control
group, suggesting that the increased BMD in the abdomen
and legs were solely because of the greater weight bearing activity in those parts of the body (Turner, et. al. 2012).
While this seems to support the claim that dancing can in
fact improve bone strength and development, it is unclear
from the ramifications of the study if the increased BMD
was a direct result of the subjects’ dance training. Being
that the dancers ranged from ages 11-14, the bone mass
augmentation could have been related to their pubertal
growth spurts, in which exponential growth in the hip
and leg area often occurs, as opposed to their training.
Therefore, the reason behind early osteopenia and osteoporosis in dancers has yet to be completely clarified.
One specific dance move commonly referred to as
“turn-out”, refers to the total outward rotation of the
hips required at all times during classical ballet training.
Considering this isn’t the natural state for one’s hips to be
in, this repeated movement often causes pain and degeneration in the pelvic-femoral joint. Turn-out movement
can cause dysplasia to develop in the ball-and-socket hip
joint so that the two bones don’t fit together as they
should; specifically the acetabulum socket of the pelvis
and the femoral head are misaligned. Over time a dancer may begin to feel pain and deterioration. Studies have
observed that ballerinas will ironically lose full range of
motion, namely internal rotation and adduction, caused
by overuse of the external rotator muscles (Storm, et. al
2018). Additionally, a group of 11-14 year old ballerinas
were observed and shown to have a significant decrease
in femoral torsion. Many of the dancers were observed to
have labral tears, in which the labrum cartilage surrounding the hip joint ripped (Hamilton, et. al. 2006) .
While the effects of dance training on maturation and
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body health generally seem to be negative, some researchers have suggested there to be some positive effects as well. A study was conducted involving a group of
dancers who were rehearsing ballet 10 hours a day over
a 17 week period leading up to a professional competition.The study observed girls between the ages of 12 and
15 and attempted to monitor the impacts such training
might have on the cardiac autonomic system, puberty,
biochemical variabilities, as well as body mass changes.
The subjects were tested before and after the 17 week
period, and were found to have an increase in body mass,
total protein production, and testosterone and cortisol
levels. To measure the effects on the autonomic system,
the subjects’ heart rate variability (HRV) was observed
pre and post training and overall higher HRVs were observed after completing the training period (Da Silva, et.
al. 2015). Scientists compared this to a previous study that
displayed significant improvement in HRV in 16 year old
male gymnasts, as well as other studies which showed
increased HRV in prepubertal swimmers (Tomova, et. al.
2015)). While this could possibly support the idea that
intense physical exertion could improve autonomic performance, it doesn’t necessarily take into account other
factors that may play a role in the 17 week dance training
study specifically. The two studies used as support evidence involved either post pubertal (or at the very least,
the tail-end of adolescent maturation), and prepubertal
subjects. The dance group experiment, however, was
aimed to specifically examine the physiological effects on
12-15 year old girls, in the prime of pubertal maturation.
The hormonal changes and increased growth rate that
happens during these years may contribute to increased
HRV and general fluctuations in the autonomic system.
Furthermore, this could also explain the results showing
increased body mass and height over the training period.
One must consider that the subjects could have likely
been in the middle of a growth spurt common to that age
group, as well as experienced a general increase in body
mass. Perhaps dance training augmented these factors,
but there is no specific evidence of such reasoning, especially since this experiment included no control group.
Moreover, the study’s results also showed that while
body mass increased, the BMI for their age group declined
as they continued to train. A dancer’s body mass index
(BMI) also relates to their delayed development. Studies
found that as BMI decreases, the first onset of menarche
increases. Since it is common for dancers to have a below
average BMI, many will experience their first menses at a
later age, demonstrating delayed development (Tomova
et. al. 2015). A 2014 study observed 4030 boys from ages
7 to 19 and found that their BMI was directly related to
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the timing of puberty onset.The overweight group generally experienced early puberty compared to the normal
group, and underweight boys demonstrated a delay in
every stage of development (Natural Institute of General
Medical Sciences).
Pubertal and specifically menstrual disruption is also
commonly caused by a disturbance in one’s circadian
rhythm. Many young dancers train for numerous hours a
day, getting up before dawn and leaving after the sun has
already set and spending all those hours in between in a
fluorescently lit studio with mirrors instead of windows.
This means their body may not be getting enough light
stimuli during the day to keep their inner clocks balanced.
The circadian rhythm is how the body regulates sleep
and alertness based on light stimuli from the surrounding
environment. It is a network involving communication between certain parts of the DNA, such as the Period and
Cryptochrome genes, and various proteins.These specific
genes code for proteins that play a major role in building
and nourishing the nucleus in nerve cells while one sleeps.
This genetic activity is significantly reduced in the daytime
while one is awake. The main “clock” which regulates the
body’s circadian rhythm is the suprachiasmatic nucleus
(SCN), referring to a group of 20,000 neurons located in
the hypothalamus.This bundle of nerve cells receives light
input directly from the eyes stimulating the brain to signal
and inform the rest of the body as to what time of day
it is (Reilly 2000). When such a regulation system is disturbed, such as spending too much time indoors without
windows or having long work hours beyond the body’s
natural circadian clock, the body can react in many ways.
One side effect observed was amenorrea. The circadian
rhythm was found to have an inhibitory effect on luteinizing hormone production, causing there to be a shorter
luteal phase in the menstrual cycle, and ultimately leading
to amenorrhea. Studies have shown that dancers, flight attendants, and anyone who often experiences quick changes in time zones commonly display disturbances in their
hormonal and menstrual cycles (Zhu, et. al. 2020). While
the job description of a professionally-training dancer
may not include an abnormal night/day schedule such as
stewardess or world travelers, it is implicit in the method
of training to practice all day in a studio with no access to
sunlight and admittedly disturbing their circadian rhythms
(Turner, et al. 2012).
Some treatments have been explored as to how best
to prevent and treat dancers with delayed maturation.
The idea of sex-steroid therapy is a common approach
to late onset of puberty. These steroids influence the
hypothalamus and pituitary gland to secrete growth hormones and initiate secretion of reproductive hormones.

This helps individuals with low GnRH, LH, and FSH levels
to mature and to be fertile in the future. An assessment
involving a group of health providers revealed that 83
percent of the providers agreed that sex-steroid therapy
could jump-start puberty in adolescents experiencing a
delay in that area. Other providers have suggested that
a method known as “watchful waiting” is ideal, in which
continued observation of the subject occurs (Zhu, et al.
2020). However, this proposition may not be aggressive
enough, considering how time sensitive the onset of puberty is. A doctor might be careful tracking a patient’s
development and decide not to introduce medication or
therapy since the patient is progressing, albeit slowly. At
the point in which the rate of growth is understood to
not be improving further, it may be too late. There are
also preventative courses of action that can be implemented to lessen the negative conditions that allow delayed puberty to occur. Since malnutrition is so common
in dancers, having children eat a balanced diet with plenty
of high energy foods is key to avoiding eating disorders
and low energy availability. One way to counteract the
negative effects of too much time spent indoors could be
to instigate light therapy.This requires the subject to sit in
front of a light box that emits UV rays, helping the body
sleep better and experience a more consistent circadian
rhythm. Vitamin D supplements can also be taken to support the buildup of bone and retain calcium levels in the
skeletal system.
Conclusion
Conclusively, the physiological effects that intensive dance
training has on the growing body must be carefully considered. While ultimately it is up to each individual to decide if dance training is worth all the biological long term
risks, there are clearly many signs that point to negative
impacts in the areas of maturation, bone development,
and onset of puberty. However, one must take into account that each individual has pre-existing conditions and
physiological circumstances which may influence how
significantly dance plays a role. There are still many areas
in which more research must be done to clarify the direct correlations between dance and development, and
doctors and researchers today still strive to get a deeper
understanding of this phenomenon.
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Abstract
Spina bifida is one of the most common NTD’s (neural tube defects) to occur during embryonic development, when the neural
tube fails to close properly during neurulation.
Myelomeningocele is the most severe form of spina bifida. Characterized by an open posterior neuropore with meninges and parts
of the spinal cord protruding from the fetus’s body, it manifests in a variety of physical and neurological symptoms that vary both
by the individual and by the state of the lesion. Until the late 1990’s, the standard course of treatment was surgical closure of the
lesion at birth, followed by standard protocols and treatments to treat the accompanying issues. However, once the first in-utero
repair of myelomeningocele was performed in 1997, a new world of possibilities opened up. In-utero repair demonstrated distinct
advantages over the standard method of postnatal repair; specifically, it reduced the likelihood of hydrocephalus and hindbrain
herniation and showed significant improvement in motor and neurological function.This paper will discuss, analyze, and compare
the outcomes of both the prenatal and postnatal methods of repair and discuss emerging research in the field as well as some
of the inherent risks of the procedure.
Introduction
Fetal development, with all its extraordinary inner workings, is considered by many to be one of the most remarkable miracles of life—yet the more intricate processes
involved, the greater the potential for damage. Neural
tube defects, or NTD’s, are among the possible disorders
in fetal development, the most common of which are anencephaly and spina bifida. Spina bifida, in turn, is one of
the most widespread birth defects, as well as the most
common congenital defect of the central nervous system
that is actually compatible with life (Adzick et al., 2013).
As such, it is the focus of much study and intervention.
Spina bifida is characterized by an open vertebral column. In its least severe form, spina bifida occulta, the gap
is merely a gap in the vertebral arches. It does not impair functioning and may never even be discovered. The
most severe form of spina bifida, though, and the focus
of this review, is spina bifida aperta, or open spina bifida. Commonly referred to as myelomeningocele, this is a
form of spina bifida where the neural tube itself fails to
close during neurulation. In cases like these, neural tissue
from the spinal cord and meninges are pushed through
the open vertebral arches, muscle, and skin into a sac
of cerebrospinal fluid protruding from the fetus’s body
(Sacco et al., 2019).
The exposed neural tissue, in turn, degenerates further
with increased exposure to the intrauterine environment.
Thus, myelomeningocele is often considered a “two-hit”
process, as damage occurs first due to the open neural
tube and secondly, and more progressively, due to prolonged exposure of the neural tissue to the amniotic
fluid environment. Based on the severity of the defect,
the infant will be afflicted with lifelong disabilities such as
impaired bladder and bowel function, paralysis, and neurological deficits, and will be at risk for hydrocephalus and
hindbrain herniation (Copp et el., 2015).
The etiology is not fully understood, especially considering the various types of spina bifida; various factors are

often at play in such a situation. It is understood, however,
that the predominant cause of spina bifida worldwide is
insufficient blood folate concentrations among women of
childbearing age (Oakley, 2020) – a problem easily preventable in many cases, though folate intake is not a cure-all.
Up until the late 1990’s, myelomeningocele was repaired postnatally: the defect was surgically closed at
birth and the various associated health issues managed
with standard medical procedures and therapies. In 1997,
though, the first successful in-utero repair of myelomeningocele was performed, which paved the way for many
more successful prenatal surgeries. Prenatal repair of myelomeningocele exhibits several distinct advantages over
standard postnatal repair; chiefly, the fact that it actively
reduces the need for shunting for hydrocephalus and results in better mental and motor function at 30 months
of age (Adzick et al., 2013).
As miraculous as it may seem, prenatal surgery still
comes with its own set of risks.This paper will discuss the
current methods of treating myelomeningocele as well as
examine new research and modern advances in the field,
and evaluate the risks involved to the best course of action regarding myelomeningocele repair.
Methods
The articles and journals used in this review were found
mostly on ProQuest, PubMed, and the National Institute
of Health. Among the key phrases used were “spina bifida,”
“myelomeningocele,” “in-utero repair,” “stem cell therapy,”
and “folic acid.”
Discussion of Spina Bifida
In a normally developing embryo, primary neurulation begins at the beginning of the third week of gestation. This
process is characterized by the formation of the neural
plate, a thickened portion of ectoderm—the very beginning of the central nervous system. Through cell division
and cell migration, the neural groove is formed in the
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center of the neural plate while the sides of the plate form
the neural folds. These folds rise, come together, and fuse
to form the neural tube; closure begins in the cervical region and extends both cranially and caudally. By the end of
the fourth week of gestation, the neural tube is closed and
primary neurulation is complete (Fichter et al., 2008.
The problem arises when the neural tube fails to
close properly. Researchers are still uncertain as to what
precisely causes this to happen, but what is clear is the
outcome: an open posterior neuropore. The end result,
therefore, is a neural tube defect characterized by an
open vertebral arch and open meninges, fused to the
skin, that forms a sac containing parts of the spinal cord
(Fichter et al., 2005).
Individuals with spina bifida may experience a multitude of
difficulties in various aspects of life—specifically with regard
to mobility, though much of it is dependent upon the severity and location of the lesion. Though lower limb weakness,
lack of sensation, or paralysis below the level of the lesion
are frequent, many individuals do achieve independent ambulation as adults, approximately 57% with an L4 lesion and
as many as 93% with a sacral lesion (Sacco et al., 2019).
Bladder and bowel dysfunction are common secondary
conditions of spina bifida; these are normally managed
with catheterization, enemas, laxatives, and the like. Some
experience sexual dysfunction as well, specifically with
regard to erectile dysfunction in men. In addition, leakage of cerebrospinal fluid through the spinal lesion often
causes brain changes such as the Chiari II malformation
which causes hindbrain herniation.The herniation impairs
development of the cerebrospinal fluid pathways in the
brain; this causes hydrocephalus, or a buildup of excess
fluid. Hydrocephalus is typically managed with a ventriculoperitoneal shunt, though shunt complications may and
do occur (Sacco 2019).
Moreover, children with spina bifida often have significant medical expenses as well as learning disabilities
and lower IQ’s than average, and many cannot live independently as adults (Adzick, 2013).
Historical Background
In the early 1970’s, the advent of prenatal biochemical
screening techniques first made it possible to diagnose
neural tube defects such as spina bifida; the presence of
alpha-fetoprotein (AFP) in a sample of blood or amniotic
fluid was a good indicator. As the use of ultrasound technology to detect anomalies became more widespread,
the use of biochemical screening techniques, though still
useful in some cases, became less relevant, since sonograms are more accurate and specific (Copp et al., 2015).
Still now, the standard traditional treatment for
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myelomeningocele is postnatal repair and closure of the
defect within two days after birth. Among other reasons,
this helps avoid the risk of the open wound leading to
an infection that can cause meningitis (Copp et al.,
2015). The treatment includes the placement of a ventriculoperitoneal shunt to treat the hydrocephalus that
will probably occur (Grivell, RM; Andersen, C; Dodd, JM,
2014). The shunt drains the excess fluid from the brain
into the peritoneal cavity and needs lifelong monitoring
(Adzick et al, 2013).
The main argument for in-utero repair of myelomeningocele can be made as follows. The “two-hit hypothesis”
(Joyeux et al., 2018) states that a good deal of the damage caused by myelomeningocele is not due to a failure
in neurulation. Rather, the development of neurological
damage is progressive; that is to say, exposure of the neural tissue to the amniotic fluid in the intrauterine environment, as well as other mechanical damage, serves to
exacerbate the issue and is responsible for much of the
loss of function (Fichter et al., 2008). As a result of exposure to the toxicity of the amniotic fluid, the exposed spinal cord may hemorrhage and neural connections may be
interrupted, leading to neural death (Copp et al., 2015).
This hypothesis is supported by observations such as in
cases where spontaneous leg movement was observed
early on during a pregnancy, and the same leg was seen to
be paralyzed or deformed later on (Grivell et al., 2014).
In-utero surgical closure of the lesion, while unable to
completely repair the condition, goes a long way toward
preventing further damage and worsening an already unfortunate situation.
MOMS Trial
In 1997, the first in-utero myelomeningocele repair by
uterine hysterotomy was performed; by 2003, more than
200 fetuses had undergone the surgery (Adzick et al.,
2013). However, its efficacy was not yet proven. In 2003,
the MOMS Trial, or Management of Myelomeningocele
Study, was started; this was a randomized controlled
trial aimed at investigating and comparing the outcomes
of prenatal vs postnatal repair of myelomeningocele
(Kabagambe et al., 2017).
The trial was conducted at three maternal-fetal surgery centers in the United States and went on for seven
years (Grivell et al., 2014). The standardized procedure
across all three maternal-fetal centers included a maternal laparotomy and stapled hysterotomy; the neurosurgical repair of the lesion was performed as it would have
been postnatally (Sacco et al., 2019).
The trial was evaluated for two main outcomes, at 12
and 30 months of age. At 12 months, patients underwent

What Is the Safest and Most Effective Method of Repairing Myelomeningocele?

radiography and magnetic resonance imaging to determine the current state of the lesion. The outcome was
based firstly on the patients surviving past birth and infancy, as well as the need for a shunt. At 30 months of age
the babies were evaluated once more and given scores of
infant development, specifically with regard to motor and
mental development, while adjusting for the anatomical
level of the lesion (Adzick et al., 2013).
The overall results were arguably and overwhelmingly in favor of the prenatal procedure. In-utero repair of
the lesion reduced the need for a ventriculoperitoneal
shunt by almost half and drastically improved the rate
of hindbrain herniation (Sacco et al., 2019). The patients
who underwent in-utero repair also demonstrated substantially better motor skills at 30 months of age—and
this was despite the fact that the lesions in the prenatal
group were, on average, worse than those in the postnatal
group (Copp et al., 2015).
The MOMS Trial was the first of its kind, but it paved
the way for other similar non-randomized studies in the
years to come, many of which reported similar shortterm outcomes. In addition, it was found that in cases
where the procedure was performed at an earlier gestational age, the risk of chorioamniotic membrane separation, premature rupture of membranes, and premature
birth increased. Therefore, it is now recommended that
the procedure should not be performed before 23 weeks
of gestation (Sacco et al., 2019).
New Research
In-utero closure of myelomeningocele goes a long way
towards reducing spina bifida related challenges, but what
it cannot do is reverse the neurological damage that has
already been done. A promising course of treatment may
lie in the field of stem cell therapy, which when used in
conjunction with the standard course of treatment aims
to improve neurological function by facilitating spinal cord
regeneration and even seeking to prevent the damage in
the first place (Biancotti et al., 2020.)
Type 1 stem cell therapies, which are capable of replacing damaged tissue, seem not to be the answer in the
case of prenatal spina bifida repair; the ultimate goal here
is to prevent the tissue from becoming damaged in the
first place, and while regeneration of damaged tissue is
certainly useful, it is only helpful after the fact.
Type 2 therapies, on the other hand, create an environment of protection and can minimize damage to
the developing spinal cord. These therapies show more
promise for in-utero treatment of spina bifida in the long
run, because they seek to prevent the damage from ever
happening at all (Long, C; Lankford, L; Wang, A., 2019).

Experimental results, specifically with rodent and ovine
models, have already shown potential for great change. One
study experimented with five different types of stem cells:
human embryonic stem cells, neural stem cells, induced
pluripotent stem cells, human amniotic fluid stem cells, and
mesenchymal stem cells. The results indicated that mesenchymal stem cells were the best candidate for myelomeningocele repair because they were easy to obtain in large
amounts, they could enable recovery from spinal cord injuries, and they demonstrated the biggest improvement in
motor function (Dugas et al., 2020). Additionally, bone marrow-derived mesenchymal stem cells have the ability to
specifically differentiate into the various types of defective
tissue, and they were found to induce skin repair in fetuses,
reducing the skin lesion area by almost 30%. Transamniotic
fluid injection was found to be the most effective method
of delivering stem cells (Wei et al., 2020).
However, the use of animal models has its shortcomings: the size of fetal rats and other small rodents
presents difficulties in reliably and accurately performing
in-utero repair.There is a risk of postoperative death, and
often they do not survive long enough postnatally to examine the results properly. Larger animals have the added
concern of being too expensive to work with regularly
(Biancotti et al., 2020).
As of now, stem cell therapies for NTD’s, specifically for myelomeningocele, are still in experimental stages; there have
not been any human test subjects yet. However, promise for
great change seems to lie in this relatively new field.
Maternal Mortality/Risks
As with any surgical procedure, in-utero repair of myelomeningocele carries inherent risks for both the mother
and the fetus simply by virtue of opening the mother’s
abdomen and uterus mid-pregnancy (Grivell et al., 2014).
Possible obstetrical complications associated with the procedure include placental abruption, oligohydramnios, and
chorioamniotic membrane separation, as well as the risk
of premature rupture of membranes and preterm delivery
(Kabagambe et al., 2017).The risk of pulmonary edema and
the need for a blood transfusion at birth was slightly higher
in the prenatal group as well (Sacco et al., 2019). The average delivery in the prenatal group was 34 weeks while the
average delivery in the postnatal group was at 37 weeks.
Additionally, 25% of the women in the MOMS trial experienced thinning and partial or complete tissue edge
separation at the hysterotomy site, though none experienced a complete hysterotomy rupture. There were no
deaths, but the side effects show that the procedure is
not without its risks (Copp et al, 2015).
Because of this, it was necessary for the MOMS trial to
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implement strict guidelines regarding maternal health prior
to the procedure. Among the requirements for participation were a singleton pregnancy, a gestational age of 19-26
weeks, and myelomeningocele of particular severity as well
as evidence of hindbrain herniation. Mothers had to be at
least eighteen years of age and United States citizens, as
well as have no contraindications for surgery (Adzick et
al., 2013). Over the years, the MOMS trial criteria became
standard, and most maternal-fetal research centers offering
the procedure still use these criteria to determine eligibility
for surgery (though some centers will not consider a body
mass index of over 40 or carefully managed diabetes to be
contraindications for the procedure) (Sacco et al., 2019).
Prevention
Both genetic and non-genetic causes play a role when it
comes to spina bifida, or neural tube defects in general. In
most instances, the cases are sporadic and do not occur
in conjunction with any other syndrome, though in an
approximate 10-20% of the cases the NTD is associated
with a chromosomal abnormality such as trisomy 13 or
18 (Copp et al., 2015).
Maternal obesity and diabetes as well as certain anticonvulsant drugs have been shown to contribute to
NTD’s (Fichter et al., 2005), but the role of folic acid has
been the most widely investigated (Sacco et al., 2019).
Folate deficiency among women of childbearing age is
currently the best-known non-genetic cause of neural
tube defects (Copp et al., 2015). Therefore, the World
Health Organization currently recommends that women
take a supplement of 400 µg of folic acid daily from before
they conceive until 12 weeks gestation (Sacco et al., 2019);
however, many women do not keep to these guidelines,
which has led some countries to implement mandatory
folate fortification of certain basic food staples. In 2017,
for instance, 59 countries mandated fortification of wheat
and maize flour with folate, and the incidence of spina bifida that year was significantly reduced Sacco et al., 2019).
According to Oakley, every country should mandate
fortification of food staples such as rice and flour with
folate to decrease to frequency of spina bifida; inaction, he
feels, is unethical (2020). This approach has validity, but it
may not be practical on a global level. Additionally, ethical
concerns cannot be determined by one man.
The long-term solution is unclear, but it is evident that
proper folate intake goes a long way towards preventing
neural tube defects.
Discussion and Conclusion
In-utero repair of myelomeningocele is still a relatively new
procedure, as it has only been developed within the past
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twenty years. Though it has been extensively studied, researched, and documented, and though new advances in the
field are constantly emerging, there is still room for extensive studies and research to further improve the process.
Nevertheless, based on the evidence from the studies
that have already been performed, it appears that because
of the reduced need for shunting, potential for reversal of
hindbrain herniation, and vastly improved neurologic function, in-utero repair is the most effective method of treatment for myelomeningocele. True, there are inherent risks.
However, as demonstrated by numerous studies, both the
maternal and fetal risks are relatively low (Sacco et al., 2019).
Additionally, the procedure is only performed in some of the
safest settings possible in order to minimize risk.
The benefits of the procedure are evident and undeniably advantageous. It is not yet standard medical care
by any means; however, with continued research, particularly with regard to stem cell therapies which seek to
restore function in addition to halting neurodegeneration,
in-utero repair may and possibly should become the new
normal for fetuses afflicted with myelomeningocele.
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Abstract
Osteoporosis is a disease of the skeleton that becomes more common with advanced age, especially in postmenopausal women.
Osteoporosis increases the risk of fractures, thereby reducing the quality of life for those who suffer from it. Due to the aging
population, direct costs resulting from osteoporosis are projected to reach upward of $25 billion per year by 2025. The main
pharmaceuticals primarily target osteoclasts. Exercise may be an effective method of preventing osteoporosis, although more
research needs to be done. More research should be conducted to explore potential ways to enhance osteoblastic activity as a
method to treat and/or reverse osteoporosis. This review compares the pros and cons of major methods to treat osteoporosis.
Introduction:
Osteoporosis is a disease of the skeleton that becomes
more common with advanced age, especially in postmenopausal women. The CDC reported based on the
data from the NHANES (National Health and Nutrition
Examination Survey) that 10.2 million adults had osteoporosis and 43.4 million had low bone mass, as of 2010
(Looker, 2015). Osteoporosis leads to an increased risk
of fractures, reducing quality of life for those who suffer
from it. Due to the aging population, direct costs resulting
from osteoporosis are projected to swell upward of $25
billion by the year 2025 (Dempster, 2011).The goal of this
review is to present the causes of osteoporosis, explain
the current treatments, and weigh the pros and cons of
the various therapeutics. Can osteoporosis be prevented,
treated, or perhaps even reversed?
Bones are not inanimate objects that the body produces,
rather bone is living tissue that continually undergoes a
process called remodeling, i.e. the continuous degradation and rebuilding of the bone tissue.
Bones are composed of cells connected through a large
extracellular matrix, which is comprised of 15 percent
water, 20 percent collagen fibers, and 55 percent mineralized salts. The main salt is calcium phosphate, which
combines with calcium hydroxide to form crystals of
hydroxyapatite. These crystals continue to combine with
other mineral salts to form a hardened tissue. This process, referred to as calcification, is initiated by cells called
osteoblasts. Mineral salts crystallize in between and then
around collagen fibers. The mixture of stiff crystalized
minerals and flexible collagen provides bones with both
strength and flexibility. Bone tissue is often compared to
reinforced concrete. Collagen is analogous to flexible
metal rods that provide support for the concrete-like
mineral component (Totora & Derrickson, 2014).
There are many reasons for remodeling. Bones can buffer the amount of calcium in the blood by building more
bone mass to use up excess calcium or degrade existing
bone to release calcium when needed. The proper concentration of calcium must be maintained in the body, as
too much calcium can cause a heart attack while too little can cause breathing to stop. There are two hormones
regulating this process. PTH promotes the degradation
of bone, releasing calcium, while Calcitonin promotes the
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deposition of bone, storing calcium.
Other factors that may affect remodeling and the rate
of bone deposition include the availability of minerals that
make up the bone, especially calcium and phosphorus.
Vitamins, particularly Vitamin A which stimulate osteoblasts (the cells that build new bone), and Vitamin C, used
in collagen production, are needed as well. Thyroid hormones (T3 and T4) from the thyroid gland promote bone
growth by stimulating osteoblasts. In addition, the hormone insulin from the pancreas promotes bone growth
by increasing the synthesis of bone proteins (Totora &
Derrickson, 2014).
Sex hormones, including estrogen and testosterone,
also affect bone growth. They are responsible for increased osteoblast activity, which is why post puberty,
many teenagers experience growth spurts. As the level
of sex hormones diminishes during middle age, especially
estrogen in women after menopause, a decrease in bone
mass occurs because bone resorption by osteoclasts
outpaces bone deposition by osteoblasts. Estrogen can
contribute to bone growth by promoting the death of
osteoclasts. In addition, women who have smaller bones
with less mass than those of men run a high risk of developing osteoporosis (Totora & Derrickson, 2014).
Bone remodeling happens in two stages. First, old bone
tissue is broken down and reabsorbed into the blood via
cells called osteoclasts. Then, bone deposition occurs,
whereby osteoblasts deposit collagen fibers and minerals.
Aside from calcium concentrations, remodeling may also
be triggered by factors such as exercise, sedentary lifestyle, and changes in diet. Remodeling helps to fix injured
bone and strengthen areas of bone subject to high stress.
Newer bone is also more fracture-resistant than older
bone (Totora & Derrickson, 2014). If the rate of degradation is higher than the rate of deposition, loss of bone
mass will occur and result in osteoporosis.
Methods
The Touro library’s database and Google were used to find
peer-reviewed articles and papers. Search terms used included “prevention of osteoporosis”, “treatment of osteoporosis”, “adverse effects of osteoporosis treatments”, etc. The
Principles of Anatomy and Physiology 14th edition was used
as well.
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Discussion
Prevention
Although there are several pharmaceuticals that treat
osteoporosis, treatments regimens are often poorly followed. A study of 178 patients on a course of treatment
for osteoporosis found that 23% of patients did not stick
to the prescribed treatment and dropped out. The study
reported a number of reasons for noncompliance, ranging
from expense, inconvenience of use, and fear of side effects (Segal, Tamir, & al, 2003). A large review of 24 studies on osteoporosis treatments found that “One-third to
half of patients do not take their medication as directed.
Nonadherence occurs shortly after treatment initiation”
(Kothawala, Badamgarav, & al, 2007). As mentioned, bone
is living tissue which respond to stress by strengthening
itself. Therefore, applying stress through weight-bearing
exercises could help to stimulate bone strengthening.
A study showed that postmenopausal women who underwent back-muscle training for two years had a higher
bone density than that of a control group. Interestingly,
the effects were not immediately apparent, and were only
evident when measured 8 years after the exercise regimen stopped. Apparently, exercise has long term, but not
immediate effects (M. Sinaki, 2002). Aside from increased
bone health, the impact of stronger muscles results in
enhanced balance, which contributes to fewer falls and
fractures. Conversely, an experiment was conducted to
determine bone loss due to lack of physical stress. Ninety
healthy men were placed on bed rest for 36 weeks and
urine calcium concentration was measured to determine
bone loss. The study found that urine calcium concentrations became elevated to 100 mg a day, showing demineralization of bone. This elevated excretion of calcium in
urine continued for 36 weeks (Schneider, 1984).
How do bones react to physical stress? Bones react
to physical stress through biochemical reaction resulting from mechanical stimulus. Bones contain cells called
osteocytes, osteoblasts that have matured and reside
within bone. Osteocytes are positioned in a way that
the deformation of bone tissue is amplified by 20-100
times on its cell membrane. The deformation on the cell
membrane signals that the bone is undergoing stress.
This is thought to trigger a host of processes within the
cell, resulting in osteogenesis. The process by which osteocytes signal is extremely complex and still not fully
understood (Gusmão & Belangero, 2015). One way osteocytes can signal is through a chemical known as sclerostin, which promotes bone degradation and is coded
for by the gene SOST. Mice with SOST gene deletion and
humans with mutations on this gene have higher bone
density. Mechanical loading has been reported to reduce

sclerostin expression as well. New research is being conducted for an antibody against sclerostin to treat osteoporosis (Bonewald, 2011).
Treatments
The first line of treatment for osteoporosis is currently
Bisphosphonates (BP), which disrupts osteoclastic activity. Because osteoclast are the cells responsible for bone
degradation, many treatments seek to inhibit osteoclast
activity. Osteoclasts degrade bone by releasing hydrogen
ions, thereby creating a acidic environment. They use a
ruffled border that attaches to the bone’s surface. The
ruffled border has crevices created by its protrusions
which act as containers for the acid secreted by the osteoclast. The acid remains in these crevices, which form
small pockets known as sub-osteoclastic compartments
when sealing onto bone. The acidic environment causes
the mineral component of bone to become more soluble, allowing bone’s minerals to be absorbed by the
osteoclasts.
BP has a strong affinity for calcium ions, which are
found in bone, due to the presence of two phosphate
groups, this results in the rapid localization of BP to bone
material. Experiments using radio labeled BP has shown
that BP are taken up and adsorbed in to bone primarily
(Xiao-Long Xu, 2013).
When osteoclasts attach to bone that contains BP the
acidic environment protonates the BP. Protonated BP has
a lowered affinity for calcium ions, allowing for the release of BP into the sub osteoclastic compartment where
BP is taken up by the osteoclast.
BP disrupts cell functions in the osteoclast, BP have
a similar chemical structure to that of pyrophosphate.
Pyrophosphate is involved in many cell processes in the
osteoclast. Due to its similarity to pyrophosphate, BP is
likely to interfere with any of the processes that involve
pyrophosphate. It is thought that the BP inhibits prenylation of protein to the cell membrane, the lack of these
proteins at the membrane results in loss of the ruffled
border and prevents the osteoclast from being able to
degrade the bone.This is shown as bisphosphonate-treated osteoclasts lack a ruffled border (Russell & Rogers,
1999).
Side Effects of BP
Doctors I have spoken with report that patients reported gastrointestinal (GI) discomfort while taking oral BP,
and an NCBI continuing education paper for doctors
states “ All oral bisphosphonates have correlations with
upper gastrointestinal adverse effects, including gastrointestinal reflux, esophagitis, esophageal/gastric ulcers, and
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gastritis. Gastrointestinal side effects are the most common reason for discontinuation of oral bisphosphonates.”
The article recommends avoiding BP in patient that are
at a higher risk of gastrointestinal distress (Ganesan K,
2021). A study conducted to determine the compliance
of patient to osteoporosis treatment found that the
major reason reported by patients for discontinuation of
alendronate (a BP) was indeed GI side effects. Counter
to this, a study conducted to determine if there is any
correlation between alendronate (a BP) use and GI
problems found no correlation of BP use and GI issues.
The experiment was a randomized, double-blind, placebo-controlled trial with a mean follow-up of 3.8 years.
Women were initially randomized to receive alendronate
sodium, 5 mg/d, or placebo. After 2 years, the alendronate
sodium dose was increased to 10 mg/d.The study did not
find any significant correlation between BP use and GI
problems. “The overall incidence of upper GI tract events
was similar in the alendronate and placebo groups”. The
study goes on to suggest that GI side effects reported
may be due to the higher age of osteoporotic patients
(Bauer DC, 2000). The study that found that noncompliance in BP-taking patients also tracked patient adherence
to Raloxifene (a different class of treatment known as a
SERM), none of the Raloxifene-taking patients attributed
the reason of their discontinuation of treatment due to
gastrointestinal issues (Segal,Tamir, & al, 2003).This would
call into question the suggestion that the gastrointestinal
affects attributed to BP are really age related and not resultant of BP. Both groups were of the same population
yet only the BP-taking group reported gastrointestinal
issues. The study cited as well as other studies I came
across that showed no correlation with oral BP use and
upper GI issues were sponsored by pharmaceutical companies that produce oral BPs. These conflicting reports
of gastrointestinal distress due raise eyebrows as to the
potential biases in studies. Patients given intravenous BP
do not report GI issues and the intravenous BPs need to
be administered far less often. (Papapetrou, 2009) Both
reasons make it more likely that a patient will maintain
their intravenous treatment over an oral one and seem
to make intravenous BP optimal.
Another method of treatment for osteoporosis is
monoclonal antibodies. Osteoclasts originate from macrophages. The macrophage precursor cells have a receptor called RANK which binds to RANK ligand (RANKL)
to differentiate into osteoclastic cells. Antibodies can bind
to a ligand to prevent it from binding to its receptor. The
antibodies bind to RANKL inhibiting their ability to bind
with the RANK receptor on the macrophage precursor cells. As a result of the rate at which osteoclasts
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differentiate is decreases resulting in less osteoclastic
cells that break up bone. (D. A. Hanley, 2012)
Antibody treatment, which circulate in the blood, can
reach all skeletal sites. However, unlike BP which bind to
bones and can have affects after cessation of treatment,
antibodies lose their affect soon after cessation of treatment. Adverse events are rarely associated with denosumab. (Harshika Awasthi, 2018)
Calcium concentration is regulated by hormones PTH,
and calcitonin. Calcitonin is produced in the thyroid gland
and causes lower serum calcium concentration by acting on the renal tubules, causing them to excrete more
calcium, and on osteoclasts, causing them to contract
(temporarily), reducing their motility and ability to resorb bone. It also causes inhibition of carbonic anhydrase
II, which disrupts the acidic environment that is optimal
for osteoclast activity. Calcitonin also prevents osteoclast
precursors from differentiating into their mature form.The
ultimobranchial gland of salmon produces calcitonin with a
different makeup of amino acids. Salmon calcitonin is a 32
amino acid, alpha-helical polypeptide that differs significantly from human calcitonin along amino acids 10-27. Salmon
calcitonin is more potent then endogenous calcitonin due
its difference in amino acids (Felsenfeld AJ, 2015)
Adverse Side Effects of Calcitonin
Adverse effects of calcitonin can include hypocalcemia, a
dangerous condition. Since the calcitonin used to treat
osteoporosis is sourced from salmon, patients who are
allergic to fish can have an allergic reaction. Ten percent
of patients taking calcitonin experience mild nausea that
subsides as therapy continues. A meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon
(nasal spray and investigational oral forms) suggests an
increased risk of malignancies in calcitonin-salmon-treated patients (4.1%) compared to placebo-treated patients
(2.9%). A definitive causal relationship between the calcitonin-salmon use and malignancies cannot be established
from this meta-analysis, the benefits for the individual
patient should be carefully evaluated against all possible
risks. (F. Cosman, 2014)
Further studies point to the questionable efficacy of
calcitonin overall and show a definitive lack of efficacy
in nonvertebrate fractures. This contrasts with both bisphosphonates and denosumab which both demonstrated
a lowered fracture risk in vertebral, hip, and other nonvertebral fractures. (Overman RA, 2013)
Calcitonin has been shown to reduce fracture pain.The
exact mechanism for its analgesic effects, is not known.
There is a hypothesis that calcitonin may act on the
central nervous system, and it has been used with some
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success in patients with migraine pain, phantom limb
pain, malignancy, Paget’s disease, and other pathologies. It,
however, has not been compared directly to NSAIDs in
terms of effectiveness of pain relief. Regardless, Calcitonin
may be helpful for pain in patients that cannot tolerate
NSAIDS. (Linsey A Blau, 2016)
Post-menopausal women have low levels of estrogen,
an essential hormone for bone remodeling. Osteoporosis
is attributed to the diminished estrogen levels of postmenopausal women. Estrogen can inhibit osteoclasts from
forming, cause osteoclastic apoptosis, as well as increase
osteoblasts by inhibiting osteoblastic apoptosis (Sundeep
Khosla, 2012) . An obvious therapeutic approach would
be to provide hormone replacement therapy. However,
hormone therapy is found to increase the risk of breast
cancer (Beral, 2003) , and is therefore not widely used .
Raloxifene, a drug that is an estrogen antagonist and agonist is promising drug, in bone, it behaves as an estrogen
antagonist, increasing bone density, in reproductive and
breast tissue it acts as an estrogen agonist.Thus, raloxifene
both increases bone density and reduces risk of cancer.
Raloxifene has not been shown to reduce non-vertebrate
fractions and more research is necessary to determine
its efficacy in non-vertebrate fractures. A meta-analysis
found that “In comparison to other osteoporosis therapies, raloxifene has a lesser impact on bone mineral
density, a similar effect on the occurrence of vertebral
fractures, but no effect on the frequency of non-vertebral
fractures. Raloxifene can be recommended for the prevention of vertebral fractures in women with osteopenia/
osteoporosis who are not at high risk of non-vertebral
fractures and who do not have a past history of venous
thromboembolism” (Ann Cranney, 2005)

exercise, as there is some evidence that links mechanical stress on bones to lasting improved bone mass., and
stronger muscles can improve balance to further help
reduce the risk of falls and fractures. Further research
should be conducted to determine how it might be possible to enhance bone-building osteoblasts.

Conclusion
The most effective current method of treatment are
bisphosphonates, which accumulate in bone and inhibit
osteoclasts from functioning. However, many patients
suffer gastrointestinal pain as a side effect. For those
patients an antibody (denosumab) that prevent RANKL
from signaling the osteoclastic precursor cells to mature,
has also proven to be relatively effective. Other methods
of treatment such as calcitonin and raloxifene while in
theory look promising, proved to not be very effective
in clinical trials. Calcitonin, while not necessarily very effective at reducing bone loss, may still play an important
role in treating pain, especially in patients where NSAIDS
aren’t well tolerated. More research is needed to determine how effective exercise can be in the prevention of
osteoporosis and what specific exercises, if any, would be
most effective. Regardless, patients should be advised to

Felsenfeld AJ, L. B. (2015). Calcitonin, the forgotten hormone: does it deserve to be forgotten? clinical kidney
journal , 8. Retrieved from https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC4370311/
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Abstract
Autism spectrum disorder (ASD) is a broad, heterogeneous neurodevelopmental disorder encompassing a range of presentation
and severity. The common characteristics include communication deficits, impaired social skills, dependency on routine, sensitivity to
environmental change, and stereotyped behavior (DSM-5, 2013). When ASD is accompanied by a host of other symptoms it is often
referred to as syndromic autism. Syndromic autism is usually severe and can usually be traced to deletions or duplications on a specific gene. These monogenic disorders are by definition easier to diagnose and are good candidates for study since specific biological
markers can be assessed and tracked. There have been many discoveries about monogenic autism which help provide insight into
the mechanisms of disease. Nonsyndromic autism (also called idiopathic autism) is defined by the absence of additional symptoms
or underlying syndromes. Although nonsyndromic autism is far more common and often manifests in a milder form of the disorder,
the genes and proteins involved are much more difficult to nail down, and therapeutics are harder to discover. Family and twin studies
have provided evidence that the majority of cases are due to common genetic variation (Gaugler et al., 2014).
Shifting the focus to syndromic autism has been a critical step in understanding the disease process that underlies the different
manifestations of ASD. This is the key to solving the complex web of common genetic variants implicated in nonsyndromic autism.
Keywords: Autism, ASD, monogenic, syndromic, common variants, loss of function.
Introduction
Autism Spectrum Disorder (ASD) has been historically
classified into two basic categories, syndromic and nonsyndromic. In nonsyndromic autism, communication and
social impairment, accompanied by stereotyped behaviors represent the main symptoms observed. Syndromic
ASDs are disorders wherein the autistic presentation
is just one part of a broader neurological syndrome.
In Phelan-McDermid Syndrome, for example, which is
caused by mutations in the SHANK3 gene, the autistic
phenotype is accompanied by developmental delay, intellectual disabilities, seizures, and hypotonia (Phelan et al.,
1992). Another example is tuberous sclerosis complex,
caused by mutations in either TSC1 or TSC2 (European
Chromosome 16 Tuberous Sclerosis Consortium, 1993),
wherein ASD is featured along with many other developmental and physical symptoms (Slegtenhorst et al., 1997).
Many other chromosomal deletion and duplication syndromes include ASD as a feature of the disease, including
Smith Magenis syndrome, Wolf-Hirschhorn syndrome,
and Rett syndrome (Laje et al., 2010, Fisch et al., 2008,
Hu et al., 2018).
Autism was first described in 1943 (Kanner, 1943).
Even then it was assumed to be caused by an inborn (i.e
genetic) disturbance. Great scientific and technological
strides have been made since then and we are just beginning to uncover the molecular pathways involved. At
this point, most ASD diagnoses are still made based on
behavior (Lord et al., 2012), and most available therapies
target symptoms and not underlying pathophysiology.
The extreme range of ASD manifestation adds a level of
complexity when trying to understand its biology. Its very
name indicates that there is a continuum of clinical phenotypes that make up what would seem more appropriate
to call a category of neurodevelopmental disorders that
are similar in symptomatology. On a genetic level, autism

becomes even more complicated, as hundreds of diverse
genes are found to have an association with autism susceptibility (Berg & Geshwind, 2012).
Dramatic advances over the last few years have led to
an unraveling of the mystery that is ASD. The complete
picture is not yet clear, but we are beginning to see coherence and cohesion within the wide range of variants
and presentations and this has led to a reevaluation of the
way we currently classify ASD.The newer classification will
likely stratify ASDs by which biological pathway is affected.
This will enable a more targeted approach to therapy and
treatment, which will focus on the restoration of underlying biological issues and not just symptom control.
Methods
To gain a better perspective on the current direction
of autism study, the available literature on Touro Online
Library was searched using the search term “monogenic
autism”. Many review articles from the last 10 years were
read and their information was synthesized to form a coherent overview of the latest thinking on ASD. The focus
has been to highlight the differences between syndromic
and nonsyndromic autism, as well as the areas in which
they are beginning to converge.
Autism Etiology
The causes of autism were presumed to be genetic since
it was first described (Kanner, 1943). Although there has
been lots of speculation about environmental causes of
autism, most of this has been thoroughly debunked (e.g.
Wakefield’s vaccine hypothesis). Environmental causes
for ASD have been implicated only in a small percentage
of cases (Newschaffer et al., 2007).
Genetic factors have been demonstrated to cause autism
in many of the monogenic syndromes in which autism is
commonly featured, such as Rett,ADNP, Phelan-McDermid,
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and Fragile X. Additionally, epidemiological evidence from
family and twin studies make it clear that genetics plays a
large role in etiology. Nearly 20% of babies with an affected older sibling will develop ASD (Ozonoff et al., 2011).
Twin studies show that monozygotic twins share a higher concordance rate of diagnosis for autism as compared
with dizygotic twins (Hallmayer et al., 2011).
Although the case for genetic etiology of ASD is quite
convincing, it has been very difficult to identify which
genes account for the majority of incidence. One of the
major problems with studying ASD is that its heterogeneity creates small sample sizes within each manifestation of
autism along the spectrum. Much larger sample sizes are
needed to locate the responsible genetic variants.
Autism Sequencing Consortium
One of the main advances in autism over the last decade
has come about due to the cooperation of many different
autism research centers under one umbrella group called
the Autism Sequencing Consortium (ASC). The goal of
ASC is to increase the power of genetic analysis by pooling
resources and samples from research centers around the
world. A large sample size is obtained through the consortium, allowing for meta-analysis of tens of thousands
of samples. This increases the power of genome-wide association studies (GWAS) and more can be extrapolated
from the data.
By February 2020, the ASC had identified 102 genes associated with ASD, of which, 31 are novel risk genes never
previously identified. These genes are quite diverse and
run the gamut of different cell functions. However, further
analysis showed lots of connections between the biological
pathways mediated by these genes (Satterstrom et al., 2020).
Understanding the Genetics of Autism
When thinking about genetic mutations there are two
key classifications. The first is the frequency of the allele,
namely if it is common, low frequency, or rare. The second is the potency of its effect; whether it is penetrant or
if the effect is modest. Generally, the more penetrant a
mutation is for a syndrome like ASD, the less frequent it is
due to natural selection. Namely, someone carrying such
a gene is far less likely to reproduce and thus the allele
will become less common. Additionally, a variant that is
rare and has a mild ASD causing effect is not part of the
discussion since the sample size would have to be enormous to pick up such a rare and subtle ASD contributor.
Thus the current autism discourse is focused on the
linear progression of genetic variation; there are the most
common variants, which tend to have smaller effect sizes,
while the rarer are highly penetrant and the likelihood
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of an autism diagnosis is almost certain (Manolio et al.,
2009, Figure 1). Of the 102 ASD risk genes discovered by
the ASC, it is clear that some have a larger impact than
others. For example, there is an 80% chance of ASD in
those with a SHANK3 mutation (Soorya et al., 2013), the
gene deletion that causes Phelan-McDermid syndrome
(Nesslinger et al., 1994). Meanwhile, there are many gene
variants among the 102 genes which are prevalent in the
population and this is because they only marginally predispose a person to ASD. Each of these common genetic
variants individually only represents a small effect size in
producing an autistic phenotype. Enough of these variations en masse seems to push the patient over a figurative threshold. Thus these common variants combine to
increase the possibility of ASD (Gaugler et al., 2014).
The Focus of Autism Research
The challenge upon identifying these mutations is in
mapping the variation to specific biological changes and
understanding their outcome. This step is crucial in creating a model for that particular mutation. Once a model
is made, the mechanics in which that gene is involved
can be analyzed, which will help identify the pathogenic
pathways. Eventually, experiments can be designed to try
to counteract the effects created, leading to a potential
treatment.
It is extremely difficult to measure the biological changes they create with common genetic variants since the
effect size is often infinitesimal ((Manolio et al., 2009).
Consequently, the path toward understanding and discovering treatments for idiopathic autism runs through monogenic syndromic autism (Ziats, et al., 2021). These rarer variants
have major effects and are highly penetrant. Figuring out the
biological conditions created by these variations is straightforward. Therefore, the potential for designing biological
models–both cell and animal–is very high.
Thus, the current thinking on autism research is a move
to personalized medicine. Narrowing the focus to one
or several of the monogenic ASDs allow researchers to
create models, discover phenotypes, and establish baseline biomarkers, all to discover treatments that can work
for that particular autistic presentation. In doing so, not
only can this provide relief for patients who struggle with
some of the most severe forms of autism, but the hope is
that these studies can help uncover the mystery of idiopathic autism, as well.
The discovery of a new drug for one small subset of
ASD can help further the science in autism more broadly. Firstly, the new drug can be tested on the wider autistic population in the hope that its efficacy might not
be limited to just that subset. Secondly, drug discovery
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often proves or provides clarity to a particular theory of
disease. For example, if we find a compound that helps
to normalize biomarkers in a certain disease phenotype,
this can lead to the confirmation of a previous disease
hypothesis or the formation of a new one. All of these
findings may offer clues for pathophysiological pathways
in other disorders on the autism spectrum in addition to
the one being studied.
Modeling Autism Spectrum Disorder Pathophysiology
Despite all the progress made in identifying genes and
fashioning animal models, there is a lot more to uncover
in ASD. We can potentially create many different models
for all of the different genetic mutations but it may not
be necessary. After all, the various mutations all lead to
similar symptomatology, namely, the autistic phenotype.
This seems to imply convergence of biological pathways at
some point to create a common result (Geschwind, 2008).
This is another angle that autism researchers are probing.
Systems biology is put to excellent use in connecting
the various genes that have been associated with risk for
autism. It has been repeatedly demonstrated that the
autism implicated genes are part of networks that involve
gene expression and synaptic modeling (Voineagu, et al.,
2011, Gilman, et al., 2011). Different cutting edge techniques were used in these studies that all show how these
genes are grouped together in performing neurodevelopmental work, particularly, in the prenatal and neonatal
period. This also demonstrates a relationship among ASD
risk genes that is statistically significant as well as gives
evidence of their function (Chen et al, 2015).
Finally, as the power of genome-wide association studies increases, the more we can connect common genetic
variants to the rare ones. From a molecular perspective,
polygenic autism is more similar to monogenic autism
than previously thought. This is because risk genes for
syndromic and nonsyndromic converge in several different cellular pathways (De Rubeis et al., 2014). Mastering
these pathways will help us to classify and treat autistic
disorders in groups with the same affected pathway.

for monogenic autism is high. The reason for this is because many of the mutations discovered through GWAS
are loss of function (LoF) de novo (arising in the germ
cell of a parent) mutations (De Rubeis et al., 2014). The
fact that autism is a result of a heterozygous LoF allele is
an optimistic finding. It implies that the problem can be
corrected if we can find a way to boost the remaining (i.e.
functioning) allele. If it is overexpressed sufficiently, it may
fully compensate for the mutated allele.
Drug Discovery is a multi-step process and takes years
to go from promising compounds to clinical trials. It
starts with isolating peripheral blood mononuclear cells
(PBMCs) derived from syndromic ASD patients and their
unaffected siblings or parents. These PBMCs are given
reagents that regulate gene expression and dedifferentiate them back to pluripotency. In this state, they are
called IPSCs (induced pluripotent stem cells). Then, using
a retrovirus, the IPSCs are infected with a plasmid that
contains certain genes which induce neuron differentiation (Yang et al., 2011).
After the induced neuronal (iN) cells are created, the
goal is to find a method of distinguishing the neurons obtained from the proband vs the immediate relative which
can be employed in a high-throughput assay. That way, a
normal and abnormal phenotype can be defined in terms
of this disorder. One potential test is to see if conductance can be altered between the two phenotypes given
certain conditions. This can lead to many hundreds or
even thousands of prospective drugs being tested simultaneously to see which has the potential to restore the
iN cells to their normal phenotype.
If compounds that restore patient-derived iN cells to
a healthier phenotype are identified, they can be studied
further, used on animal models, and ultimately, a clinical
trial can be conducted on actual patients. Using these
steps has the potential to identify treatments that are
aimed not merely toward symptom relief but the treatment of underlying biology. Additionally, the drug can be
tried on other ASD variants and may shed light on the
broader ASD pathophysiology.

Drug Discovery for Monogenic Autism
The next step would be to create human neurons derived
from patient-induced pluripotent stem cells and develop
tests to measure their protein expression and function. All
of these studies brought into a systems biology framework
will help piece together multiple levels of anatomical, physiological, and genomic data. This will enhance the ability to
test the functional, spatial, and temporal convergence of
ASD genes (Dolmetsch & Geschwind, 2011).
The potential for the discovery of an effective treatment

Conclusion: Rethinking Autism Classification
Over the last decade, autism research has grown in leaps
and bounds. Its heterogeneity and wide variations in phenotype make it difficult to determine etiology. However,
through the use of an array of new technologies which
can map the genome down to the base pair, much information has come out regarding particular genes that
contribute to autism predisposition.
The wide variation in ASD phenotypes and the different genes and pathways would seem to fly in the face
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of a biological convergence, yet we have encountered
evidence from many studies that indicate how ASD etiologies can be organized by the intermediate pathway in
which it plays a part. Perhaps as more research is done
and treatments are discovered, it will become clear that
ASD is a very particular manifestation that can result
from many different genes that share common pathways.
There is a great deal of evidence that shows convergence
on intermediate biological levels which corroborate a
“many genes, common pathways” hypothesis (Geschwind,
2008, Chen et al., 2015).
Therefore, a shift of focus toward the rare variants that
cause syndromic autism has begun to garner results. This
is because these variants represent low-hanging fruit in
that they are really easy to detect and study. Normal and
knockout phenotypes can be described, created in models, studied, and tested. This avenue of research can also
benefit nonsyndromic autism research by helping define
certain parameters and mechanisms of autism pathology.
While the historical classification between syndromic
and nonsyndromic autism has been useful, it seems likely
that this classification scheme will come to an end. As we
start to see some convergence between syndromic and
idiopathic autism on the level of molecular pathways, the
various disorders will start being categorized–and treated–based on their individual pathogenic routes.
References
Berg J.M., Geschwind D.H., Autism genetics: searching for
specificity and convergence. Genome Biol. 2012; 13: 247.
Chen, J.A., Peñagarikano, O., Belgard, T.G., Swarup,
V., Geschwind, D.H., The emerging picture of autism spectrum disorder : genetics and pathology. Annu Rev Pathol. 2015;10:111-44. doi: 10.1146/
annurev-pathol-012414-040405.
European Chromosome 16Tuberous Sclerosis Consortium,
Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305–1315 (1993)
De Rubeis, S., He, X., Goldberg,A.P., Poultney, C.S., Samocha,
K., Cicek, A.E., et al. Synaptic, transcriptional and chromatin
genes disrupted in autism. Nature, 515 (2014), pp. 209-215
Diagnostic and Statistical Manual of Mental Disorders.
Arlington,VA: American Psychiatry Association, 2013.
Dolmetsch, R., Geschwind, D.H., The human brain in a
dish: the promise of iPSC-derived neurons. Cell (2011)
145:831–34
Fisch, G.S., Battaglia, A., Parrini, B., Youngblom, J., and
Simensen, R., Cognitive-behavioral features of children
with Wolf-Hirschhorn syndrome: preliminary report of
42

12 cases. Am. J. Med. Genet. C. Semin. Med. Genet. 2008;
148C: pp. 252-256
Gaugler, T., Klei, L., Sanders, S. et al. Most genetic risk for
autism resides with common variation. Nat Genet 46,
881–885 (2014). https://doi.org/10.1038/ng.3039
Geschwind, D.H., Autism: many genes, common pathways?
Cell. 135 (2008), pp. 391–95
Gilman, S.R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M.,
Vitkup, D., Rare de novo variants associated with autism
implicate a large functional network of genes involved
in formation and function of synapses. Neuron (2011)
70:898–907
Hallmayer, J., Cleveland, S.,Torres, A., et al., Genetic heritability and shared environmental factors among twin pairs
with autism. Arch Gen Psychiatry. 2011;68(11):1095-1102.
doi:10.1001/archgenpsychiatry.2011.76
Hu, C.C., Sun, Y.J., Liu, C.X., et al, NSDHL-containing duplication at Xq28 in a male patient with autism spectrum disorder: a case report. BMC Medical Genetics.
2018:19(1):192
Kanner, L., Autistic disturbances of affective contact.
Nervous Child, (1943) 2, 217–250.
Laje, G., Morse, R., Richter, W., Ball, J., Pao, M., and Smith,
A.C., Autism spectrum features in Smith-Magenis syndrome. Am. J. Med. Genet. C. Semin. Med. Genet. 2010;
154C: pp. 456-462
Lord, C., Petkova, E., Hus, V., Gan, W., Lu, F., et al. A
Multisite Study of the Clinical Diagnosis of Different
Autism Spectrum Disorders. Arch Gen Psychiatry.
2012;69(3):306-313.
Manolio, T.A., Collins, F.S., Cox, N.J., et al. Finding
the missing heritability of complex diseases. Nature.
2009;461(7265):747-753. doi:10.1038/nature08494
Nesslinger NJ, Gorski JL, Kurczynski TW, Shapira SK,
Siegel-Bartelt J, Dumanski JP, et al., Clinical, cytogenetic,
and molecular characterization of seven patients with
deletions of chromosome 22q13.3. Am. J. Hum. Genet.
1994 Mar;54(3):464-72.
Newschaffer, C.J., Croen, L.A., Daniels, J., et al., The
Epidemiology of Autism Spectrum Disorders. Annual
Review of Public Health, 2007; 28: 235-258.
Ozonoff, S., Young, G.S., Carter, A., et al., Recurrence risk
for autism spectrum disorders: a Baby Siblings Research
Consortium study. Pediatrics. 2011;128(3):e488-e495.
doi:10.1542/peds.2010-2825
Phelan, M.C., Thomas, G.R., Saul, R.A., Rogers, R.C.,
Taylor, H.A., Wenger, D.A., McDermid, H.E., Cytogenetic,

Understanding Pathophysiology of Nonsyndromic Autism

biochemical, and molecular analyses of a 22q13 deletion.
Am. J. Med. Genet. 43, 872–876 (1992).
Satterstrom, F.K., Kosmicki, J.A., Wang, J., Breen, M.S., De
Rubeis, S., An, J.Y., et al., Large-Scale Exome Sequencing
Study Implicates Both Developmental and Functional
Changes in the Neurobiology of Autism. Cell. 2020 Feb
6;180(3):568-584.e23.
Slegtenhorst, M.V., Hoogt, R.D., Hermans, C., Nellist, M.,
Janssen, B.,Verhoef, S., et al., Identification of the tuberous
sclerosis gene TSC1 on chromosome 9q34. Science 277,
805–808 (1997).
Soorya, L., Kolevzon, A., Zweifach, J. et al. Prospective
investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3
deficiency. Molecular Autism 4, 18 (2013). https://doi.
org/10.1186/2040-2392-4-18
Voineagu, I., Wang, X., Johnston, P., Lowe, J.K., Tian. Y., et
al., Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature (2011) 474:380–84
Yang, N., Ng, Y.H., Pang, Z.P., Südhof, T.C., Wernig, M.,
Induced neuronal cells: how to make and define a neuron. Cell Stem Cell. 2011;9(6):517-525. doi:10.1016/j.
stem.2011.11.015
Ziats, C.A., Patterson, W.G., Friez, M., Syndromic Autism
Revisited: Review of the Literature and Lessons Learned.
Pediatric Neurology. 2021; 114: 21-25,

43

Etiology and Associations of Oral and Oropharyngeal Cancer
Aron Yaghar
Aron Yaghar graduated in May 2021 with a Bachelor of Science degree in Biology and is attending Touro
College of Dentistry

Abstract
This research paper discusses oral cavity cancer, which is one of the 11th most common cancers in the world. According to newer
research, some important possible causes include smokeless tobacco, marijuana, and citrus fruits. Some research attributes it to
one’s genetic makeup and include exposure to Human Papillomavirus (HPV) and diagnosis of Diabetes mellitus, all in conjunction
with one’s age. In this research paper, each of these factors are discussed in depth, and their association with this illness is considered and debated. Review of the literature reveals that the high concentrations of nicotine found in smokeless tobacco products is
deleterious to oral health. Citrus fruits have been shown to prevent oral cancer. Multiple studies reviewed implicated HPV-16 and
HPV-18 as having a gross etiologic role in many cancers of the oropharynx and the oral cavity. The causes for this cancer have
been previously attributed to inaccurate, or unclear factors.This paper works to identify some unfamiliar factors that could quite
possibly be important risk factors for this illness. Much of this research is fairly new and requires additional studies to substantiate
the causes and help raise awareness, especially in lesser developed countries.
Introduction
Cancers of the oral cavity are the 11th most common
cancers in the world. About 145,000 deaths were estimated to have occurred in 2018 across all areas of the
globe. Etiology of most cancers that occur in the mouth
has been attributed to a complex interplay of genetic and
environmental factors, as with almost all other types of
cancer. Some of the more well known and preventable
causes include smoking and excessive alcohol consumption. However, though the rate of cigar and cigarette
smoking have trended downwards throughout the world,
the rate of cancer associated with the oral cavity has
steadily increased (Warnakulasuriya, 2020). Therefore, it
is imperative to explore the many other, less known, risk
factors that are associated with oral cancer. In the last
ten years much research has been conducted regarding
cancers that affect the oral cavity and new, surprising associations have come to light. Many of these associations
are environmental factors that can be eliminated including smokeless tobacco, marijuana, and citrus food intake.
Other associations are related to one’s genetic makeup
and include exposure to Human Papillomavirus (HPV) diagnosis of Diabetes mellitus, all in conjunction with one’s
age (Petersen, 2009).
Before one can explore the many potential causes of
oral cancer, it is important to understand the types of
soft tissue cancer that can be found in the oral cavity.
Ninety percent of all cancers found in the oral cavity
are Squamous cell carcinomas (SCC). Squamous cells
line most of the oral cavity and provide a smooth and
protective layer to the mouth. The other ten percent of
cancers that occur in the oral cavity include Verrucous
carcinomas, minor salivary gland carcinomas, Lymphomas,
and many benign tumors including granular cell tumors,
fibromas, and granulomas. Minor salivary gland tumors, as
the name suggests, affect the many minor salivary glands
that are found in the hard palate (60%), lips (25%) and
buccal mucosa (15%). Subtypes of this type of carcinoma
include adenoid cystic carcinoma, mucoepidermoid carcinoma and polymorphous low-grade adenocarcinoma.
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Lymphomas of the oral cavity develop in lymphatic tissue
found in the tonsils and the posterior 1/3 of the tongue.
Additionally, some of the benign tumors found in the
mouth have a tendency to become malignant over time
and are often excised as a precaution. The final group
of soft tissue cancer of the oral cavity includes mucosal
melanomas (Scully and Porter, 2001). These can often be
found at the vermilion border or the hard palate and can
be locally aggressive.
Dentists and oral pathologists have identified key premalignant lesions that have a strong association with SCC.
These lesions include leukoplakias, erythroplakias, oral
lichen planus, and oral submucous fibroses. The WHO
(2018) further classifies these according to degree of
dysplasia; mild, moderate, severe, and carcinoma in situ.
Leukoplakias are simply defined as a “white patch or
plaque that cannot be characterized clinically or pathologically as any other disease” (Van der Waal, 2015). It is
important to note that these lesions or patches are not
wipeable. Lesions of this nature that can be wiped away are
often fungal related like Candidiasis albicans.About 2-5% of
leukoplakias annually go on to become malignant. Dentists
and health care providers will often biopsy these lesions
and monitor them consistently for changes in color or size.
One of the biggest risk factors for malignancy is the location of lesion. Lateral borders of the tongue and the floor
of the mouth are known to be the most common areas for
malignancy to appear. Erythroplakia is defined as a “bright
red velvety patch that cannot be characterized clinically
or pathologically as being caused by any other condition”
(Van der Waal, 2015). These have a much higher malignant
potential than leukoplakias and are mostly associated with
severe dysplasia and carcinoma in situ. These will generally
be excised entirely and biopsied.
The goal of this paper is to delve into the research
surrounding some of the stronger environmental and genetic associations of oral and oropharyngeal cancers. The
topics covered will include citrus fruit intake, smokeless
tobacco use, human papillomavirus, and inflammatory
bowel diseases. Systematic reviews and meta-analysis will
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be utilized to understand the possible pathophysiology
behind these associations, along with their prevalence,
and thoughts on preventative measures.
Citrus Fruits
Oral cancer accounts for over 3% of the overall burden
of cancer globally, with an incidence of 350,000 cases in
2013. Patients with oral cancer have a poor prognosis despite advances in treatment as they continue to present
with late-stage disease. Indeed, the 5-year survival rate
for oral cancer is only 46% for men and 54% for women.
In the last 10 years, many studies have provided evidence
that a regular intake of citrus fruits is associated in prevention of oral cancer. A meta-analysis discusses results
that indicate that there is an inverse association between
citrus food intake and prevalence of oral and oral-pharyngeal cancers.
Seventeen studies were reviewed for this meta-analysis.
The authors begin the review by listing the confounders
each study controlled for. These include age, sex, BMI,
smoking status, alcohol use, and education levels. Most
studies gathered data from participants using a food frequency questionnaire. Meta-analysis was conducted by
grouping participants with an increased risk of oral cancer
based on their average citrus fruit intake. Upon statistical
analysis of the pooled results, it was determined that participants had a maximum of 50% reduction in risk of oral
cancer based on the degree of intake. (Cirmi, et. al., 2018)
The study also goes on to outline possible mechanisms
by which citrus fruits can work to combat cancer. Citrus
fruits are known to have high levels of Vitamin C. Vitamin
C has been proven to combat inflammation and damage to
DNA structures, which can initiate cancer. Furthermore,
the antioxidant properties of Vitamin C work to kill cancer cells that may be proliferating (Grosso, et. al.,2013).
Another hypothesis delves into the bioactive compounds
that can be found in citrus fruits.These include flavonoids,
carotenoids, and limonoids. Of these three, flavonoids are
known to reduce inflammation, risk of infection, and oxidative stress. Oxidative stress and inflammation can lead
to oxidative damage which works to initiate and promote
cancer (Ravishankar, 2013). As such, both hypotheses
conclude that the components of citrus fruits provide an
antioxidant environment for the oral cavity and pharynx.
Smokeless Tobacco
Another important area of study in regard to oral cancer
is the use of smokeless tobacco. This includes chewing
(spit) tobacco, moist snuff and other tobacco containing products that are not smoked. Many wrongfully believe that the health concerns surrounding cigars and

cigarettes are caused by the ‘smoke’ element. Thus, they
believe chewing tobacco and snuff are a safer alternative.
Nicotiana rustica and Nicotiana tabacum are the two
major varieties of tobacco. Nicotine, a volatile alkaloid, is
the most essential component obtained from the leaves
of this herb. Nicotine is one of the most stimulating and
harmful substances on the market. Nicotine affects all
organs, and can bind to CNS receptors, and raises brain
dopamine levels, rendering it a highly addictive substance.
Muthukrishnan et al states, “Chewing tobacco and other
smokeless tobacco products are known to be deleterious
to oral health.” His group has done much research in this
field showing that smokeless tobacco has more deleterious negative effects on the oral cavity, in comparison
to their smoke-fueled counterpart. They further detail
the main health risks associated with smokeless tobacco,
namely, oral squamous cell carcinoma (SCC), verrucous
carcinomas, and tobacco-induced oral mucosal leukoplakia (Muthukrishnan , 2018).
Not only do SLTs contribute to cancer risks through their
nicotine content, but they can also increase this risk by the
oral abrasion they cause. Many abrasives are added to SLTs
in order to accelerate nicotine absorption through oral mucosa. These abrasives wear down enamel, dentin and root
surfaces along with the sensitive mucosal lining. Prolonged
trauma to these sites can create irritation fibromas that have
an increased malignant potential (Janbaz, 2014).
To further this idea, it has been documented by WHO
that the country with the highest prevalence of oral and
oropharyngeal cancer in the last 10 years is India. Oral
cancer incidence rates in many parts of India surpass 6
per 100,000 males, and in some areas, they are as high as
10.8 per 100,000. About one-half of all tobacco used in
India is smokeless tobacco, and nearly 100 million people
use smokeless tobacco products daily. A study was conducted on this subject in India from October–November
2003. Indian smokeless tobacco products that were
bought from retail stores in Gujarat, Karnataka, and
Mumbai, India were quantified. Each purchase’s date and
location, as well as the batch number, were recorded. The
32 labels that were gathered for research are items that
are widely used in India. There were also five common
brands of non-tobacco chewing mixtures (supari) included. Analysis of both groups of recreational chewing products concluded that the SLT products not only had high
levels of nicotine, but also excessively high levels of nitrosamines (nitrates), in comparison to levels of nitrates we
have in foods like cold cuts and hot dogs. Nitrosamines
are known to be carcinogenic in high volumes, as so may
be contributing to the risk of oral cancer along with the
nicotine. (Stepanov, 2005)
45

Aron Yaghar

To reduce the morbidity and mortality associated with
the use of these drugs, immediate public health interventions are needed. It is both ironic and disheartening
to realize that many third-world countries lack so much
health literacy that people are choosing nicotine options
that are actually worse for one’s health, thinking that they
are opting for the ‘healthier’ alternative. Ideally, advocacy
campaigns to strengthen and enforce policies restricting
SLT and smoking are needed in most of Southeast Asian
countries, but these efforts require more resources,
which many countries just cannot support at this time.
Human Papillomavirus
The Human Papillomavirus is an ancient pathogen infecting epithelial tissues in amphibians, reptiles, and mammals. Its composition includes a double-stranded DNA
surrounded by a protein capsid, similar to many other
viruses on the Papovaviridae family. There are more than
thirty strains of this virus, of which a fourth are associated
with oropharyngeal cancers. The most common low risk
strains found in HPV-related oropharyngeal cancer are
HPV- 6 and 11, while the most common high-risk strains
are 16 and 18.The high-risk strains are mainly transmitted
via frequent vaginal and/or oral sex with multiple partners
and without barrier usage. The pathophysiology behind
this virus is mainly a result of its oncoprotein production.
HPV protein E6 has been shown to interfere with p53
mechanisms in the body and protein E7 interferes with
pRb tumor suppressor protein in the host. These interruptions lead to abnormal cell growth by inhibiting the
apoptosis pathways and dysregulating the cell cycle. As
such, the early HPV oncoproteins E6 and E7 are responsible for the malignant phenotype.
It is important to appreciate the nuisances between
HPV related oropharyngeal cancers and non-HPV related ones. The most critical difference can be seen in the
detection and initial manifestations. Most HPV associated
oropharyngeal cancers begin with a protruding neck mass,
while non-HPV related ones often begin with symptoms
of sore throat and dysphagia. Research has also shown
that oropharyngeal cancers associated with HPV have
a much better prognosis, but the end-term side-effects
can be more drastic (Timbang, 2019). As the oropharynx
regulates speech, swallowing reflexes, and airway patency, surgery or other medical treatments in the area pose
substantial risk of morbidity. Standard treatment for HPV
related oral and oropharyngeal cancers is currently chemotherapy, radiation and sometimes surgery.The after-effects of these procedures often wreak havoc on the oral
cavity. Xerostomia, worsening periodontal condition, loss
of taste, trismus and osteoradionecrosis are only some of
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the risks involved after treatment.
Several studies have looked into the prevalence of
HPV in oropharyngeal cancers, but HPV identification
rates vary widely based on the population, subsite combinations, specimen type, and detection process. HPV
is more commonly seen in oropharyngeal and tonsillar
cancers than in other head and neck cancers. One study
provides a clear and insightful connection between HPV
and oropharyngeal cancer (Herrero, 2003). From April
1996 to December 1999, the research was conducted in
Italy, Spain, Northern Ireland, Poland, India, Cuba, Canada,
Australia, and Sudan. Patients were recruited from cancer
referral clinics, and control groups were drawn from the
same clinics or nearby general hospitals that served the
same populations as the case patients. Control subjects
were chosen based on sex and were within a 5-year age
gap from the case participant. Control participants were
disqualified if they had a history of oral cavity or oropharyngeal disease.
Their methods included obtaining an interview, collecting exfoliated oral cells, bloodwork, and biopsy specimen
from all case patients. HPV DNA was detected by polymerase chain reaction testing (PCR). The results indicate
that HPV DNA was detected in 3.9% of biopsy specimens
of 766 cancers of the oral cavity and of 142 cancers of the
oropharynx. HPV DNA in cancer biopsy specimens was
detected more frequently among subjects who reported
more than one sexual partner or who practiced oral sex.
HPV-16 DNA was found in 94.7% of HPV DNA-positive
case patients. Their conclusion was that HPV, especially
strain HPV-16, plays an important etiologic role in many
cancers of the oropharynx and the oral cavity. However,
there is still uncertainty regarding the mechanism of
transmission, that requires further investigation.
In the last ten years much headway has been made in
terms of prevention of HPV-related cancers of the oropharynx and oral cavity. Public health campaigns have been
instituted to increase barrier contraceptive use when engaging in oro-genital intercourse. Much of this is based on
the vast amount of research implicating HPV16 and 18
in cancers of the oral cavity and oropharynx. These campaigns are especially geared towards older adults who
are beyond the vaccination age. In terms of vaccination,
the first vaccine related to HPV was released in 2006
by the CDC and called Gardasil-4. This vaccine protects
against the four main strains implicated in HPV-related
cervical cancer in women. Recently a newer version of
this vaccine was released, preventing against 9 different
strains, and covering over 90% of strains implicated in
cervical cancer. The initial roll out of this vaccine was
geared towards boys and girls ages 9-26, with the optimal
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administration at 11 or 12 years of age. The idea behind
this was to administer the vaccine prior to initiation of
sexual activity and at an age when the body has the strongest immune response. Since then, the age recommendation has increased to 45 years old, though its efficacy at
this older point in life is exceedingly less.
It is important to note that the CDC has not approved
the vaccine for fighting oropharyngeal cancers related to
HPV. This stems from a broad lack of knowledge in the
medical world regarding cancers of the head and neck.
When surveyed, 15.5% of members of the Louisiana
Chapter of the American Academy of Pediatrics were
not aware of the link between oral cancer and HPV, and
less than half knew its prevalence in this country (Mehta,
2017). One of the main reasons the CDC has chosen not
to endorse vaccines for HPV related oral cancers is because this type of cancer may not develop for many years
after initial infection with the virus. As such, clinical trials
establishing correlation between increasing vaccine use
and decreasing oral cancer rates may be exceedingly difficult. Another critical distinction between oral and cervical cancers related to HPV is detection. Papanicolaou
tests for cervical cancer are administered regularly and
with high accuracy. No similar test with the same acuity is
available for oropharyngeal cancers. As such, this vaccine
may be the strongest form of prevention.
Inflammatory Bowel Diseases
Inflammatory bowel diseases has also been associated
with oral cancers. Inflammatory bowel disease (IBD)
refers to two diseases, Crohn’s disease, and Ulcerative
Colitis, under which the gastrointestinal (GI) tract is inflamed over a long time. While the exact cause of IBD is
unclear, it is caused by a malfunctioning immune system.
To defend the body, a fully functioning immune system destroys infectious species such as viruses and bacteria. The
immune system reacts inappropriately to environmental
stimuli in IBD, resulting in gastrointestinal inflammation.
There tends to be a genetic factor as well, with someone who has a family history of IBD being more likely to
have this abnormal immune response. Much research has
been conducted on this subject in relation to the field of
dentistry to understand oral manifestations of IBD, and if
there are any links between the disease and oral/oropharyngeal cancer.
One study, compared subjects with Ulcerative Colitis
and Crohn’s Disease in comparison to a healthy control
group. The goal of this study was to understand whether IBD has an effect on the oral cavity. The case group
was divided into five classes based on their medication
and treatment regimen: untreated, salicylate treatment,

corticosteroid therapy, immunosuppressant medications
(azathioprine and cyclosporine), and biological therapy (infliximab and adalimumab). Patients who agreed to
participate in the study completed a structured questionnaire that asked about their age, ethnicity, medical
background, medications, smoking habits, and oral hygiene
habits. Patients were also asked to mention any unusual
oral manifestations they experience, such as xerostomia,
halitosis, dysphagia, regurgitation, and dysgeusia, as well as
other signs of oropharyngeal cancer.
The results garnered indicate a higher incidence of oral
manifestations as well as oral and oropharyngeal cancer
in the case group vs the control group, though statistical
significance was not achieved. They also noted that the
majority of complications were seen in the corticosteroid and immunosuppressant therapy groups. However,
the authors state, somewhat confusingly, that the pharmacological therapy of IBD did not show a statistically significant relation with the presence of lesions of the oral
mucosa or oral cancer (Laranjeira, 2015). This is difficult
to understand when the untreated group did not show
any signs of oral manifestations. As such, much of this data
fails to serve clinical significance.
A recently published systematic review on this topic
works to provide a pathophysiology behind IBD and
cancers of the oral cavity and oropharynx. Their search
strategy included PubMed, Embase, and Scopus articles
on this topic from 1946 to January 2015, published in
any language. The results of this study indicate that the
connection between IBD and oral cancers are the extensive use of immunosuppressive drugs in this patient
population. “Immunosuppressants may promote cancers
by various mechanisms including carcinogenic mutations
of cell DNA, impaired immunosurveillance of tumor cells,
impaired number or function of immune cells chronically
infected by Epstein-Barr Virus [EBV] or HPV, and several
others (Katsanos, 2016).”
As such, prolonged immunosuppression for chronic
graft-vs-host disease or IBD increases the risk of oral
cancer. It is important to note that oral cancerous and
precancerous lesions have been reported in patients with
IBD as reported for other groups of immunosuppressed
or transplanted patients. Unfortunately, there are no
precautions implemented to modify this risk and there
are no routine oral cancer screenings recommended for
this patient population. It would behoove the medical and
dental communities to collaborate on ways to manage
the increased risks faced by people undergoing immunosuppressant treatment for IBD and other conditions
involving immunosuppression.
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Conclusion
Many lesser known and novel causes of oral cancer and
oropharyngeal cancer were discussed in this literature
review. The purpose of this was to broaden our understanding of the disease and consider possible etiologies
that had not been associated with the oral cavity in the
past. With this knowledge, we can better educate the
public in preventative measures as well as encourage
more routine screenings for those practicing higher risk
behaviors. As the saying goes, prevention is the best form
of treatment.
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Abstract
The aim of this study is to investigate the common factors that may influence the success of dental implants. Addressing these
factors may potentially aid experts in the field in delivering dental implants without approaching or decreasing the number of failures. Smoking, diabetes, implant maintenance, age, and implant size have significantly influenced implant success. It is suggested
that patients are advised to quit smoking at least one week before surgery to minimize risk factors. Inadequate glycemic control
also contributes to periodontal destruction and is associated with the severity of peri-implant complications. However, if patients
maintain good glycemic control, dental implants will still have a high success rate. As a result, treating diabetic patients primarily
with proper glycemic control is a safe and successful treatment option. Peri-implant maintenance treatment (PIMT) is another
important component for dental implant success. Furthermore, physical, metabolic, and endocrine changes frequently occur as
people become older. These changes may lead to an increased risk of osteoporosis that may cause the development of dental
implant failure. Lastly, the use of inadequate implant for a certain area of the maxilla or mandible may lead to dental implant
failure.This research also shows that short implants should only be utilized in exceptional circumstances, but conventional size implants should be the primary mechanism of implant delivery. As a result, the longer the implant, the better the chance of survival.
Furthermore, if the buccolingual width of edentulous crest is sufficient, the use of wide implants is shown to be the best strategy
for implant delivery. Having long and wide implants is established to improve the implants strength and resistance to fracture.
Introduction
There are several different methods for replacing missing
teeth such as dental implants or dentures. However, dental
implants have emerged as the new treatment modality for
many patients and are expected to play a significant role
in oral rehabilitation in the future. Conventional dentures
have restricted indications and outcomes, but implant dentures have advantages in function, stability, comfort, and can
replace one to all missing teeth if they are supported by
healthy oral (bone quality and quantity) and overall health
(Sidjaja, et. al. 2006). Dental implants are defined as surgical
components that interact with the jaw or skull bone to
support a dental prosthesis, such as a crown, bridge, denture, or facial prosthesis, or to function as an orthodontic
anchor (Raikar, et. al. 2017). Dental implants can improve a
person’s look, confidence, self-esteem, improve their ability
to talk and chew properly, and remove the need for complete and partial dentures (Krishnan, et. al. 2020). Over the
past 10 years, 90%–95% of dental implants were reported
to be successful (Raikar, et. al. 2017). Even though dental
implants have a very good survival rate, a rising number
of patients are developing peri-implant illnesses. Given the
potential systemic consequences of chronic inflammation,
it is critical to have a better understanding of peri-implant
disease occurrence and risk factors to prevent or manage peri-implant inflammation. These peri-implant illnesses
can cause pain, need surgical or non-surgical therapy, have
significant consequences on systemic health, or result in
implant failure. The future burden of peri implant illnesses
must be determined for patient consent, physician decision-making, and resource allocation. Peri-implant illnesses
are divided into two categories: peri-implant mucositis
and peri-implantitis, both of which are infectious diseases.
Soft tissue inflammation around a functional dental implant with bleeding on probing (BOP) has been classified

as peri-implant mucositis, and peri-implantitis is differentiated by associated loss of supporting marginal bone past
normal bone remodeling. Peri-implant mucositis is reversible, whereas peri-implantitis is more difficult to reverse
(Daubert, et. al. 2015).
Prosthetic implants can fail for a variety of reasons, both
mechanical and biological. Incomplete osseointegration, infection, and poor healing are the most common reasons of
implant failure (Sakka, Coulthard, 2011). Osseointegration
is a biological tissue healing process in which a direct functional and structural connection between organized live
bone and the surface of a loadbearing implant. The direct
anchorage of the implant fixture to surrounding host bone
is a very important feature to affirm the reported long
term clinical success of dental implants. Several factors
with insufficient control can jeopardize the implant’s solid
anchoring to the bone tissue. These factors can be categorized as surgical (primary stability and surgical technique),
tissular (quality and quantity of bone, healing, remodeling),
and implantological (macrostructure, microstructure, and
dimensions) (Georgiopoulos, et. al. 2007). In addition, a
dentist should assess several factors to ensure that a patient is a good candidate for a dental implant treatment and
that the surgery will not lead to implant disease. Smoking,
diabetes, implant maintenance, age, and implant size are all
possible factors that may influence the success rate for
dental implant.
Methods
The literature in this research helped provide a thorough
examination of the subject and enabled a conclusion to be
established on the research topic. Databases including EBSCO,
ProQuest, PubMed, and Google Scholar that were primarily
accessed through Touro College’s Online library, were extremely useful for locating essential and appropriate articles.
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Smoking
Cigarette smoking has been linked to an increase of plaque
formation, a higher prevalence of gingivitis and periodontitis, a higher rate of tooth loss, and increased alveolar ridge
resorption in the oral cavity (Scabbia, et. al. 2001). When
it comes to dental implant rejection and implant-related
complications, nonsmokers have a huge advantage. About
the time of implant insertion and second-stage surgery,
smoking has been linked to implant failure, with smokers
having a failure rate double that of nonsmokers (Gorman,
et.al. 1994). Smoking may lead to problems with oral connective tissue repair, dignity, and interference with wound
healing by inhibiting cellular protein synthesis and reducing
the ability of gingival fibroblasts to adhere as a product of
nicotine (Hoffman, 1997). The elevated amounts of fibrinogen, hemoglobin, and blood viscosity, abnormal levels of
carboxyhemoglobin in blood, impaired polymorphonuclear
neutrophil (PMN) leukocyte activity, and increased platelet adhesiveness have all been proposed as mechanisms
through which smoking impairs wound healing (Lawrence,
et. al. 1984). In a study to evaluate the influence of smoking,
2,194 implants were placed in 540 patients over a 6-year
period. The overall failure rate was 5.92% which is consistent with other studies; however, when patients were subdivided into smokers and nonsmokers, it was found that
a significantly greater percentage of failures occurred in
smokers (11.28%) than in nonsmokers (4.76%) (Bain, Moy,
1993). Although, the authors demonstrated that implants
malfunction because of smoking, there are some reports
that have shown no significant differences between smokers and nonsmokers in the success of implants.A meta-analysis study monitored the performance of machined surface
implants and Osseotite implants in which he was able to
isolate the effect of smoking. The study showed that there
was no difference observed between the smoking groups
and the non-smoking group, however, there was a clinically relevant difference observed between the two types of
implants (Bain, et. al. 2002).The results of this meta-analysis
revealed that the risks of smoking are not represented in
this group of patients who smoke around 12 cigarettes a
day on average. The author does, however, emphasize that
there may be a significant difference regarding implant failure between heavier smokers and nonsmokers than there
are in the current sample.
Even though smoking seems to be harmful to implants,
quitting smoking can significantly reduce the rate of implant failure. A smoking cessation plan was developed, and
it was discovered that there was a statistically important
gap in the failure rates between those who tended to
smoke and those who followed the non-smoking protocol
(Bain, 1996). Other studies show there was no statistically
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significant difference between complications and past smoking, this suggests that quitting smoking may even reduce the
likelihood of complications to the level of a nonsmoker’s
(Levin, et. al. 2004). Since smoking has such a negative impact on implants, Bain and Moy’s initial guidelines say that
long periods of abstinence are needed.They recommended
that the patient quit smoking at least one week before surgery to allow for the reversing of increased platelet adhesion and blood viscosity, as well as the nicotine’s short-term
effects. The patient can refrain from smoking for at least
two months after the implant has been placed, by which
time bone healing will have advanced to the osteoblastic
process and early osseointegration will have occurred (Bain,
Moy, 1993). Furthermore, according to certain research, the
volume of cigarettes consumed is linked to a higher rate of
implant failure. In a prospective study on mandibular implant
overdentures found that heavy smokers (30-40 cigarettes
per day) with type IV bone had a higher rate of implant
failure (Fartash et. al. 1996). Furthermore, other research
found that heavy smokers (>14 cigarettes a day) had slightly
more marginal bone damage across implants than people
who smoked less (14 cigarettes per day) (Lindquist et. al.
1996). This indicates that the higher the rate of cigarette
consumption, the more likely it will lead to implant failure.
In general, smoking tends to have a greater effect on
maxillary implants than it does on mandibular implants.
In a retrospective analysis of over 200 implants, a gap
of the success rates in smokers was observed between
maxillary and mandibular implants prior to loading. The
performance rates in the maxilla were impaired, but not
in the mandible (Bruyn, Collaert, 1994). In addition, other
research discovered peri-implantitis was slightly worse in
smokers than in nonsmokers in the maxilla, but not in the
mandible (Hass, et. al. 1996). Posterior maxillary bone is
likely to be of poor consistency, making it more vulnerable to the negative effects of smoke. Others observed
that bone loss around anterior sites was almost twice
as large as bone loss around posterior (Lindquist et. al.
1997). However, it seems logical to say that since it is the
region most insulated from the local influence of tobacco
smoke and is, moreover, covered by the tongue, there
should be lower failure rates in the posterior mandible
among smokers than the anterior region. However, this
is an area that needs to be looked at more thoroughly.
Diabetes
Diabetes mellitus is a chronic carbohydrate metabolism
disease characterized by hyperglycemia, which reflects a
disruption of metabolic balance in glucose consumption
by tissues, glucose release by the liver, pancreatic, anterior
pituitary, and adrenocortical hormone output liberation.
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Recent studies have shown that diabetes mellitus affects
any tissue of the body in some way, either directly or indirectly (Chauhan, et. al. 2019). This metabolic disease affects
an estimated 15.7 million people in the United States, or
5.9% of the population (national institute of health, 1995).
Diabetes occurs when the pancreas doesn’t contain enough
insulin (type 1) or when the body can’t use the insulin it
produces efficiently (type 2) (Chauhan, et. al. 2019). In the
oral environment alone, diabetes has been associated with
periodontitis, xerostomia, increased levels of salivary glucose, swelling of the parotid gland, an increased incidence
of caries, and slower healing after surgeries leading to tissue necrosis (Rothwell, Richard, 1984). If diabetes is not
managed properly, elevated levels of extracellular glucose
may also form covalent bonds with macromolecules in the
body (Salvatierra, et. al. 2016).
Diabetes is a crucial modifying factor in periodontitis,
but its connection to peri-implant diseases has yet to
be thoroughly investigated. however, diabetes may be
considered one of the most encountered contraindications to dental implant therapy. Animal studies have
proven that poor bone-implant healing and delayed osseointegration are linked to inadequate glycemic control (Eskow, Oates, 2017).
A study contained 200 diabetic patients and 200 non-diabetic control patients. Success occurred in 192 cases
in diabetic group, while it occurred in 196 cases in the
control group. The results obtained were not significantly
different comparing the prognosis of dental implants in
diabetic and non-diabetic patients (Chauhan, et. al. 2019).
Although a study observed an association between diabetic patients and peri-implantitis, it reported peri-implantitis diagnosed in 24% of diabetic patients and 7%
of non-diabetic patients (Ferreira, et. al. 2006). However,
these results refer to patients with diabetes regardless of
their glycemic management. Furthermore, another study
reported a high risk in diabetic patients for peri-implantitis (Daubert, et. al. 2015). However, it seems logical to say
that since their study only had five diabetic patients that
may have influenced their statistical analysis. Therefore,
high success rate is achievable when dental implants are
placed in diabetic patients whose disease is under control,
but patients that do not have the proper control may be
susceptible to implant failure.
Studies were conducted to observe the relationship
between the level of metabolic control of diabetes and
peri-implantitis. When comparing poorly controlled diabetic patients to well-controlled diabetic patients, certain
clinical parameters, such as periodontal disease and radiographic bone degradation, were slightly higher. Authors
concluded that inadequate glycemic regulation could play a

role in the modulation of periodontal destruction and may
be linked to the seriousness of peri-implant complications
(Venza, et. al. 2010). Other studies conclude that regardless
of the level of glycemic control, type 2 diabetic patients
have a significantly higher risk of peri-implantitis and marginal bone loss (Lagunov, et. al. 2019).
A systematic review investigated whether hyperglycemia/diabetes mellitus is associated with peri-implant
diseases. According to the meta-analyses, the chance of
peri-implantitis is around 50% higher in diabetics than in
non-diabetics. Importantly, nonsmokers with hyperglycemia have a 3.39-fold increased chance of peri-implantitis
relative to those of normoglycemia. In contrast, the connection between diabetes and peri-implant mucosa was
not significant. Therefore, the study concluded that the
risk of peri-implantitis is greater in people with hyperglycemia compared to those with normal blood glucose
levels. In addition, nonsmokers with hyperglycemia have
an increased risk of peri-implantitis, demonstrating that
smoking is not needed to intensify the effects of hyperglycemia (Monje, et. al. 2017a). However, only 11 percent
of their studies included subjects with satisfactory plaque
control, the remaining 89 percent did not report any oral
hygiene criteria and thus likely included subjects with low
plaque control, which may have influenced their findings.
In addition, only three of the experiments used in their
comparative analysis omitted smokers, so smoking may
have confounded the effects of hyperglycemia for implant
success in the other studies.
Although this study suggests that diabetic patients with
strong glycemic control may have a high success rate for
dental implants, precautionary measures may increase the
likelihood of a successful outcome. Before implant therapy, a comprehensive health history should be obtained by
the doctor, adequately screening the candidate to ensure
that they are taking their diabetic drug, and if their metabolic control seems to be inadequate, delaying implant
treatment until improved control is reached is the safest
option (Balshi, et. al. 1999).
Future research is required to look at the connection
between peri-implant tissue health and long-term changes
in glycemia and HbA1c levels. The major glycemic control
parameters should be monitored not only for scientific
purposes, but also for physicians since inadequate metabolic control can lead to problems such as an increased
risk of infection. Under the limitations of this research,
the findings suggest that implant therapy in diabetic patients with strong glycemic control is a safe and effective
treatment choice.
Implant Maintenance
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With the use of dental implants for teeth replacement
and denture stabilization, the need for maintenance
and repair is becoming more relevant in daily clinical
practice. Periodontium is the tissue that surrounds
and supports the teeth. If those in the field can understand the biological mechanisms of the gingiva and
periodontium in normal teeth versus implants, it will
demonstrate how much more critical implant tooth
oral hygiene is compared to normal tooth oral hygiene.
The peri implant mucosal seal is a region established
to apply a tight seal to isolate the implant and the
bone from bacterial plaque in the oral environment.
However, unlike the periodontium surrounding a normal tooth, the peri-implant mucosal seal still lacks an
effective barrier against bacterial invasion from plaque
(Weyant, 1994). In addition, the vasculature in the gingival tissue that surrounds dental implants, is not as efficient as the vasculature in normal teeth, thereby, preventing the destruction of biofilms. Furthermore, the
oriented collagen fibers around the implant are parallel
as supposed to being perpendicular, which makes it
more susceptible to bacterial invasions (Nevins, Langer,
1995). Therefore, the lack of proper oral hygiene may
not only cause bacteria invasion from plaque accumulation which may lead to periodontitis or gingivitis, it
can also induce the development of peri-implantitis
(Kurtzman, Silverstein, 2014).
A cross-sectional study was performed on patients
who were healthy and partly edentulous. 206 implants
were fulfilled on 115 patients that were divided into
three categories; 1) usual compliers which experienced
peri-implant maintenance therapy (PIMT) at least twice
a year; 2) erratic compliers which experienced PIMT
less than twice a year; 3) non-compliers which didn’t
experience any PIMT. The study discovered that association between compliance and peri-implant condition
were statistically significant. Compliance was associated with 86% fewer conditions of peri-implantitis.
The probability of PIMT compliance was substantially
associated with frequency of peri-implantitis (Monje,
et. al. 2017b). As a result, PIMT enforcement could be
the path to maintaining an inflammation-free condition
that allows hard and soft tissue integrity to coexist.
For instance, it was demonstrated that the failure rate
of dental implants was decreased by 90 percent of patients who received routine maintenance compared to
those who did not. In fact, patients who received at
least one maintenance appointment on a yearly basis
had a 60 percent lower failure rate than those who
did not have any maintenance (Gay, et. al. 2016). In this
regard, it has been stated that patients who receive
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regular PIMT have a lower risk of peri-implant bone
loss development. To stress the importance of PIMT, in
a systematic review, the long-term results of patients
with periodontitis who underwent periodontal therapy and implant placement were evaluated. According
to the findings, patients of periodontitis had good implant outcomes, within trials with a 10-year follow-up,
implant survival was high (92.1 percent) (Zangrando,
et. al. 2015). The high success rate of implant therapy
in patients with periodontitis who received adequate
treatment and routine periodontal care, demonstrates
the significance for implant maintenance.
Regarding this, many patients remain unaware of
the critical steps that must be taken to ensure proper implant maintenance. A study was performed out
to assess the knowledge of oral hygiene measures in
patients with dental implants. A questionnaire that involved 50 patients on a basis of assessing the awareness
about hygiene maintenance for their implants. Patients
who had dental implants rehabilitated were asked approximately ten questions. Patients were questioned
about their brushing method, the kinds of brushes
they used for implants, if they used mouthwash and
floss to keep their implants clean, and if they used any
other implants aids. Around 80% of patients said they
are aware of the oral hygiene measures required for
implants, and that they learned about them from their
dentist; however, 10% of patients were unaware of the
importance of hygiene measures in preserving dental
implants. The findings of this survey shows that the patients in the study had a poor understanding of dental
implant hygiene and its effects, and the experience of
dental implant maintenance in patients is inadequate
(Krishnan, et. al. 2020). As a result, dentists should be
advised to provide routine dental exams and give oral
hygiene tips to all patients who have dental implants.
Services aimed at improving oral hygiene and implant
management for implant patients are required.
Unfortunately, implant failure is associated with a
lack of professional implant maintenance. It has been
proposed that a professional mechanical plaque removal procedure should be programmed to avoid the
formation of peri-implantitis. Disruption of the assemblage of surface associated microbial cells enclosed in
an extracellular polymeric matrix must be routinely removed through self-performed oral hygiene measures.
Accordingly, Peri implant maintenance compliance,
experiencing at least 2 PIMT yearly has been demonstrated as a crucially essential factor for preventing
peri-implantitis in healthy patients.
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Age
Patients’ conditions vary greatly, particularly among
the elderly. Implant failure seems to be a multi-factorial
problem, so it’s unclear if age is a risk factor for implant
placement. However, there are physical, metabolic, and
endocrine changes that occur as people age, and clinicians must consider that these changes can impact implant treatment. The human skeleton accumulates bone
until around the age of 30 years, at which point it begins
to lose bone, causing the bone to weaken (Heersche, et.
al. 1998). In addition, since diabetes and osteoporosis are
prevalent in the elderly population, these conditions may
influence dental implant success.
Age-associated bone loss is related due to an uncoupling of osteoblastic and osteoclastic activity, since the
osteoblastic activity that creates new bone can’t keep up
with the osteoclastic activity that breaks down bone to
rebuild it (Freemont, et. al. 2007). Furthermore, as age
increases, the rate of bone healing slows down. Possible
suggestions for the cause of delayed healing may include,
reduction of the osteogenic stem cell numbers, a decrease in the proliferation and differentiation capability,
and reduced local blood flow (Strube, et. al. 2008). An
analysis was conducted to see how long it took for bone
to heal and close a fracture gap for rats. By 4 weeks after
fracture, young 6-week-old rats have formed bone to
close the fracture gap, adult 26-week-old rats took 10
weeks, and older 52-week-old rats require more than
26 weeks (Meyer, et. al. 2004). The causes for poor bone
healing may be because open wounds compress more
slowly, and incised wounds develop strength more slowly
as age increases. In addition to weak bone regeneration,
increased aging may also cause reduced keratinization of
the epithelium, a decrease in the synthesis of collagen in
periodontal ligaments, and a reduction in the number of
cells on the osteogenic layer of the alveolar bone, all leading to implant failure.
A prospective study was carried out with 2 groups of
healthy edentulous patients to determine the influence of
age on peri-implant tissues in patients treated with implant-supported overdentures in the mandible. The mean
age of the younger group was 46 years, and the mean age
of the older group was 68 years. After three years, the
mean bone loss in the younger group was 1.2 mm, and in
the older group it was 0.8 mm, but the difference was not
significant. The clinical performance of implant-supported overdentures in the mandible was similarly effective
in younger and older patients (Meijer, et. al. 2001). This
study indicates that increased age alone is not a contradiction to implants. However, another study looked at a
vast number of patients who had been operated on by

an experienced surgeon and discovered that elderly age
raised the likelihood of implant failure; patients over 60
years old were twice as likely to have negative results
(Brocard, et. al. 2000). Furthermore, a 7-year prospective
trial was observed in a private practice with the same
model of implants, and it was discovered that only a limited minority of implants existed in patients over the age
of 60 (Moy, et. al. 2005).
A rat study involved three age groups, 6 weeks (younger group), 12 weeks (older group), and around 2 years
(old group), the young group demonstrated that new
trabecular bone developed aggressively around the implant and that strong bone interaction was reached more
quickly than the adult group. The old group, on the other
hand, had less recently developed trabecular bone around
the implant and had less bone interaction than the other
groups (Shirota, et. al. 1993). The findings showed that as
rats get older, the rate and amount of new bone development around implants decreased. This study demonstrates that as patients increase in age the likelihood for
developing osteoporosis increases as well.
Diabetes mellitus is a serious disease that affects
people all over the world. Diabetic patients get more
prevalent as people get older, particularly those over 50
(Harris, et. al. 1998). Diabetic patients have poorer wound
healing, greater chance of microvascular disease, a slower
response to infection, and are more susceptible to periodontal disease, all of which can make implant placement
more difficult (Olson, et. al. 2000). Mineral metabolism is
also changed which can potentially disturb the integration
process (Fiorellini, et. al. 2000). Furthermore, the time
span of diabetes may affect implant performance, as an
increase in diabetes duration could induce microvascular
disruptions, which could lead to implant complications
(Olson, et. al. 2000). As a result, implant failure is more
likely to occur in elderly patients who have been diabetics
for a longer time.
The reduction of bone mass and density in the body, including the jaws, is known as osteoporosis. Osteoporosis
is closely linked to estrogen deficiency, so postmenopausal women are at risk for osteoporosis. The reduction in
estrogen during the menopausal transition process causes more bone resorption than development, resulting in
osteoporosis. There are two types of postmenopausal
women. Type one or ‘postmenopausal osteoporosis, in
which trabecular bone loss is prevalent, resulting mostly
in vertebral and wrist fractures, and Type two or senile
osteoporosis, in which both cortical and cancellous bone
are missing, resulting in hip fractures.
A study that examines the relationship between premenopausal and postmenopausal women and implant
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failure found no evidence of a higher failure rate for implants in women over 50 relative to women under 50
or between women and men over 50 (Dao, et. al. 1993).
However, according to a survey, women lost about 10
percent of their hip bone mineral density between the
ages of 50 and 60, compared to just 2 percent for men.
(Looker, et. al. 1998). Just like other bones in the body
can decrease bone mass for postmenopausal women,
the alveolar ridges have been stated to decreased bone
mass in postmenopausal women as well (Humphries,
et. al. 1989). Although some evidence indicates that the
mandible varies sufficiently from postcranial skeletal sites,
and it is therefore unclear if bone mass throughout the
skeleton corresponds to bone mass in the mandible and
maxilla (Boyde, Kingsmill, 1998). However, mandibular
bone mineral content declines with age, and mandibular
bone density was shown to be lower in elderly female
subjects than in male subjects (Heersche, et. al. 1998),
which indicates that postmenopausal women are more
likely to develop osteoporosis even in the mandible and
maxilla due to estrogen deficiencies.
According to a study that looked at jaw variations in
pre- and postmenopausal women, the effect of postmenopausal estrogen status on impaired implant healing
was seen in the maxilla but not in the mandible. In addition, hormone replacement therapy decreased the rate
of maxillary bone loss by 41 percent. Since osteoporosis
affects trabecular bone rather than cortical bone, and the
maxilla has more trabecular bone composition than the
mandible, the authors reasoned that the maxilla is more
vulnerable to systemic osteoporosis (August, et. al. 2001).
Therefore, postmenopausal women may be more likely
to experience implant failure especially in the maxilla due
to hormone deficiency.
Implant Size
Optimizing implant geometry to maintain a healthy stress
level at the bone-implant contact is a complex issue. The
use of an inadequate implant for a certain area of the
maxilla or mandible may lead to dental implant failure.
Dental implants come in a variety of lengths, ranging from
5.0 to 20 mm.The most frequent implant length is 8 to 15
mm, which corresponds to the length of a normal root.
The diameter of currently available implants ranges from
3.0 to 7.0 mm. The implant diameter requirements are
based on both surgical and prosthetic concerns.
It is not always possible to deliver dental implants of
sufficient length since many situations lack having more
than 8 mm of residual vertical bone height. Therefore, clinicians must choose between augmentation of the bone
or the placement of short implants (Renouard, Nisand,
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2006). For clinicians to prevent the use of short implants,
resorbed bone should be augmented using different
bone-grafting procedures. This will allow the clinician
to place a longer implant. However, short implants may
still be a better option than bone augmentation, since
augmentation treatments can lead to extra surgical interventions, serious postoperative morbidity and complications, higher cost, and take longer before patients can
chew on their implant-supported prostheses (Esposito,
et. al. 2011). A study suggests that 5 mm short implants
yield equal, if not better, outcomes than longer implant
placed in bone one year after loading. Using the bone
levels at implant placement as baseline data, there was a
statistically significant difference between short and long
implants. Short implants lost an average of 1 mm and long
implants lost around 1.2 mm in peri-implant marginal
bone levels one year after loading (Esposito, et. al. 2011).
However, this study has limitations due to the small sample size, because only a few individuals had enough bone
width (at least 8 mm) to tolerate implants with a 6 mm
diameter. Short implants with diameters of 4.0 to 5.0 mm
should also be assessed since clinicians often compensate for a lack of height by using implants with a larger
diameter (Esposito, et. al. 2011). Therefore, it’s logical to
assume that the larger diameter of 6 mm in this study
was responsible for the positive success rate of shorter
implants. However, short implants with narrow diameters
may lead to implant failure.
According to the findings of a systematic study, the
placement of short rough-surface implants is not a less
efficacious treatment modality than the placement of
conventional rough-surface implants (Kotsovilis, et. al.
2009). Furthermore, a study involving 7-, 8.5-, and 10-mm
implants were analyzed, and it was determined that
short implants should be explored as an alternative to
advanced bone augmentation operations (Neves, et. al.
2006). Another study established that when delivering 6and 7-mm implants, short implants with a press-fit shape
and a sintered porous surface geometry exhibited the
highest performance (Hagi, et. al. 2004). However, other
research demonstrate that short implants may be linked
to decreased survival rate (Lee, et. al. 2005). According
to the findings from a systematic review, short (<10 mm)
implants can be successfully placed in the partially edentulous patients, though with a tendency of an increasing
survival rate per implant length (Telleman, et. al. 2011). As
a result, short implants should only be utilized in exceptional circumstances, but conventional implants should
be the primary mechanism of implant delivery. Several
presumed reasons to explain why short implants are likely to have a worse survival probability in the posterior
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region may be because there is less bone to implant contact due to the smaller surface area of short implants.
Furthermore, due to substantial resorption in the posterior region, a larger crown to implant ratio is created
over short dental implants, which may lead to a greater
implant failure rate (Telleman, et. al. 2011). In addition, it
has been proposed that as the length of the surface area
rises, the stress levels for a given applied load decreases
on longer implants. The mechanical resistance to masticatory forces is also improved because of this (Hoon,
et. al. 2005). Aside from implant length, having an implant
in a threaded design rather than a smooth design may
increase its surface area. This will aid in the transmission
of axial tensile or compressive loads better than smooth
implant types (Hoon, et. al. 2005).
Aside from implant length, the usage of implants with a
larger diameter may provide numerous advantages. From
a biomechanical standpoint, larger diameter implants can
help provide engagement of a maximum bone and better
stress distribution in the surrounding bone (Arisan, et.
al. 2010). The use of wider components also enables for
more torque to be applied in the placements of prosthetic component (Lee, et. al. 2005). In addition, wide diameter implants will provide an Increase bone-to-implant
contact, bicortical engagement, and rapid insertion at failure locations, as well as a reduction in abutment stresses
and strains. As a result, having a larger contact area improves initial stability and minimizes stress. By increasing
the diameter of the implant, it is possible to improve its
strength and resistance to fracture (Lee, et. al. 2005).
However, wide implants are restricted due to the the
width of the residual ridge and aesthetic requirements for
a natural emergence profile (Lee, et. al. 2005). However,
when the buccolingual width of the edentulous crest is
insufficient, narrow diameter implants can be used to replace missing teeth. According to an article examining the
clinical and radiographic outcome of mini dental implants
(MDIs), in comparison to conventional-diameter implants,
MDIs are cost-effective, have fewer complications during
flapless implant placement, and can be used in edentulous
arches with minimal remaining bone in a facial–lingual dimension to avoid bone graft. In addition, MDIs also has
a great advantage because of its short healing time, reduced post-operative discomfort and quick restoration
of mastication and aesthetics for patients throughout the
healing phase (Elsyad, et. al. 2011).
Although increasing the diameter of the implant may
decreases the amount of bone in the surrounding area,
a recent study examined the success and survival rates
of narrow diameter implants over a 10-year period, as
well as peri implant characteristics and mechanical and

prosthetic post loading complications. They concluded
that narrow diameter implants can be utilized safely in
situations only when a conventional diameter implant is
not appropriate, since most of the bone loss surrounding
narrow diameter implants happened within the first two
years of loading and was minor afterwards (Arisan, et.
al. 2010). As a result, the primary strategy should be the
use of wide implants, since increasing implant diameter
decreases the maximum value of Von Mises equivalent
stress. Therefore, as the surface area transmitting a horizontal component of force applied to a dental implant
increased, the stress distribution in the maxilla and mandible have become more effective.
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Abstract
Multiple Sclerosis (MS) is a neurological disorder that affects about one million people in the United States. The disease results
from an abnormal immune response where T cells damage the myelin sheath in the central nervous system, causing scarring.The
lesions can occur in any part of the brain or spinal cord, and thus affects every patient differently. One of the most detrimental
effects the disease has on patients’ lives is the decreased ability to walk. There has been research and treatments to manage
pain and slow progression of the disease, but little progress has been made to enable MS patients to walk more comfortably.
Previously, there have been gait training devices in use. However, many require intensive manual labor which causes the patient
and the physical therapist to fatigue easily. Recently, Ekso, a self-supporting robotic exoskeleton, designed for patients with spinal
cord damage, has been shown to improve gait and overall quality of life in patients with MS.
Introduction
Multiple Sclerosis is a degenerative neurological disease
affecting the Central Nervous System. Unfortunately, it
affects many younger people, mostly diagnosed in women
between the ages of 20 and 50. There is often physical
and emotional pain associated with the disease. There are
various medications in use that can treat those symptoms
and help improve the patients’ quality of life (Ziemssen,
2011). However, change in natural gait is a consequence of
MS that disrupts patients’ daily lives. Over time, a patient’s
ability to walk deteriorates. Progressive worsening of gait is
self-reported and is also demonstrated through data measured on various scales by researchers (Motl, et al., 2018).
Robotic exoskeletons have been shown as an effective way
to retrain gait. Exoskeletons are designed to mimic the
movements of human limbs.They attach to the extremities
and can control the position and alignment of the joints.
Exoskeletons can also be programmed to provide support
based on the patient’s motor capabilities (Iandolo, et al.,
2019).This paper discusses the pathology and musculoskeletal effects of MS and examines the effectiveness of robotic
exoskeletons in improving gait of MS patients.
Methods
The information in this review is collected from various
academic and scientific articles obtained from the EBSCO,
PubMed, and ProQuest databases accessed through the
Touro College library. Each article was analyzed in order
to determine its relevance to the thesis.
Discussion:
Glial Cells and the Myelin Sheath
The nervous system is made of separate parts that work
in tandem. Included is the central and peripheral nervous
systems. The central nervous system is made up of the
brain and spinal cord while the peripheral nervous system
is composed of the nerves that connect the CNS to the
rest of the body. Although they are not neurons, glia are a
fundamental component of the nervous system. The glial
cells espouse the neurons and enable them to function
properly. Astrocytes are the most common type of glial
cell. Astrocytes fill the spaces between neurons, providing
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support. Astrocytes also contribute to the maintenance
of the chemical balance in the neuron by controlling the
extracellular chemical concentration and assisting in the
reuptake of neurotransmitters. There are also microglia
that are involved in removing debris in the nervous system, ensuring that messages can travel without blockage.
Another type of glial cell is myelinating glia. Myelinating
glia are divided into two subtypes, oligodendrocytes
and Schwann cells. Oligodendrocytes are in the central
nervous system, while Schwann cells are present in the
peripheral nervous system. These cells provide insulation
to the neurons by wrapping around their axons in a covering known as myelin, forming the myelin sheath. Myelin
provides insulation, allowing signals to be transported
faster. There are small gaps in the myelin sheath known as
nodes of Ranvier. When an action potential moves down
an axon it is regenerated at the node of Ranvier in a process known as saltatory conduction (Bear, et al., 1996).
Pathology of MS
Multiple Sclerosis is a condition where the body’s immune
system attacks the myelin sheath. MS usually presents at
first with an attack that lasts between a few days and a
few weeks. It is followed by a period of relief that can
last from a few months to a few years. The reprieve is a
result of an autoimmune reaction. This mild form of MS
usually lasts for about ten years, but varies by case. As the
disease progresses, the attacks become less distinct, and
the patient’s condition greatly deteriorates. During the
later stages of the disease, the underlying axon is damaged in addition to the myelin sheath.The axon loss in the
spinal cord causes spinal cord atrophy which can make
it difficult for the patient to walk and lead to paralysis
(Lucchinetti, et al., 1996).
Many protein sequences on the myelin sheath are similar
to microbial protein sequences. As a result, the immune
system attacks the myelin in a process known as molecular
mimicry. Many relapses of MS occur as a result of infection
from a virus. Herpesvirus 6, influenza, measles, papilloma
virus, and Epstein-Barr virus all have gene encoding sequences that are similar to the main protein structures of
the myelin. Antibodies bind to the myelin instead of the
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microbe. If a T-cell or B-cell is activated by the microbe,
it can penetrate the blood-brain barrier (Steinman, 2001).
The diagnosis of MS is a complex process and multiple
factors need to be taken into account. Firstly, there need
to be lesions in the white matter of two separate parts of
the CNS that developed at least a month apart from each
other. All other neurological disorders with similar symptoms need to be ruled out. In addition, an MRI must be
performed. The MRI will display the lesions and successive MRI scans can be a tool to help the physician track
the progression of the disease. It also needs to be determined that the CNS is chronically inflamed, which can be
assessed by a spinal tap. A spinal tap allows the physician
to see if there are oligoclonal bands in the fluid which
indicate neurological disorders. In addition, each episode
of attacks needs to be distinct and last for 24 hours or
more. As the disease progresses, it can be subcategorized
(Garg, Smith, 2015).
MS affects the myelin of the CNS. Each part of the brain
and spinal cord control different neurological functions,
so the effects of the lesions can manifest in different ways.
Relapsing–remitting MS is the most common form of MS.
The person will have separate attacks that can last from
a few days to a few months. In between attacks, there is a
period of reprieve where symptoms get better and there
is no neurological degeneration. The next type of MS is
Secondary Progressive MS (SPMS). In a patient with SPMS,
the condition worsens gradually with time and the patient does not experience any episodes of relief. Primary
progressive MS (PPMS) affects a minority of MS patients.
It is characterized by an unrelenting decline in neurological function. There are no relapses or remissions, but
there are occasional periods where there is no significant
deterioration. Lastly is progressive-relapsing MS (PRMS).
PRMS is the rarest form of MS. From the beginning of
PRMS, the symptoms get progressively worse. However,
it is different from other types of MS because there are
periods where the attacks are more intense and debilitating with no periods of remission (Loma, Heyman, 2011).
In the worst stages of MS, there are no phases of relief,
as there is destruction to the axons and atrophy of the
brain and spinal cord. AMPA is an ionotropic transmembrane receptor for glutamate that allows for fast synaptic transmission in the central nervous system. AMPA
receptors are present on oligodendrocytes. During an
MS attack, lymphocytes, brain microglia and macrophages
release large amounts of glutamate, which activate the
AMPA receptors and cause overstimulation. However, if
the receptors are blocked, it can mitigate some of the
damage from the glutamate. AMPA is not involved in the
immune response, but it can protect the oligodendrocytes

from being damaged. Medications that block glutamate
receptors are being utilized to treat this aspect of MS
(Steinman, 2001).
The Effect of MS on Gait
Since MS affects the spinal cord, the main support of the
body, a patient’s gait can be affected, causing difficulty
walking. Damage to certain areas of the spinal cord can
lead to muscle spasticity. Muscle spasticity is an increase
in rigidity of the muscles. The stiffness can be mild or it
can cause involuntary uncontrolled movements of the
extremities. The stiffness can make straight limbs hard to
bend or bent limbs hard to straighten. Since many MS
patients suffer from fatigue, extreme tiredness can make
coordinating movement challenging. MS patients can also
suffer from weakness in the leg muscles, altering normal
stride. The change in walking pattern can cause pain, furthering the difficulty of walking (nationalmssociety.org).
MS patients can also suffer from balance issues, affecting their ability to walk properly. The balance issues can
be caused by many different factors, such as vision and
sensory issues. A patient may have reduced visual acuity
or lack proper depth perception. This can be hazardous
to a patient because it affects their ability to be aware of
their surroundings. MS-related sensory issues can cause
numbness which results from reduced muscle spindle and
joint receptor activity. This can lead to decreased sensation in the feet which compromises stability and makes
it difficult to navigate uneven surfaces. There is also the
vestibular impact of MS on balance.The vestibulocochlear
nerve is responsible for both hearing and balance. In MS
patients, the vestibulo-ocular reflex is reduced, affecting
the ability to stabilize gaze, causing dizziness and unsteadiness (nationalmssociety.org).
Motor systems can also be affected by MS. Patients with
MS often have decreased muscle strength and endurance.
This makes it difficult for patients to use a wheelchair or
scooter on their own. There are also issues with muscle
control and range of motion. This can lead to an inability
to anticipate changes in the environment, resulting in an
increased response time. Patients may also over or under
compensate with other muscles in order to make up for
the decreased function. These issues can lead to uneven
gait (nationalmssociety.org).
Neurological Impact of MS on Gait
A study was done with patients in the early stages of MS
to assess the way gait is affected by neurological deficits.
Depending on how the gait and neurological systems are
impaired, gait patterns will be different among patients and
even differ in the same patient over time. Disturbance of
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normal gait is reported as the most debilitating symptom
by MS patients. The gait of MS patients was compared to
a control group of healthy people. MS patients walked
slower and used shorter steps. In addition to walking less
efficiently overall, there was a decrease in velocity and
stride length over the course of the day as the patients
became more fatigued. The patients in the study were
scored on the Expanded Disability Status Scale (EDSS)
scale by a neurologist. The EDSS scale measures neurological disability by assessing motor, sensory, cerebellar,
brain stem, visual, and mental abilities. Gait was measured
using the GAITRite Analysis System, a computerized mat
with sensors that measured contact of the feet with the
mat. The system combined the time and distance into a
score known as the Functional Ambulation Performance
(FAP) score. The system removed points for dysfunction
of each leg, lack of lower limb strength, and the use of assistive devices. The FAP score was highly correlated with
neurological abilities. The more neurological impairments
a patient had, the less efficient their gait. The data also
suggests that the impairments in upper motor neuron
function lead to abnormal gait in MS. Significant changes to the FAP score would suggest a relapse in the MS
(Givon, et al., 2009).
Gait Training
Conventional physical therapy involves different techniques that help patients improve gait and reduce the
risk of falls. Treatment for MS involves stretching to reduce spasticity of the muscles and maintain the patient’s
range of motion at the joints. Exercises also work toward
improving trunk control and increasing strength in the
upper arms. Physical therapists also teach MS patients
how to adapt to the environment and use aids such as
wheelchairs and braces (Schwartz et al., 2011).
Physical therapists work with patients on balance exercises as well as strength and resistance training. In the
past, Bodyweight-supported treadmill training (BWSTT)
was a popular method to improve gait in patients with
MS. BWSTT is based on the effectiveness of intensive and
task-specific gait training. The user wears a harness which
is held up and supported by the therapist. The patient has
minimal support from a rope attached to the harness and
walks on a treadmill, while the legs are physically guided
by the therapist. However, this is extremely exhausting
for both the patient and the therapist. It is also impractical for patients that have limited function of their legs
(van Kammen, et al., 2016).
A study compared walking on a treadmill regularly to
walking on a treadmill with body weight support in 10
healthy individuals. Normal gait pattern was disrupted
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when body weight support was provided. In addition, neuromuscular control of walking was affected. As gait speed
increased, the differences between walking with and without support were less pronounced. It was recommended
that higher speeds and less bodyweight support should
be provided to patients when trying to reinstate a natural
gait (van Kammen, et al., 2014).
Recently, robot-assisted gait training devices have been
recognized for their ability to provide walking assistance
to patients with severe gait disabilities. The robots, also
known as exoskeletons, allow the patient to walk on flat
ground. The parts of the exoskeleton that attach to the
lower extremities are connected to a computer. The physical therapist can use the software to manually adjust the
angles of the different parts in order to mimic the ideal gait
of the specific patient (Berriozabalgoitia, et al., 2021).
What is Ekso?
The Ekso is a robotic exoskeleton developed by Ekso
Bionics in Richmond, California. The Ekso is made of carbon fibers and steel. It functions as an exoskeleton by
attaching to the thigh, lower leg, and foot. The sensors
embedded in the attachments respond to input from the
user’s muscles. A backpack that is worn to support the
torso (Lajeunesse, et al., 2015). There are motors located
at the knees and hips. A spring-loaded footplate ensures
that the patient’s steps clear the floor. The device supports itself and does not add any additional weight to the
user.The user may require the assistance of a gait aid such
as a walker or cane at first, but eventually many patients
can walk on their own. The advanced software allows the
physical therapist to set the parameters for the level of
assistance that the robot provides, including the areas of
step height, step length, and swing speed. The purpose of
this is to promote participation from the patient in a way
that is reasonably challenging (Wee, et al., 2020).
There are three levels of assistance that the Ekso
software can provide. The lowest level, named FirstStep,
requires the physical therapist to initiate the step using
a controller. The patient is not involved in initiating the
movement. This is often used in the beginning stages of
treatment when the patient is learning to use the device.
In ActiveStep, the patient presses a button and the device initiates a step forward. The most advanced level is
ProStep, where the device moves when the patient engages in normal walking behavior such as lifting the foot and
shifting the weight forward. The Ekso is highly beneficial
because it can be programmed to work with patients that
have mild to severe gait issues (Thomassen et al., 2019).
A main goal of physical therapy in neurologically impaired patients is to recover gait. Walking is important
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for physical and mental wellbeing. The best outcome is
based on the principles of relative and repetitive training.
The Ekso is relative because it allows the patient to experience a real walking position. It can be used in both
indoor and outdoor environments. The Ekso training is
repetitive because the patient spends multiple sessions
walking wearing the device. Exercise that is high-intensity
and is task-specific has been shown to promote the most
progress toward recovery (Russo, et al., 2021).
Gross Motor Improvements
The trunk muscles are an integral part of maintaining
proper posture during sitting and standing. Proper posture is also the first step in achieving a normal gait. Trunk
muscles are activated systematically during walking to
keep the body steady. Faster gait speed requires higher
levels of trunk muscle engagement to keep the body stable. Engaging the trunk muscles to improve trunk function
can provide many rehabilitative benefits. As opposed to
other exoskeleton devices, Ekso requires the user to initiate the stepping movement by shifting their weight. This
requires full body weight-bearing, which forces the user
to activate their trunk muscles. Usage of the Ekso showed
an increase in trunk activity both in the anterior-posterior and medial-lateral directions.The level of trunk muscle
activation was much higher with the Ekso than voluntarily induced contraction. Research also suggested that the
voluntary stepping promoted activity in the cortical and
vestibulospinal pathways which shows the Ekso can promote neuromuscular improvement (Alamro, et al., 2018).
A study was done with 36 MS patients that required
assistance when walking outside. Both the control group
and the intervention group participated in weekly sessions with a physical therapist. However, the intervention
group engaged in biweekly training with a robotic exoskeleton for three months. The parameters of the exoskeleton were set according to each individual patient’s
motor skills and joint mobility. The length of the sessions
increased as time progressed, and endurance improved.
The sessions were stopped early if the patient requested
or if the physical therapist noticed signs of fatigue such as
increased muscle tone and stumbling. At the end of each
session cooling therapies were used on knee extensors
and ankle plantar flexors to prevent exercise-induced hyperthermia and muscle fatigue. The study displayed that
robotic gait training in addition to regular rehab sessions
preserves gait speed and improves functional mobility in patients with MS. The exoskeleton did not cause
increased fatigue in the participants. The control group
showed an overall decline in physical function. The effects
were two-fold as the symptoms did not improve, and the

disease got progressively worse. The Ekso exoskeleton is
a crucial tool in rehabilitation because it encourages cognitive control of body movements, specifically in the area
of weight shift (Berriozabalgoitia, et al., 2021).
Quality of Life Improvements
A robotic exoskeleton can also improve the quality of life
in patients with MS. The exoskeleton provides a highly repetitive and intensive gait training experience. The user is
held in an upright position while walking around. The exoskeleton is portable, which allows it to be used in any environment, including outdoors.This is engaging and rewarding
to the patient to be able to experience walking in a way
very similar to a healthy individual. A study was done with
a 51-year-old non-ambulatory patient. The goal for this patient was for her to be able to assist in transfers, to reduce
the burden on her caregivers, and to improve her quality of
life. Compared to other studies, the purpose here was not
to promote ambulation. The patient used the Ekso robotic
exoskeleton for a total of 15 sessions that occurred for one
hour twice a week. The distance covered during each session was dependent on the patient’s level of fatigue. After
the Ekso sessions, the patient showed an increase in right
knee extensor strength which made the sitting to standing
transition easier.As the therapy progressed, the patient’s endurance increased as well, and she was able to walk further
distances. There was no change in spasticity, trunk control,
or balance. However, the most notable improvement was
in the patient’s quality of life. Prior to using the exoskeleton,
the patient was depressed and did not want to participate
in social activities. After treatment, the patient expressed to
the researchers how her self-confidence and self-esteem
improved (Wee, et al., 2020).
Patients with impaired walking function are often confined to wheelchairs. However, wheelchairs do not promote muscle movement and can lead to muscle atrophy. In
addition, the patient sitting in the wheelchair is lower than
everyone that is standing, leading to feelings of inferiority.
Participants reported feeling free and independent when
using the Ekso. Additionally, patients that required walking
aids such as a walker or a cane had previously felt unsteady
while walking and feared falling. While using the Ekso, they
felt supported and secure, so they were able to focus on
the actual leg movement (Thomassen et al., 2019).
Conclusion
The impairment of gait is reported as the most debilitating symptom of MS. Although many gait training methods
have been used over the years, few have led to significant
improvements. Ekso is a new robotic exoskeleton that
has recently been trialed for its effectiveness in improving
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the gait of MS patients. Studies have shown that using
Ekso, patients’ gait and quality of life has improved. There
is hope that the Ekso will become more widely available
in order to provide more patients with the euphoric experience of walking again.
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